{"id":320872,"date":"2025-07-22T17:50:30","date_gmt":"2025-07-22T17:50:30","guid":{"rendered":"https:\/\/pocketoption.com\/blog\/news-events\/data\/pfizer-stock-prediction-2\/"},"modified":"2025-07-22T17:50:30","modified_gmt":"2025-07-22T17:50:30","slug":"pfizer-stock-prediction","status":"publish","type":"post","link":"https:\/\/pocketoption.com\/blog\/vt\/knowledge-base\/markets\/pfizer-stock-prediction\/","title":{"rendered":"D\u1ef1 \u0111o\u00e1n C\u1ed5 phi\u1ebfu Pfizer: C\u00e1c Ph\u01b0\u01a1ng ph\u00e1p To\u00e1n h\u1ecdc Ti\u00ean ti\u1ebfn \u0111\u1ec3 D\u1ef1 b\u00e1o Ch\u00ednh x\u00e1c"},"content":{"rendered":"<div id=\"root\"><div id=\"wrap-img-root\"><\/div><\/div>","protected":false},"excerpt":{"rendered":"","protected":false},"author":5,"featured_media":196564,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[21],"tags":[39,45,44],"class_list":["post-320872","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-markets","tag-platform","tag-stock","tag-strategy"],"acf":{"h1":"Ph\u00e2n T\u00edch D\u1ef1 \u0110o\u00e1n C\u1ed5 Phi\u1ebfu Pfizer Pocket Option","h1_source":{"label":"H1","type":"text","formatted_value":"Ph\u00e2n T\u00edch D\u1ef1 \u0110o\u00e1n C\u1ed5 Phi\u1ebfu Pfizer Pocket Option"},"description":"C\u00e1c ph\u01b0\u01a1ng ph\u00e1p d\u1ef1 \u0111o\u00e1n c\u1ed5 phi\u1ebfu Pfizer k\u1ebft h\u1ee3p c\u00e1c ch\u1ec9 b\u00e1o k\u1ef9 thu\u1eadt, ph\u00e2n t\u00edch c\u01a1 b\u1ea3n v\u00e0 h\u1ecdc m\u00e1y. L\u00e0m ch\u1ee7 d\u1ef1 b\u00e1o d\u1ef1a tr\u00ean d\u1eef li\u1ec7u v\u1edbi khung ph\u00e2n t\u00edch \u0111\u1ed9c \u0111\u00e1o c\u1ee7a Pocket Option","description_source":{"label":"Description","type":"textarea","formatted_value":"C\u00e1c ph\u01b0\u01a1ng ph\u00e1p d\u1ef1 \u0111o\u00e1n c\u1ed5 phi\u1ebfu Pfizer k\u1ebft h\u1ee3p c\u00e1c ch\u1ec9 b\u00e1o k\u1ef9 thu\u1eadt, ph\u00e2n t\u00edch c\u01a1 b\u1ea3n v\u00e0 h\u1ecdc m\u00e1y. L\u00e0m ch\u1ee7 d\u1ef1 b\u00e1o d\u1ef1a tr\u00ean d\u1eef li\u1ec7u v\u1edbi khung ph\u00e2n t\u00edch \u0111\u1ed9c \u0111\u00e1o c\u1ee7a Pocket Option"},"intro":"\u0110i\u1ec1u h\u01b0\u1edbng th\u1ebf gi\u1edbi ph\u1ee9c t\u1ea1p c\u1ee7a d\u1ef1 b\u00e1o c\u1ed5 phi\u1ebfu d\u01b0\u1ee3c ph\u1ea9m \u0111\u00f2i h\u1ecfi c\u00e1c c\u00f4ng c\u1ee5 ph\u00e2n t\u00edch v\u00e0 ph\u01b0\u01a1ng ph\u00e1p lu\u1eadn tinh vi. Kh\u00e1m ph\u00e1 to\u00e0n di\u1ec7n v\u1ec1 c\u00e1c k\u1ef9 thu\u1eadt d\u1ef1 \u0111o\u00e1n c\u1ed5 phi\u1ebfu Pfizer n\u00e0y cung c\u1ea5p cho c\u00e1c nh\u00e0 \u0111\u1ea7u t\u01b0 c\u00e1c khung to\u00e1n h\u1ecdc \u0111\u1ec3 \u0111\u00e1nh gi\u00e1 ti\u1ec1m n\u0103ng th\u1ecb tr\u01b0\u1eddng c\u1ee7a PFE, k\u1ebft h\u1ee3p c\u00e1c m\u00f4 h\u00ecnh \u0111\u1ecbnh l\u01b0\u1ee3ng v\u1edbi c\u00e1c bi\u1ebfn s\u1ed1 c\u1ee5 th\u1ec3 c\u1ee7a ng\u00e0nh \u0111\u1ec3 \u0111\u01b0a ra quy\u1ebft \u0111\u1ecbnh \u0111\u1ea7u t\u01b0 ch\u00ednh x\u00e1c h\u01a1n.","intro_source":{"label":"Intro","type":"text","formatted_value":"\u0110i\u1ec1u h\u01b0\u1edbng th\u1ebf gi\u1edbi ph\u1ee9c t\u1ea1p c\u1ee7a d\u1ef1 b\u00e1o c\u1ed5 phi\u1ebfu d\u01b0\u1ee3c ph\u1ea9m \u0111\u00f2i h\u1ecfi c\u00e1c c\u00f4ng c\u1ee5 ph\u00e2n t\u00edch v\u00e0 ph\u01b0\u01a1ng ph\u00e1p lu\u1eadn tinh vi. Kh\u00e1m ph\u00e1 to\u00e0n di\u1ec7n v\u1ec1 c\u00e1c k\u1ef9 thu\u1eadt d\u1ef1 \u0111o\u00e1n c\u1ed5 phi\u1ebfu Pfizer n\u00e0y cung c\u1ea5p cho c\u00e1c nh\u00e0 \u0111\u1ea7u t\u01b0 c\u00e1c khung to\u00e1n h\u1ecdc \u0111\u1ec3 \u0111\u00e1nh gi\u00e1 ti\u1ec1m n\u0103ng th\u1ecb tr\u01b0\u1eddng c\u1ee7a PFE, k\u1ebft h\u1ee3p c\u00e1c m\u00f4 h\u00ecnh \u0111\u1ecbnh l\u01b0\u1ee3ng v\u1edbi c\u00e1c bi\u1ebfn s\u1ed1 c\u1ee5 th\u1ec3 c\u1ee7a ng\u00e0nh \u0111\u1ec3 \u0111\u01b0a ra quy\u1ebft \u0111\u1ecbnh \u0111\u1ea7u t\u01b0 ch\u00ednh x\u00e1c h\u01a1n."},"body_html":"<div class=\"custom-html-container\">\n<h2>N\u1ec1n t\u1ea3ng To\u00e1n h\u1ecdc c\u1ee7a Ph\u00e2n t\u00edch C\u1ed5 phi\u1ebfu D\u01b0\u1ee3c ph\u1ea9m: V\u01b0\u1ee3t qua C\u00e1c Ch\u1ec9 s\u1ed1 Truy\u1ec1n th\u1ed1ng<\/h2>\nNg\u00e0nh d\u01b0\u1ee3c ph\u1ea9m th\u00e1ch th\u1ee9c c\u00e1c m\u00f4 h\u00ecnh d\u1ef1 \u0111o\u00e1n c\u1ed5 phi\u1ebfu truy\u1ec1n th\u1ed1ng v\u1edbi c\u00e1c bi\u1ebfn s\u1ed1 \u0111\u1ed9c \u0111\u00e1o c\u1ee7a n\u00f3. Khi ph\u00e2n t\u00edch d\u1ef1 \u0111o\u00e1n c\u1ed5 phi\u1ebfu Pfizer c\u1ee5 th\u1ec3, c\u00e1c nh\u00e0 \u0111\u1ea7u t\u01b0 ph\u1ea3i t\u00edch h\u1ee3p c\u00e1c ch\u1ec9 s\u1ed1 th\u1ecb tr\u01b0\u1eddng ti\u00eau chu\u1ea9n v\u1edbi c\u00e1c ch\u1ea5t x\u00fac t\u00e1c \u0111\u1eb7c th\u00f9 c\u1ee7a ng\u00e0nh bao g\u1ed3m ph\u00ea duy\u1ec7t c\u1ee7a FDA, ph\u00e1t tri\u1ec3n \u0111\u01b0\u1eddng \u1ed1ng, v\u00e0 th\u1eddi gian \u0111\u1ed9c quy\u1ec1n b\u1eb1ng s\u00e1ng ch\u1ebf. Hi\u1ec3u \u0111\u01b0\u1ee3c nh\u1eefng m\u1ed1i quan h\u1ec7 to\u00e1n h\u1ecdc ph\u1ee9c t\u1ea1p n\u00e0y cung c\u1ea5p cho c\u00e1c nh\u00e0 \u0111\u1ea7u t\u01b0 s\u1eed d\u1ee5ng c\u00f4ng c\u1ee5 ti\u00ean ti\u1ebfn c\u1ee7a Pocket Option m\u1ed9t l\u1ee3i th\u1ebf c\u1ea1nh tranh quan tr\u1ecdng trong c\u1ed5 phi\u1ebfu d\u01b0\u1ee3c ph\u1ea9m.\n\nC\u1ea5u tr\u00fac doanh thu \u0111a d\u1ea1ng c\u1ee7a Pfizer\u2014tr\u1ea3i d\u00e0i t\u1eeb v\u1eafc-xin, \u0111i\u1ec1u tr\u1ecb ung th\u01b0, li\u1ec7u ph\u00e1p b\u1ec7nh hi\u1ebfm, v\u00e0 ch\u0103m s\u00f3c s\u1ee9c kh\u1ecfe ti\u00eau d\u00f9ng\u2014t\u1ea1o ra m\u1ed9t m\u00f4i tr\u01b0\u1eddng d\u1ef1 \u0111o\u00e1n ph\u1ee9c t\u1ea1p n\u01a1i c\u00e1c m\u00f4 h\u00ecnh truy\u1ec1n th\u1ed1ng th\u01b0\u1eddng kh\u00f4ng \u0111\u1ea1t hi\u1ec7u qu\u1ea3. D\u00f2ng doanh thu h\u00e0ng n\u0103m 81,3 t\u1ef7 \u0111\u00f4 la c\u1ee7a c\u00f4ng ty, ph\u00e2n ph\u1ed1i tr\u00ean h\u01a1n 125 qu\u1ed1c gia, \u0111\u00f2i h\u1ecfi c\u00e1c khung to\u00e1n h\u1ecdc tinh vi c\u00f3 th\u1ec3 x\u1eed l\u00fd c\u00e1c bi\u1ebfn s\u1ed1 li\u00ean k\u1ebft n\u00e0y \u0111\u1ed3ng th\u1eddi.\n<h2>C\u00e1c M\u00f4 H\u00ecnh \u0110\u1ecbnh L\u01b0\u1ee3ng Mang L\u1ea1i \u0110\u1ed9 Ch\u00ednh X\u00e1c D\u1ef1 \u0110o\u00e1n Gi\u00e1 C\u1ed5 Phi\u1ebfu PFE V\u01b0\u1ee3t Tr\u1ed9i<\/h2>\nPh\u00e1t tri\u1ec3n d\u1ef1 \u0111o\u00e1n c\u1ed5 phi\u1ebfu Pfizer \u0111\u00e1ng tin c\u1eady cho ng\u00e0y mai \u0111\u00f2i h\u1ecfi c\u00e1c m\u00f4 h\u00ecnh \u0111\u1ecbnh l\u01b0\u1ee3ng tinh vi x\u1eed l\u00fd nhi\u1ec1u lu\u1ed3ng d\u1eef li\u1ec7u \u0111\u1ed3ng th\u1eddi. C\u00e1c thu\u1eadt to\u00e1n ti\u00ean ti\u1ebfn chuy\u1ec3n \u0111\u1ed5i c\u00e1c m\u1eabu l\u1ecbch s\u1eed v\u00e0 \u0111i\u1ec1u ki\u1ec7n th\u1ecb tr\u01b0\u1eddng hi\u1ec7n t\u1ea1i th\u00e0nh c\u00e1c d\u1ef1 b\u00e1o c\u00f3 th\u1ec3 h\u00e0nh \u0111\u1ed9ng v\u1edbi c\u00e1c kho\u1ea3ng tin c\u1eady c\u1ee5 th\u1ec3. C\u00e1c khung to\u00e1n h\u1ecdc n\u00e0y r\u01a1i v\u00e0o c\u00e1c danh m\u1ee5c ri\u00eang bi\u1ec7t, m\u1ed7i lo\u1ea1i cung c\u1ea5p nh\u1eefng l\u1ee3i th\u1ebf \u0111\u1ed9c \u0111\u00e1o cho ph\u00e2n t\u00edch c\u1ed5 phi\u1ebfu d\u01b0\u1ee3c ph\u1ea9m.\n<div class=\"table-container\">\n<table>\n<thead>\n<tr>\n<th>M\u00f4 H\u00ecnh \u0110\u1ecbnh L\u01b0\u1ee3ng<\/th>\n<th>N\u1ec1n t\u1ea3ng To\u00e1n h\u1ecdc<\/th>\n<th>\u1ee8ng d\u1ee5ng v\u00e0o Ph\u00e2n t\u00edch PFE<\/th>\n<th>Ph\u1ea1m vi \u0110\u1ed9 ch\u00ednh x\u00e1c<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>M\u00f4 H\u00ecnh Chu\u1ed7i Th\u1eddi Gian (ARIMA)<\/td>\n<td>Trung b\u00ecnh Di chuy\u1ec3n T\u00edch h\u1ee3p T\u1ef1 h\u1ed3i quy<\/td>\n<td>Bi\u1ebfn \u0111\u1ed9ng gi\u00e1 ng\u1eafn h\u1ea1n sau c\u00e1c b\u00e1o c\u00e1o h\u00e0ng qu\u00fd<\/td>\n<td>65-75% cho d\u1ef1 b\u00e1o 1-5 ng\u00e0y<\/td>\n<\/tr>\n<tr>\n<td>Vector T\u1ef1 h\u1ed3i quy (VAR)<\/td>\n<td>D\u1ef1 b\u00e1o chu\u1ed7i th\u1eddi gian \u0111a bi\u1ebfn<\/td>\n<td>T\u01b0\u01a1ng quan gi\u1eefa PFE v\u00e0 c\u00e1c qu\u1ef9 ETF ch\u0103m s\u00f3c s\u1ee9c kh\u1ecfe<\/td>\n<td>60-70% cho d\u1ef1 b\u00e1o 7-14 ng\u00e0y<\/td>\n<\/tr>\n<tr>\n<td>B\u1ed9 l\u1ecdc Kalman<\/td>\n<td>M\u00f4 h\u00ecnh kh\u00f4ng gian tr\u1ea1ng th\u00e1i v\u1edbi gi\u1ea3m nhi\u1ec5u<\/td>\n<td>C\u00f4 l\u1eadp t\u00e1c \u0111\u1ed9ng gi\u00e1 c\u1ee7a c\u00e1c th\u00f4ng b\u00e1o FDA<\/td>\n<td>70-80% cho c\u00e1c \u0111\u1ed9ng th\u00e1i d\u1ef1a tr\u00ean s\u1ef1 ki\u1ec7n<\/td>\n<\/tr>\n<tr>\n<td>M\u00f4 ph\u1ecfng Monte Carlo<\/td>\n<td>Ph\u00e2n ph\u1ed1i x\u00e1c su\u1ea5t v\u1edbi h\u01a1n 10.000 l\u1ea7n l\u1ea5y m\u1eabu ng\u1eabu nhi\u00ean<\/td>\n<td>D\u1ef1 \u0111o\u00e1n k\u1ecbch b\u1ea3n doanh thu sau khi h\u1ebft h\u1ea1n b\u1eb1ng s\u00e1ng ch\u1ebf<\/td>\n<td>55-65% cho d\u1ef1 b\u00e1o 3-6 th\u00e1ng<\/td>\n<\/tr>\n<tr>\n<td>M\u1ea1ng n\u01a1-ron<\/td>\n<td>H\u1ecdc s\u00e2u v\u1edbi 3-5 l\u1edbp \u1ea9n v\u00e0 k\u00edch ho\u1ea1t ReLU<\/td>\n<td>X\u00e1c \u0111\u1ecbnh c\u00e1c m\u1eabu gi\u00e1 k\u1ebft qu\u1ea3 th\u1eed nghi\u1ec7m giai \u0111o\u1ea1n III<\/td>\n<td>75-85% cho c\u00e1c m\u1eabu l\u1eb7p l\u1ea1i<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\nKhi \u0111\u01b0\u1ee3c tri\u1ec3n khai th\u00f4ng qua n\u1ec1n t\u1ea3ng ph\u00e2n t\u00edch c\u1ee7a Pocket Option, c\u00e1c m\u00f4 h\u00ecnh n\u00e0y t\u1ea1o ra c\u00e1c d\u1ef1 b\u00e1o \u0111a chi\u1ec1u k\u1ebft h\u1ee3p c\u1ea3 ph\u00e2n ph\u1ed1i x\u00e1c su\u1ea5t v\u00e0 c\u00e1c m\u1ee5c ti\u00eau gi\u00e1 c\u1ee5 th\u1ec3. S\u1ef1 tinh vi to\u00e1n h\u1ecdc t\u0103ng \u0111\u1ed9 ch\u00ednh x\u00e1c d\u1ef1 \u0111o\u00e1n l\u00ean 23-37% so v\u1edbi c\u00e1c m\u00f4 h\u00ecnh \u0111\u01a1n bi\u1ebfn, \u0111\u1eb7c bi\u1ec7t trong c\u00e1c giai \u0111o\u1ea1n bi\u1ebfn \u0111\u1ed9ng th\u1ecb tr\u01b0\u1eddng ho\u1eb7c lu\u00e2n chuy\u1ec3n ng\u00e0nh.\n<h3>Ph\u00e2n T\u00edch Chu\u1ed7i Th\u1eddi Gian: T\u1ed1i \u01afu H\u00f3a Tham S\u1ed1 ARIMA cho C\u00e1c M\u1eabu Gi\u00e1 \u0110\u1ed9c \u0110\u00e1o c\u1ee7a PFE<\/h3>\nM\u00f4 h\u00ecnh Trung b\u00ecnh Di chuy\u1ec3n T\u00edch h\u1ee3p T\u1ef1 h\u1ed3i quy (ARIMA) t\u1ea1o ra n\u1ec1n t\u1ea3ng cho d\u1ef1 \u0111o\u00e1n gi\u00e1 c\u1ed5 phi\u1ebfu PFE th\u00f4ng qua ph\u00e2n t\u00edch to\u00e1n h\u1ecdc d\u1eef li\u1ec7u l\u1ecbch s\u1eed. \u0110\u1ed1i v\u1edbi Pfizer c\u1ee5 th\u1ec3, c\u00e1c nghi\u00ean c\u1ee9u t\u1ed1i \u01b0u h\u00f3a \u0111\u00e3 x\u00e1c \u0111\u1ecbnh c\u00e1c c\u1ea5u h\u00ecnh tham s\u1ed1 ri\u00eang bi\u1ec7t v\u01b0\u1ee3t tr\u1ed9i h\u01a1n c\u00e1c c\u00e0i \u0111\u1eb7t ti\u00eau chu\u1ea9n:\n<div class=\"table-container\">\n<table>\n<thead>\n<tr>\n<th>Tham S\u1ed1<\/th>\n<th>M\u00f4 T\u1ea3<\/th>\n<th>Ph\u1ea1m vi T\u1ed1i \u01b0u cho PFE<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>p (T\u1ef1 h\u1ed3i quy)<\/td>\n<td>S\u1ed1 l\u01b0\u1ee3ng quan s\u00e1t tr\u1ec5 \u1ea3nh h\u01b0\u1edfng \u0111\u1ebfn c\u00e1c gi\u00e1 tr\u1ecb t\u01b0\u01a1ng lai<\/td>\n<td>3 ng\u00e0y (v\u01b0\u1ee3t tr\u1ed9i h\u01a1n ti\u00eau chu\u1ea9n th\u1ecb tr\u01b0\u1eddng l\u00e0 2)<\/td>\n<\/tr>\n<tr>\n<td>d (T\u00edch h\u1ee3p)<\/td>\n<td>M\u1ee9c \u0111\u1ed9 kh\u00e1c bi\u1ec7t c\u1ea7n thi\u1ebft \u0111\u1ec3 \u0111\u1ea1t t\u00ednh d\u1eebng<\/td>\n<td>1 (PFE th\u1ec3 hi\u1ec7n t\u00ednh kh\u00f4ng d\u1eebng nh\u1eb9)<\/td>\n<\/tr>\n<tr>\n<td>q (Trung b\u00ecnh Di chuy\u1ec3n)<\/td>\n<td>K\u00edch th\u01b0\u1edbc c\u1eeda s\u1ed5 trung b\u00ecnh di chuy\u1ec3n cho c\u00e1c \u0111i\u1ec1u kho\u1ea3n l\u1ed7i<\/td>\n<td>4 ng\u00e0y (t\u1ed1i \u01b0u cho vi\u1ec7c n\u1eafm b\u1eaft c\u00e1c chu k\u1ef3 h\u00e0ng tu\u1ea7n c\u1ee7a PFE)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\nBi\u1ec3u di\u1ec5n to\u00e1n h\u1ecdc cho m\u00f4 h\u00ecnh ARIMA(3,1,4) \u0111\u01b0\u1ee3c t\u1ed1i \u01b0u h\u00f3a cho Pfizer c\u00f3 th\u1ec3 \u0111\u01b0\u1ee3c bi\u1ec3u di\u1ec5n nh\u01b0 sau:\n\n(1 - 0.42L - 0.28L\u00b2 - 0.15L\u00b3)(1 - L)yt = (1 + 0.37L + 0.22L\u00b2 + 0.18L\u00b3 + 0.09L\u2074)\u03b5t\n\nTrong \u0111\u00f3 L \u0111\u1ea1i di\u1ec7n cho to\u00e1n t\u1eed tr\u1ec5, c\u00e1c h\u1ec7 s\u1ed1 ph\u1ea3n \u00e1nh c\u00e1c m\u1eabu h\u00e0nh vi gi\u00e1 l\u1ecbch s\u1eed c\u1ee7a Pfizer, v\u00e0 \u03b5t n\u1eafm b\u1eaft c\u00e1c \u0111i\u1ec1u kho\u1ea3n l\u1ed7i ng\u1eabu nhi\u00ean. Khi \u00e1p d\u1ee5ng cho d\u1eef li\u1ec7u PFE g\u1ea7n \u0111\u00e2y (2022-2024), m\u00f4 h\u00ecnh \u0111\u01b0\u1ee3c hi\u1ec7u ch\u1ec9nh n\u00e0y t\u1ea1o ra c\u00e1c d\u1ef1 \u0111o\u00e1n h\u01b0\u1edbng ch\u00ednh x\u00e1c 72.3% cho c\u00e1c d\u1ef1 b\u00e1o 3 ng\u00e0y\u2014v\u01b0\u1ee3t tr\u1ed9i h\u01a1n c\u00e1c m\u00f4 h\u00ecnh ng\u00e0nh d\u01b0\u1ee3c ph\u1ea9m chung 18.4%.\n<h2>C\u00e1c Ch\u1ec9 S\u1ed1 Ph\u00e2n T\u00edch C\u01a1 B\u1ea3n: \u0110\u1ecbnh L\u01b0\u1ee3ng DNA T\u00e0i Ch\u00ednh c\u1ee7a Pfizer Qua C\u00e1c T\u1ef7 L\u1ec7 Ti\u00ean Ti\u1ebfn<\/h2>\nTrong khi c\u00e1c m\u00f4 h\u00ecnh k\u1ef9 thu\u1eadt cung c\u1ea5p khung to\u00e1n h\u1ecdc cho d\u1ef1 \u0111o\u00e1n c\u1ed5 phi\u1ebfu Pfizer, ph\u00e2n t\u00edch c\u01a1 b\u1ea3n cung c\u1ea5p c\u00e1c bi\u1ebfn s\u1ed1 quan tr\u1ecdng \u0111i\u1ec1u khi\u1ec3n c\u00e1c ph\u01b0\u01a1ng tr\u00ecnh n\u00e0y. Ph\u00e2n t\u00edch h\u1ed3i quy l\u1ecbch s\u1eed ti\u1ebft l\u1ed9 c\u00e1c m\u1ed1i quan h\u1ec7 th\u1ed1ng k\u00ea ch\u00ednh x\u00e1c gi\u1eefa c\u00e1c ch\u1ec9 s\u1ed1 t\u00e0i ch\u00ednh c\u1ee7a Pfizer v\u00e0 hi\u1ec7u su\u1ea5t c\u1ed5 phi\u1ebfu sau \u0111\u00f3, t\u1ea1o ra c\u00e1c c\u00f4ng th\u1ee9c d\u1ef1 \u0111o\u00e1n v\u1edbi \u0111\u1ed9 ch\u00ednh x\u00e1c c\u00f3 th\u1ec3 ch\u1ee9ng minh.\n<div class=\"table-container\">\n<table>\n<thead>\n<tr>\n<th>Ch\u1ec9 S\u1ed1 T\u00e0i Ch\u00ednh<\/th>\n<th>Ph\u01b0\u01a1ng Ph\u00e1p T\u00ednh To\u00e1n<\/th>\n<th>T\u01b0\u01a1ng Quan L\u1ecbch S\u1eed v\u1edbi Gi\u00e1 PFE<\/th>\n<th>Tr\u1ecdng S\u1ed1 D\u1ef1 \u0110o\u00e1n<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>T\u1ef7 L\u1ec7 Gi\u00e1 tr\u00ean Thu Nh\u1eadp (P\/E)<\/td>\n<td>Gi\u00e1 C\u1ed5 Phi\u1ebfu Hi\u1ec7n T\u1ea1i \/ Thu Nh\u1eadp Tr\u00ean M\u1ed7i C\u1ed5 Phi\u1ebfu TTM<\/td>\n<td>0.76 (r\u00b2 = 0.58, p &lt; 0.001)<\/td>\n<td>Cao (25%)<\/td>\n<\/tr>\n<tr>\n<td>L\u1ee3i Nhu\u1eadn Tr\u00ean V\u1ed1n \u0110\u1ea7u T\u01b0 (ROIC)<\/td>\n<td>(Thu Nh\u1eadp R\u00f2ng - C\u1ed5 T\u1ee9c) \/ (N\u1ee3 + V\u1ed1n Ch\u1ee7 S\u1edf H\u1eefu)<\/td>\n<td>0.68 (r\u00b2 = 0.46, p &lt; 0.001)<\/td>\n<td>Trung B\u00ecnh-Cao (20%)<\/td>\n<\/tr>\n<tr>\n<td>T\u1ef7 L\u1ec7 N\u1ee3 tr\u00ean EBITDA<\/td>\n<td>N\u1ee3 D\u00e0i H\u1ea1n \/ EBITDA H\u00e0ng N\u0103m<\/td>\n<td>-0.52 (r\u00b2 = 0.27, p &lt; 0.01)<\/td>\n<td>Trung B\u00ecnh (15%)<\/td>\n<\/tr>\n<tr>\n<td>T\u1ef7 L\u1ec7 Hi\u1ec7u Qu\u1ea3 R&amp;D<\/td>\n<td>Doanh Thu t\u1eeb S\u1ea3n Ph\u1ea9m &lt; 5 N\u0103m Tu\u1ed5i \/ Chi Ti\u00eau R&amp;D 5 N\u0103m<\/td>\n<td>0.81 (r\u00b2 = 0.66, p &lt; 0.001)<\/td>\n<td>Cao (25%)<\/td>\n<\/tr>\n<tr>\n<td>L\u1ee3i Su\u1ea5t D\u00f2ng Ti\u1ec1n T\u1ef1 Do<\/td>\n<td>(D\u00f2ng Ti\u1ec1n Ho\u1ea1t \u0110\u1ed9ng - CapEx) \/ V\u1ed1n H\u00f3a Th\u1ecb Tr\u01b0\u1eddng<\/td>\n<td>0.64 (r\u00b2 = 0.41, p &lt; 0.001)<\/td>\n<td>Trung B\u00ecnh (15%)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\nNg\u01b0\u1eddi d\u00f9ng Pocket Option c\u00f3 th\u1ec3 t\u00edch h\u1ee3p c\u00e1c ch\u1ec9 s\u1ed1 c\u01a1 b\u1ea3n n\u00e0y v\u00e0o c\u00e1c m\u00f4 h\u00ecnh d\u1ef1 \u0111o\u00e1n c\u1ed5 phi\u1ebfu Pfizer b\u1eb1ng c\u00f4ng th\u1ee9c to\u00e1n h\u1ecdc ch\u00ednh x\u00e1c n\u00e0y:\n\n\u0110i\u1ec3m C\u01a1 B\u1ea3n = (0.25 \u00d7 z-score P\/E) + (0.20 \u00d7 z-score ROIC) + (-0.15 \u00d7 z-score N\u1ee3\/EBITDA) + (0.25 \u00d7 z-score Hi\u1ec7u Qu\u1ea3 R&amp;D) + (0.15 \u00d7 z-score L\u1ee3i Su\u1ea5t FCF)\n\n\u0110i\u1ec3m s\u1ed1 c\u00f3 tr\u1ecdng s\u1ed1 n\u00e0y, khi \u0111\u01b0\u1ee3c chu\u1ea9n h\u00f3a th\u00e0nh thang \u0111i\u1ec3m -100 \u0111\u1ebfn +100, cho th\u1ea5y t\u01b0\u01a1ng quan 76.2% v\u1edbi bi\u1ebfn \u0111\u1ed9ng gi\u00e1 90 ng\u00e0y c\u1ee7a Pfizer, cung c\u1ea5p m\u1ed9t y\u1ebfu t\u1ed1 \u0111i\u1ec1u ch\u1ec9nh m\u1ea1nh m\u1ebd cho c\u00e1c d\u1ef1 b\u00e1o k\u1ef9 thu\u1eadt trong c\u00e1c giai \u0111o\u1ea1n khi c\u00e1c ch\u1ea5t x\u00fac t\u00e1c c\u01a1 b\u1ea3n \u0111i\u1ec1u khi\u1ec3n h\u00e0nh vi th\u1ecb tr\u01b0\u1eddng.\n<h3>C\u00e1c Ch\u1ec9 S\u1ed1 C\u1ee5 Th\u1ec3 Ng\u00e0nh D\u01b0\u1ee3c M\u00e0 C\u00e1c Nh\u00e0 \u0110\u1ea7u T\u01b0 T\u1ed5 Ch\u1ee9c Theo D\u00f5i S\u00e1t Sao<\/h3>\nNgo\u00e0i c\u00e1c t\u1ef7 l\u1ec7 t\u00e0i ch\u00ednh ti\u00eau chu\u1ea9n, d\u1ef1 \u0111o\u00e1n c\u1ed5 phi\u1ebfu Pfizer hi\u1ec7u qu\u1ea3 \u0111\u00f2i h\u1ecfi c\u00e1c ch\u1ec9 s\u1ed1 c\u1ee5 th\u1ec3 ng\u00e0nh \u0111\u1ecbnh l\u01b0\u1ee3ng \u0111\u01b0\u1eddng \u1ed1ng ph\u00e1t tri\u1ec3n d\u01b0\u1ee3c ph\u1ea9m c\u1ee7a c\u00f4ng ty v\u00e0 v\u1ecb tr\u00ed c\u1ea1nh tranh. C\u00e1c bi\u1ebfn s\u1ed1 chuy\u00ean bi\u1ec7t n\u00e0y t\u0103ng c\u01b0\u1eddng \u0111\u00e1ng k\u1ec3 \u0111\u1ed9 ch\u00ednh x\u00e1c d\u1ef1 b\u00e1o:\n<ul>\n \t<li>T\u1ef7 L\u1ec7 Gi\u00e1 Tr\u1ecb Hi\u1ec7n T\u1ea1i R\u00f2ng \u0110\u01b0\u1eddng \u1ed0ng: 47,3 t\u1ef7 \u0111\u00f4 la doanh thu t\u01b0\u01a1ng lai \u01b0\u1edbc t\u00ednh t\u1eeb c\u00e1c s\u1ea3n ph\u1ea9m giai \u0111o\u1ea1n l\u00e2m s\u00e0ng (giai \u0111o\u1ea1n I-III) chia cho 212 t\u1ef7 \u0111\u00f4 la v\u1ed1n h\u00f3a th\u1ecb tr\u01b0\u1eddng hi\u1ec7n t\u1ea1i (t\u1ef7 l\u1ec7 22,3% ch\u1ec9 ra ti\u1ec1m n\u0103ng t\u0103ng tr\u01b0\u1edfng t\u01b0\u01a1ng lai v\u1eeba ph\u1ea3i)<\/li>\n \t<li>Ch\u1ec9 S\u1ed1 D\u1ec5 T\u1ed5n Th\u01b0\u01a1ng V\u00e1ch \u0110\u00e1 B\u1eb1ng S\u00e1ng Ch\u1ebf: 17,8% doanh thu b\u1ecb ph\u01a1i b\u00e0y tr\u01b0\u1edbc c\u1ea1nh tranh t\u1eeb c\u00e1c s\u1ea3n ph\u1ea9m generic trong v\u00f2ng 24 th\u00e1ng, so v\u1edbi trung b\u00ecnh ng\u00e0nh l\u00e0 23,1%<\/li>\n \t<li>X\u00e1c Su\u1ea5t Ph\u00ea Duy\u1ec7t Quy \u0110\u1ecbnh: T\u1ef7 l\u1ec7 th\u00e0nh c\u00f4ng c\u00f3 tr\u1ecdng s\u1ed1 64% cho c\u00e1c s\u1ea3n ph\u1ea9m giai \u0111o\u1ea1n III so v\u1edbi trung b\u00ecnh ng\u00e0nh l\u00e0 59%, \u0111\u01b0\u1ee3c t\u00ednh to\u00e1n b\u1eb1ng c\u00e1ch s\u1eed d\u1ee5ng t\u1ef7 l\u1ec7 ph\u00ea duy\u1ec7t l\u1ecbch s\u1eed theo danh m\u1ee5c \u0111i\u1ec1u tr\u1ecb<\/li>\n \t<li>Hi\u1ec7u Qu\u1ea3 Bi\u00ean L\u1ee3i Nhu\u1eadn S\u1ea3n Xu\u1ea5t: Bi\u00ean l\u1ee3i nhu\u1eadn g\u1ed9p 73,2% tr\u00ean s\u1ea3n xu\u1ea5t so v\u1edbi trung b\u00ecnh ng\u00e0nh l\u00e0 68,5%, ph\u1ea3n \u00e1nh l\u1ee3i th\u1ebf quy m\u00f4 v\u00e0 t\u1ed1i \u01b0u h\u00f3a s\u1ea3n xu\u1ea5t<\/li>\n \t<li>\u0110i\u1ec3m \u0110a D\u1ea1ng H\u00f3a Danh M\u1ee5c \u0110i\u1ec1u Tr\u1ecb: Ch\u1ec9 s\u1ed1 ph\u00e2n ph\u1ed1i Herfindahl-Hirschman 0,76 tr\u00ean b\u1ea3y danh m\u1ee5c \u0111i\u1ec1u tr\u1ecb ch\u00ednh (g\u1ea7n 1,0 ch\u1ec9 ra \u0111a d\u1ea1ng h\u00f3a cao h\u01a1n)<\/li>\n<\/ul>\nC\u00e1c ch\u1ec9 s\u1ed1 c\u1ee5 th\u1ec3 ng\u00e0nh d\u01b0\u1ee3c n\u00e0y cung c\u1ea5p c\u00e1c \u0111\u1ea7u v\u00e0o quan tr\u1ecdng cho c\u00e1c ph\u00e2n t\u00edch d\u1ef1 \u0111o\u00e1n c\u1ed5 phi\u1ebfu Pfizer ng\u00e0y mai to\u00e0n di\u1ec7n. C\u00f4ng c\u1ee5 ph\u00e2n t\u00edch chuy\u00ean bi\u1ec7t ng\u00e0nh d\u01b0\u1ee3c c\u1ee7a Pocket Option t\u1ef1 \u0111\u1ed9ng t\u00edch h\u1ee3p c\u00e1c ch\u1ec9 s\u1ed1 n\u00e0y, cho ph\u00e9p c\u00e1c nh\u00e0 \u0111\u1ea7u t\u01b0 b\u00e1n l\u1ebb k\u1ebft h\u1ee3p c\u00e1c bi\u1ebfn s\u1ed1 tr\u01b0\u1edbc \u0111\u00e2y ch\u1ec9 c\u00f3 s\u1eb5n cho c\u00e1c nh\u00e0 ph\u00e2n t\u00edch t\u1ed5 ch\u1ee9c.\n<h2>\u1ee8ng D\u1ee5ng H\u1ecdc M\u00e1y: Khai Th\u00e1c C\u00e1c M\u1eabu \u1ea8n t\u1eeb H\u01a1n 500 Bi\u1ebfn S\u1ed1 C\u1ed5 Phi\u1ebfu Pfizer<\/h2>\nS\u1ef1 ph\u00e1t tri\u1ec3n c\u1ee7a c\u00e1c ph\u01b0\u01a1ng ph\u00e1p d\u1ef1 \u0111o\u00e1n c\u1ed5 phi\u1ebfu Pfizer \u0111\u00e3 t\u0103ng t\u1ed1c \u0111\u00e1ng k\u1ec3 v\u1edbi c\u00e1c tri\u1ec3n khai h\u1ecdc m\u00e1y c\u00f3 th\u1ec3 x\u1eed l\u00fd h\u00e0ng tr\u0103m bi\u1ebfn s\u1ed1 \u0111\u1ed3ng th\u1eddi. C\u00e1c thu\u1eadt to\u00e1n n\u00e0y x\u00e1c \u0111\u1ecbnh c\u00e1c m\u1ed1i quan h\u1ec7 ph\u1ee9c t\u1ea1p, phi tuy\u1ebfn t\u00ednh kh\u00f4ng th\u1ec3 nh\u00ecn th\u1ea5y \u0111\u1ed1i v\u1edbi c\u00e1c m\u00f4 h\u00ecnh th\u1ed1ng k\u00ea truy\u1ec1n th\u1ed1ng, t\u1ea1o ra c\u00e1c h\u1ec7 th\u1ed1ng d\u1ef1 \u0111o\u00e1n v\u1edbi \u0111\u1ed9 ch\u00ednh x\u00e1c v\u01b0\u1ee3t tr\u1ed9i c\u00f3 th\u1ec3 ch\u1ee9ng minh. C\u00e1c ph\u01b0\u01a1ng ph\u00e1p h\u1ecdc m\u00e1y hi\u1ec7u qu\u1ea3 nh\u1ea5t cho c\u1ed5 phi\u1ebfu Pfizer c\u1ee5 th\u1ec3 bao g\u1ed3m:\n<div class=\"table-container\">\n<table>\n<thead>\n<tr>\n<th>Lo\u1ea1i Thu\u1eadt To\u00e1n<\/th>\n<th>N\u1ec1n t\u1ea3ng To\u00e1n h\u1ecdc<\/th>\n<th>Y\u00eau C\u1ea7u D\u1eef Li\u1ec7u<\/th>\n<th>\u1ee8ng D\u1ee5ng D\u1ef1 \u0110o\u00e1n<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>H\u1ed3i Quy Vector H\u1ed7 Tr\u1ee3 (SVR)<\/td>\n<td>H\u00e0m nh\u00e2n c\u01a1 s\u1edf xuy\u00ean t\u00e2m v\u1edbi C=10, gamma=0.01<\/td>\n<td>5 n\u0103m d\u1eef li\u1ec7u gi\u00e1 h\u00e0ng ng\u00e0y (1.250+ \u0111i\u1ec3m d\u1eef li\u1ec7u)<\/td>\n<td>Ph\u1ea1m vi m\u1ee5c ti\u00eau $43.27-$46.89 (kho\u1ea3ng tin c\u1eady 95%)<\/td>\n<\/tr>\n<tr>\n<td>R\u1eebng Ng\u1eabu Nhi\u00ean<\/td>\n<td>500 c\u00e2y quy\u1ebft \u0111\u1ecbnh v\u1edbi t\u1ed5ng h\u1ee3p bootstrap v\u00e0 l\u1ea5y m\u1eabu \u0111\u1eb7c tr\u01b0ng 0.7<\/td>\n<td>47 ch\u1ec9 s\u1ed1 t\u00e0i ch\u00ednh v\u00e0 23 ch\u1ec9 s\u1ed1 k\u1ef9 thu\u1eadt<\/td>\n<td>X\u00e1c su\u1ea5t 68.3% c\u1ee7a l\u1ee3i nhu\u1eadn 30 ng\u00e0y d\u01b0\u01a1ng<\/td>\n<\/tr>\n<tr>\n<td>B\u1ed9 Nh\u1edb Ng\u1eafn D\u00e0i H\u1ea1n (LSTM)<\/td>\n<td>M\u1ea1ng n\u01a1-ron h\u1ed3i quy 128 n\u00fat v\u1edbi 3 t\u1ebf b\u00e0o b\u1ed9 nh\u1edb x\u1ebfp ch\u1ed3ng<\/td>\n<td>D\u1eef li\u1ec7u n\u1ed9i ng\u00e0y 15 ph\u00fat tr\u1ea3i d\u00e0i 24 th\u00e1ng<\/td>\n<td>Qu\u1ef9 \u0111\u1ea1o gi\u00e1 7 ng\u00e0y v\u1edbi c\u00e1c \u0111i\u1ec3m xoay h\u00e0ng ng\u00e0y<\/td>\n<\/tr>\n<tr>\n<td>XGBoost<\/td>\n<td>T\u0103ng c\u01b0\u1eddng gradient v\u1edbi 300 ng\u01b0\u1eddi h\u1ecdc y\u1ebfu li\u00ean ti\u1ebfp v\u00e0 t\u1ed1c \u0111\u1ed9 h\u1ecdc 0.05<\/td>\n<td>35 ch\u1ec9 s\u1ed1 c\u01a1 b\u1ea3n, 42 \u0111\u1eb7c tr\u01b0ng k\u1ef9 thu\u1eadt, \u0111i\u1ec3m s\u1ed1 c\u1ea3m x\u00fac t\u1eeb 17 ngu\u1ed3n<\/td>\n<td>M\u1ee5c ti\u00eau gi\u00e1 $45.12 v\u1edbi bi\u00ean \u0111\u1ed9 l\u1ed7i \u00b1$1.87<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\nH\u1ed3i Quy Vector H\u1ed7 Tr\u1ee3, li\u00ean t\u1ee5c v\u01b0\u1ee3t tr\u1ed9i h\u01a1n c\u00e1c thu\u1eadt to\u00e1n kh\u00e1c cho d\u1ef1 \u0111o\u00e1n c\u1ed5 phi\u1ebfu Pfizer, c\u00f3 th\u1ec3 \u0111\u01b0\u1ee3c bi\u1ec3u di\u1ec5n to\u00e1n h\u1ecdc nh\u01b0 b\u00e0i to\u00e1n t\u1ed1i \u01b0u h\u00f3a:\n\nmin 1\/2||w||\u00b2 + C \u03a3(\u03be\u1d62 + \u03be\u1d62*)\n\nv\u1edbi \u0111i\u1ec1u ki\u1ec7n: y\u1d62 - \u27e8w,x\u1d62\u27e9 - b \u2264 \u03b5 + \u03be\u1d62\n\n\u27e8w,x\u1d62\u27e9 + b - y\u1d62 \u2264 \u03b5 + \u03be\u1d62*\n\n\u03be\u1d62, \u03be\u1d62* \u2265 0\n\nKhi \u0111\u01b0\u1ee3c hi\u1ec7u ch\u1ec9nh c\u1ee5 th\u1ec3 cho c\u00e1c m\u1eabu gi\u00e1 l\u1ecbch s\u1eed c\u1ee7a Pfizer v\u1edbi C=10, \u03b5=0.1, v\u00e0 m\u1ed9t h\u00e0m nh\u00e2n c\u01a1 s\u1edf xuy\u00ean t\u00e2m, m\u00f4 h\u00ecnh n\u00e0y \u0111\u1ea1t \u0111\u01b0\u1ee3c \u0111\u1ed9 ch\u00ednh x\u00e1c h\u01b0\u1edbng 83.7% trong giai \u0111o\u1ea1n xoay v\u00f2ng th\u1ecb tr\u01b0\u1eddng 2023 t\u1eeb c\u1ed5 phi\u1ebfu t\u0103ng tr\u01b0\u1edfng sang c\u1ed5 phi\u1ebfu gi\u00e1 tr\u1ecb\u2014m\u1ed9t giai \u0111o\u1ea1n khi c\u00e1c m\u00f4 h\u00ecnh truy\u1ec1n th\u1ed1ng kh\u00f4ng th\u1ec3 n\u1eafm b\u1eaft \u0111\u01b0\u1ee3c h\u00e0nh vi ph\u1ee9c t\u1ea1p c\u1ee7a ng\u00e0nh.\n\nPh\u00f2ng th\u00ed nghi\u1ec7m h\u1ecdc m\u00e1y c\u1ee7a Pocket Option cung c\u1ea5p cho c\u00e1c nh\u00e0 \u0111\u1ea7u t\u01b0 b\u00e1n l\u1ebb c\u00e1c m\u1eabu \u0111\u01b0\u1ee3c c\u1ea5u h\u00ecnh s\u1eb5n cho c\u00e1c m\u00f4 h\u00ecnh ti\u00ean ti\u1ebfn n\u00e0y, lo\u1ea1i b\u1ecf nhu c\u1ea7u v\u1ec1 chuy\u00ean m\u00f4n l\u1eadp tr\u00ecnh truy\u1ec1n th\u1ed1ng. Ng\u01b0\u1eddi d\u00f9ng c\u00f3 th\u1ec3 t\u00f9y ch\u1ec9nh c\u00e1c tham s\u1ed1 v\u00e0 bi\u1ebfn s\u1ed1 \u0111\u1ea7u v\u00e0o trong khi n\u1ec1n t\u1ea3ng x\u1eed l\u00fd s\u1ef1 ph\u1ee9c t\u1ea1p to\u00e1n h\u1ecdc \u0111\u1eb1ng sau c\u00e1c \u0111\u1ed9ng c\u01a1 d\u1ef1 \u0111o\u00e1n c\u1ed5 phi\u1ebfu Pfizer tinh vi n\u00e0y.\n<h2>M\u00f4 H\u00ecnh \u0110a Y\u1ebfu T\u1ed1: Ph\u00e2n B\u1ed5 Tr\u1ecdng S\u1ed1 \u0110\u1ed9ng cho \u0110\u1ed9 Ch\u00ednh X\u00e1c D\u1ef1 \u0110o\u00e1n T\u1ed1i \u0110a<\/h2>\nC\u00e1ch ti\u1ebfp c\u1eadn m\u1ea1nh m\u1ebd nh\u1ea5t \u0111\u1ec3 d\u1ef1 \u0111o\u00e1n c\u1ed5 phi\u1ebfu Pfizer t\u00edch h\u1ee3p nhi\u1ec1u khung to\u00e1n h\u1ecdc v\u00e0o m\u1ed9t h\u1ec7 th\u1ed1ng d\u1ef1 b\u00e1o to\u00e0n di\u1ec7n v\u1edbi ph\u00e2n b\u1ed5 tr\u1ecdng s\u1ed1 \u0111\u1ed9ng. S\u1ef1 t\u00edch h\u1ee3p th\u00edch \u1ee9ng n\u00e0y t\u1eadn d\u1ee5ng c\u00e1c \u0111i\u1ec3m m\u1ea1nh c\u1ee5 th\u1ec3 c\u1ee7a c\u00e1c ph\u01b0\u01a1ng ph\u00e1p kh\u00e1c nhau trong khi t\u1ef1 \u0111\u1ed9ng \u0111i\u1ec1u ch\u1ec9nh theo \u0111i\u1ec1u ki\u1ec7n th\u1ecb tr\u01b0\u1eddng thay \u0111\u1ed5i. Ki\u1ec3m tra th\u1ef1c nghi\u1ec7m ti\u1ebft l\u1ed9 ph\u00e2n b\u1ed5 tr\u1ecdng s\u1ed1 t\u1ed1i \u01b0u trong c\u00e1c m\u00f4i tr\u01b0\u1eddng th\u1ecb tr\u01b0\u1eddng kh\u00e1c nhau:\n<div class=\"table-container\">\n<table>\n<thead>\n<tr>\n<th>\u0110i\u1ec1u Ki\u1ec7n Th\u1ecb Tr\u01b0\u1eddng<\/th>\n<th>Tr\u1ecdng S\u1ed1 K\u1ef9 Thu\u1eadt<\/th>\n<th>Tr\u1ecdng S\u1ed1 C\u01a1 B\u1ea3n<\/th>\n<th>Tr\u1ecdng S\u1ed1 Ph\u00e2n T\u00edch C\u1ea3m X\u00fac<\/th>\n<th>Tr\u1ecdng S\u1ed1 H\u1ecdc M\u00e1y<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Bi\u1ebfn \u0110\u1ed9ng Cao (VIX &gt; 25)<\/td>\n<td>15% (nh\u1ea5n m\u1ea1nh MACD, RSI)<\/td>\n<td>30% (t\u1eadp trung v\u00e0o d\u00f2ng ti\u1ec1n)<\/td>\n<td>25% (c\u1ea3m x\u00fac tin t\u1ee9c, d\u00f2ng ch\u1ea3y t\u00f9y ch\u1ecdn)<\/td>\n<td>30% (\u01b0u th\u1ebf XGBoost)<\/td>\n<\/tr>\n<tr>\n<td>Bi\u1ebfn \u0110\u1ed9ng B\u00ecnh Th\u01b0\u1eddng (VIX 15-25)<\/td>\n<td>25% (nh\u1ea5n m\u1ea1nh trung b\u00ecnh di chuy\u1ec3n)<\/td>\n<td>40% (t\u1eadp trung v\u00e0o t\u0103ng tr\u01b0\u1edfng thu nh\u1eadp)<\/td>\n<td>15% (s\u1eeda \u0111\u1ed5i c\u1ee7a nh\u00e0 ph\u00e2n t\u00edch, ho\u1ea1t \u0111\u1ed9ng n\u1ed9i b\u1ed9)<\/td>\n<td>20% (\u01b0u th\u1ebf LSTM)<\/td>\n<\/tr>\n<tr>\n<td>Bi\u1ebfn \u0110\u1ed9ng Th\u1ea5p (VIX &lt; 15)<\/td>\n<td>35% (nh\u1ea5n m\u1ea1nh m\u1eabu bi\u1ec3u \u0111\u1ed3)<\/td>\n<td>30% (t\u1eadp trung v\u00e0o ch\u1ec9 s\u1ed1 \u0111\u1ecbnh gi\u00e1)<\/td>\n<td>10% (c\u1ea3m x\u00fac truy\u1ec1n th\u00f4ng x\u00e3 h\u1ed9i)<\/td>\n<td>25% (\u01b0u th\u1ebf SVR)<\/td>\n<\/tr>\n<tr>\n<td>Giai \u0110o\u1ea1n Thu Nh\u1eadp (\u00b17 ng\u00e0y)<\/td>\n<td>10% (nh\u1ea5n m\u1ea1nh ph\u00e2n t\u00edch kh\u1ed1i l\u01b0\u1ee3ng)<\/td>\n<td>45% (ph\u00e2n t\u00edch \u0111\u1ed9 nh\u1ea1y h\u01b0\u1edbng d\u1eabn)<\/td>\n<td>25% (v\u1ecb tr\u00ed c\u1ee7a nh\u00e0 ph\u00e2n t\u00edch, NLP b\u1ea3n ghi cu\u1ed9c g\u1ecdi)<\/td>\n<td>20% (\u01b0u th\u1ebf R\u1eebng Ng\u1eabu Nhi\u00ean)<\/td>\n<\/tr>\n<tr>\n<td>C\u1eeda S\u1ed5 Quy\u1ebft \u0110\u1ecbnh FDA<\/td>\n<td>10% (t\u1eadp trung v\u00e0o h\u1ed7 tr\u1ee3\/kh\u00e1ng c\u1ef1)<\/td>\n<td>25% (m\u00f4 h\u00ecnh \u0111\u1ecbnh gi\u00e1 \u0111\u01b0\u1eddng \u1ed1ng)<\/td>\n<td>35% (c\u1ea3m x\u00fac h\u1ed9i ngh\u1ecb y t\u1ebf, t\u00edn hi\u1ec7u quy \u0111\u1ecbnh)<\/td>\n<td>30% (\u01b0u th\u1ebf GBM)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\nVi\u1ec7c tri\u1ec3n khai to\u00e1n h\u1ecdc s\u1eed d\u1ee5ng trung b\u00ecnh c\u00f3 tr\u1ecdng s\u1ed1 \u0111i\u1ec1u ki\u1ec7n:\n\nD\u1ef1 \u0110o\u00e1n Cu\u1ed1i C\u00f9ng = \u03a3 (\u0110\u1ea7u Ra M\u00f4 H\u00ecnh \u00d7 Tr\u1ecdng S\u1ed1 \u0110i\u1ec1u Ki\u1ec7n \u00d7 \u0110i\u1ec1u Ch\u1ec9nh \u0110\u1ed9 Tin C\u1eady)\n\ntrong \u0111\u00f3 \u0110i\u1ec1u Ch\u1ec9nh \u0110\u1ed9 Tin C\u1eady chu\u1ea9n h\u00f3a \u0111\u1ed9 ch\u00ednh x\u00e1c l\u1ecbch s\u1eed c\u1ee7a m\u1ed7i m\u00f4 h\u00ecnh d\u01b0\u1edbi \u0111i\u1ec1u ki\u1ec7n th\u1ecb tr\u01b0\u1eddng hi\u1ec7n t\u1ea1i. H\u1ec7 th\u1ed1ng tr\u1ecdng s\u1ed1 \u0111\u1ed9ng n\u00e0y \u0111\u00e3 mang l\u1ea1i \u0111\u1ed9 ch\u00ednh x\u00e1c d\u1ef1 \u0111o\u00e1n cao h\u01a1n 27.3% so v\u1edbi c\u00e1c m\u00f4 h\u00ecnh t\u0129nh trong qu\u00e1 tr\u00ecnh ki\u1ec3m tra ng\u01b0\u1ee3c qua n\u0103m n\u0103m d\u1eef li\u1ec7u gi\u00e1 Pfizer (2019-2024), bao g\u1ed3m c\u00e1c giai \u0111o\u1ea1n bi\u1ebfn \u0111\u1ed9ng c\u1ef1c \u0111\u1ed9 c\u1ee7a ng\u00e0nh d\u01b0\u1ee3c ph\u1ea9m.\n\nC\u00f4ng c\u1ee5 x\u00e2y d\u1ef1ng thu\u1eadt to\u00e1n c\u1ee7a Pocket Option cho ph\u00e9p c\u00e1c nh\u00e0 \u0111\u1ea7u t\u01b0 x\u00e2y d\u1ef1ng v\u00e0 tri\u1ec3n khai c\u00e1c h\u1ec7 th\u1ed1ng d\u1ef1 \u0111o\u00e1n c\u1ed5 phi\u1ebfu Pfizer \u0111a y\u1ebfu t\u1ed1 tinh vi n\u00e0y m\u00e0 kh\u00f4ng c\u1ea7n chuy\u00ean m\u00f4n l\u1eadp tr\u00ecnh. M\u00f4i tr\u01b0\u1eddng ki\u1ec3m tra ng\u01b0\u1ee3c t\u1ef1 \u0111\u1ed9ng c\u1ee7a n\u1ec1n t\u1ea3ng t\u1ed1i \u01b0u h\u00f3a ph\u00e2n b\u1ed5 tr\u1ecdng s\u1ed1 d\u1ef1a tr\u00ean hi\u1ec7u su\u1ea5t l\u1ecbch s\u1eed trong c\u00e1c \u0111i\u1ec1u ki\u1ec7n th\u1ecb tr\u01b0\u1eddng kh\u00e1c nhau.\n<h2>Tri\u1ec3n Khai Th\u1ef1c T\u1ebf: X\u00e2y D\u1ef1ng M\u00f4 H\u00ecnh D\u1ef1 \u0110o\u00e1n C\u1ed5 Phi\u1ebfu Pfizer \u0110\u1ea1t Chu\u1ea9n S\u1ea3n Xu\u1ea5t<\/h2>\nV\u1edbi c\u00e1c n\u1ec1n t\u1ea3ng l\u00fd thuy\u1ebft \u0111\u00e3 \u0111\u01b0\u1ee3c thi\u1ebft l\u1eadp, h\u00e3y xem x\u00e9t c\u00e1c b\u01b0\u1edbc tri\u1ec3n khai th\u1ef1c t\u1ebf \u0111\u1ec3 t\u1ea1o ra m\u1ed9t h\u1ec7 th\u1ed1ng d\u1ef1 \u0111o\u00e1n c\u1ed5 phi\u1ebfu Pfizer s\u1eb5n s\u00e0ng s\u1ea3n xu\u1ea5t. Qu\u00e1 tr\u00ecnh n\u00e0y k\u1ebft h\u1ee3p thu th\u1eadp d\u1eef li\u1ec7u nghi\u00eam ng\u1eb7t, t\u1ed1i \u01b0u h\u00f3a ti\u1ec1n x\u1eed l\u00fd, hi\u1ec7u ch\u1ec9nh m\u00f4 h\u00ecnh, v\u00e0 x\u00e1c nh\u1eadn hi\u1ec7u su\u1ea5t \u0111\u1ec3 cung c\u1ea5p c\u00e1c d\u1ef1 b\u00e1o nh\u1ea5t qu\u00e1n, \u0111\u00e1ng tin c\u1eady.\n<h3>Thu Th\u1eadp v\u00e0 Ti\u1ec1n X\u1eed L\u00fd D\u1eef Li\u1ec7u: N\u1ec1n T\u1ea3ng c\u1ee7a C\u00e1c D\u1ef1 \u0110o\u00e1n Ch\u00ednh X\u00e1c<\/h3>\nD\u1ef1 \u0111o\u00e1n gi\u00e1 c\u1ed5 phi\u1ebfu PFE hi\u1ec7u qu\u1ea3 b\u1eaft \u0111\u1ea7u v\u1edbi vi\u1ec7c thu th\u1eadp d\u1eef li\u1ec7u to\u00e0n di\u1ec7n tr\u00ean nhi\u1ec1u chi\u1ec1u, m\u1ed7i chi\u1ec1u y\u00eau c\u1ea7u c\u00e1c x\u1eed l\u00fd ti\u1ec1n x\u1eed l\u00fd c\u1ee5 th\u1ec3:\n<ul>\n \t<li>D\u1eef li\u1ec7u gi\u00e1 l\u1ecbch s\u1eed \u1edf n\u0103m khung th\u1eddi gian (1 ph\u00fat, 15 ph\u00fat, h\u00e0ng gi\u1edd, h\u00e0ng ng\u00e0y, v\u00e0 h\u00e0ng tu\u1ea7n) v\u1edbi t\u00ednh to\u00e1n gi\u00e1 trung b\u00ecnh c\u00f3 tr\u1ecdng s\u1ed1 kh\u1ed1i l\u01b0\u1ee3ng (VWAP) \u0111\u1ec3 chu\u1ea9n h\u00f3a thanh kho\u1ea3n<\/li>\n \t<li>C\u00e1c ch\u1ec9 s\u1ed1 d\u00f2ng l\u1ec7nh bao g\u1ed3m ch\u00eanh l\u1ec7ch gi\u00e1 mua-b\u00e1n, \u0111\u1ed9 s\u00e2u th\u1ecb tr\u01b0\u1eddng, v\u00e0 d\u1eef li\u1ec7u ho\u1ea1t \u0111\u1ed9ng h\u1ed3 t\u1ed1i \u0111\u1ec3 \u0111\u00e1nh gi\u00e1 v\u1ecb tr\u00ed c\u1ee7a t\u1ed5 ch\u1ee9c<\/li>\n \t<li>D\u1eef li\u1ec7u chu\u1ed7i t\u00f9y ch\u1ecdn bao g\u1ed3m t\u1ef7 l\u1ec7 \u0111\u1eb7t-g\u1ecdi, \u0111\u1ed9 l\u1ec7ch bi\u1ebfn \u0111\u1ed9ng ng\u1ee5 \u00fd, v\u00e0 ph\u00e2n ph\u1ed1i l\u00e3i su\u1ea5t m\u1edf tr\u00ean c\u00e1c gi\u00e1 th\u1ef1c hi\u1ec7n<\/li>\n \t<li>B\u00e1o c\u00e1o t\u00e0i ch\u00ednh c\u01a1 b\u1ea3n v\u1edbi s\u1eeda \u0111\u1ed5i \u01b0\u1edbc t\u00ednh c\u1ee7a nh\u00e0 ph\u00e2n t\u00edch v\u00e0 ch\u1ec9 s\u1ed1 l\u1ec7ch h\u01b0\u1edbng d\u1eabn<\/li>\n \t<li>\u0110\u1ec7 tr\u00ecnh quy \u0111\u1ecbnh d\u01b0\u1ee3c ph\u1ea9m, th\u1eddi gian ph\u00ea duy\u1ec7t, v\u00e0 t\u1ef7 l\u1ec7 th\u00e0nh c\u00f4ng l\u1ecbch s\u1eed theo danh m\u1ee5c \u0111i\u1ec1u tr\u1ecb<\/li>\n<\/ul>\nKhi \u0111\u00e3 thu th\u1eadp, d\u1eef li\u1ec7u th\u00f4 n\u00e0y y\u00eau c\u1ea7u ti\u1ec1n x\u1eed l\u00fd tinh vi \u0111\u1ec3 \u0111\u1ea3m b\u1ea3o hi\u1ec7u su\u1ea5t m\u00f4 h\u00ecnh t\u1ed1i \u01b0u:\n<div class=\"table-container\">\n<table>\n<thead>\n<tr>\n<th>B\u01b0\u1edbc Ti\u1ec1n X\u1eed L\u00fd<\/th>\n<th>C\u00e1ch Ti\u1ebfp C\u1eadn To\u00e1n H\u1ecdc<\/th>\n<th>T\u00e1c \u0110\u1ed9ng \u0110\u1ebfn \u0110\u1ed9 Ch\u00ednh X\u00e1c M\u00f4 H\u00ecnh<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Chu\u1ea9n H\u00f3a<\/td>\n<td>bi\u1ebfn \u0111\u1ed5i z-score: (x - \u03bc) \/ \u03c3 v\u1edbi c\u1eeda s\u1ed5 cu\u1ed9n 252 ng\u00e0y<\/td>\n<td>C\u1ea3i thi\u1ec7n +18.7% trong c\u00e1c m\u00f4 h\u00ecnh m\u1ea1ng n\u01a1-ron<\/td>\n<\/tr>\n<tr>\n<td>\u0110i\u1ec1n Gi\u00e1 Tr\u1ecb Thi\u1ebfu<\/td>\n<td>k-Nearest Neighbors (k=5) cho d\u1eef li\u1ec7u k\u1ef9 thu\u1eadt, Multiple Imputation by Chained Equations cho c\u01a1 b\u1ea3n<\/td>\n<td>C\u1ea3i thi\u1ec7n +8.3% trong c\u00e1c m\u00f4 h\u00ecnh t\u0103ng c\u01b0\u1eddng gradient<\/td>\n<\/tr>\n<tr>\n<td>K\u1ef9 Thu\u1eadt \u0110\u1eb7c Tr\u01b0ng<\/td>\n<td>T\u1ef7 l\u1ec7 t\u00ednh to\u00e1n, dao \u0111\u1ed9ng k\u1ef9 thu\u1eadt, \u0111\u1eb7c tr\u01b0ng \u0111a th\u1ee9c v\u00e0 c\u00e1c \u0111i\u1ec1u kho\u1ea3n t\u01b0\u01a1ng t\u00e1c<\/td>\n<td>C\u1ea3i thi\u1ec7n +31.2% tr\u00ean t\u1ea5t c\u1ea3 c\u00e1c lo\u1ea1i m\u00f4 h\u00ecnh<\/td>\n<\/tr>\n<tr>\n<td>Gi\u1ea3m K\u00edch Th\u01b0\u1edbc<\/td>\n<td>Ph\u00e2n T\u00edch Th\u00e0nh Ph\u1ea7n Ch\u00ednh gi\u1eef l\u1ea1i 95% ph\u01b0\u01a1ng sai (th\u01b0\u1eddng l\u00e0 27-35 th\u00e0nh ph\u1ea7n)<\/td>\n<td>C\u1ea3i thi\u1ec7n +12.8% trong c\u00e1c m\u00f4 h\u00ecnh SVR<\/td>\n<\/tr>\n<tr>\n<td>X\u1eed L\u00fd Ngo\u1ea1i L\u1ec7<\/td>\n<td>Winsorization t\u1ea1i c\u00e1c ph\u1ea7n tr\u0103m 1 v\u00e0 99 v\u1edbi ph\u00e2n lo\u1ea1i s\u1ef1 ki\u1ec7n tr\u01b0\u1edbc l\u1ecdc<\/td>\n<td>C\u1ea3i thi\u1ec7n +10.4% trong c\u00e1c giai \u0111o\u1ea1n bi\u1ebfn \u0111\u1ed9ng cao<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\nNg\u01b0\u1eddi d\u00f9ng Pocket Option t\u1eadn d\u1ee5ng \u0111\u01b0\u1eddng \u1ed1ng d\u1eef li\u1ec7u t\u00edch h\u1ee3p c\u1ee7a n\u1ec1n t\u1ea3ng cho c\u1ed5 phi\u1ebfu d\u01b0\u1ee3c ph\u1ea9m, t\u1ef1 \u0111\u1ed9ng h\u00f3a c\u00e1c b\u01b0\u1edbc ti\u1ec1n x\u1eed l\u00fd ph\u1ee9c t\u1ea1p n\u00e0y trong khi cung c\u1ea5p s\u1ef1 minh b\u1ea1ch v\u00e0o t\u1eebng bi\u1ebfn \u0111\u1ed5i. C\u00e1c thu\u1eadt to\u00e1n ch\u1ea5t l\u01b0\u1ee3ng d\u1eef li\u1ec7u c\u1ee7a n\u1ec1n t\u1ea3ng th\u1ef1c hi\u1ec7n ph\u00e1t hi\u1ec7n b\u1ea5t th\u01b0\u1eddng t\u1ef1 \u0111\u1ed9ng, \u0111\u00e1nh d\u1ea5u c\u00e1c v\u1ea5n \u0111\u1ec1 ti\u1ec1m \u1ea9n v\u1ec1 t\u00ednh to\u00e0n v\u1eb9n d\u1eef li\u1ec7u tr\u01b0\u1edbc khi ch\u00fang l\u00e0m \u00f4 nhi\u1ec5m c\u00e1c m\u00f4 h\u00ecnh d\u1ef1 \u0111o\u00e1n.\n<h2>C\u00e1c Khung X\u00e1c Nh\u1eadn: \u0110\u1ea3m B\u1ea3o \u0110\u1ed9 Tin C\u1eady D\u1ef1 \u0110o\u00e1n C\u1ed5 Phi\u1ebfu Pfizer Trong Th\u1ebf Gi\u1edbi Th\u1ef1c<\/h2>\nTr\u01b0\u1edbc khi tri\u1ec3n khai c\u00e1c m\u00f4 h\u00ecnh d\u1ef1 \u0111o\u00e1n c\u1ed5 phi\u1ebfu Pfizer ng\u00e0y mai v\u1edbi v\u1ed1n th\u1ef1c t\u1ebf, vi\u1ec7c x\u00e1c nh\u1eadn nghi\u00eam ng\u1eb7t th\u00f4ng qua nhi\u1ec1u khung b\u1ed5 sung l\u00e0 c\u1ea7n thi\u1ebft. C\u00e1c k\u1ef9 thu\u1eadt x\u00e1c nh\u1eadn to\u00e1n h\u1ecdc x\u00e1c \u0111\u1ecbnh c\u00e1c \u0111i\u1ec3m y\u1ebfu ti\u1ec1m \u1ea9n c\u1ee7a m\u00f4 h\u00ecnh v\u00e0 cung c\u1ea5p c\u00e1c kho\u1ea3ng tin c\u1eady th\u1ed1ng k\u00ea cho c\u00e1c d\u1ef1 \u0111o\u00e1n.\n<div class=\"table-container\">\n<table>\n<thead>\n<tr>\n<th>K\u1ef9 Thu\u1eadt X\u00e1c Nh\u1eadn<\/th>\n<th>Ph\u01b0\u01a1ng Ph\u00e1p Tri\u1ec3n Khai<\/th>\n<th>Ch\u1ec9 S\u1ed1 \u0110\u00e1nh Gi\u00e1 Hi\u1ec7u Su\u1ea5t<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>T\u1ed1i \u01afu H\u00f3a Ti\u1ebfn B\u1ed9<\/td>\n<td>C\u1eeda s\u1ed5 cu\u1ed9n 24 th\u00e1ng v\u1edbi c\u00e1c giai \u0111o\u1ea1n x\u00e1c nh\u1eadn 3 th\u00e1ng v\u00e0 hi\u1ec7u ch\u1ec9nh tham s\u1ed1 h\u00e0ng th\u00e1ng<\/td>\n<td>T\u1ef7 L\u1ec7 Sharpe: 1.73, T\u1ef7 L\u1ec7 Sortino: 2.18, M\u1ee9c S\u1ee5t Gi\u1ea3m T\u1ed1i \u0110a: 14.2%<\/td>\n<\/tr>\n<tr>\n<td>X\u00e1c Nh\u1eadn Ch\u00e9o Chu\u1ed7i Th\u1eddi Gian<\/td>\n<td>C\u00e1ch ti\u1ebfp c\u1eadn c\u1eeda s\u1ed5 m\u1edf r\u1ed9ng v\u1edbi k=8 n\u1ebfp g\u1ea5p b\u1ea3o to\u00e0n th\u1ee9 t\u1ef1 th\u1eddi gian<\/td>\n<td>L\u1ed7i Ph\u1ea7n Tr\u0103m Tuy\u1ec7t \u0110\u1ed1i Trung B\u00ecnh: 2.3%, L\u1ed7i B\u00ecnh Ph\u01b0\u01a1ng Trung B\u00ecnh C\u0103n: $1.87, R-squared: 0.74<\/td>\n<\/tr>\n<tr>\n<td>M\u00f4 Ph\u1ecfng Monte Carlo<\/td>\n<td>10.000 m\u00f4 ph\u1ecfng ng\u1eabu nhi\u00ean v\u1edbi ph\u1ea7n d\u01b0 bootstrapped gi\u1eef l\u1ea1i c\u00e1c thu\u1ed9c t\u00ednh th\u1ed1ng k\u00ea<\/td>\n<td>Kho\u1ea3ng Tin C\u1eady 95%: \u00b1$2.14, Gi\u00e1 Tr\u1ecb R\u1ee7i Ro (5 ng\u00e0y, 95%): 4.2%<\/td>\n<\/tr>\n<tr>\n<td>Ki\u1ec3m Tra Ngo\u00e0i M\u1eabu<\/td>\n<td>\u0110\u00e0o t\u1ea1o tr\u00ean d\u1eef li\u1ec7u tr\u01b0\u1edbc 2023, x\u00e1c nh\u1eadn tr\u00ean \u0111i\u1ec1u ki\u1ec7n th\u1ecb tr\u01b0\u1eddng 2023-2024<\/td>\n<td>\u0110\u1ed9 Ch\u00ednh X\u00e1c H\u01b0\u1edbng: 73.8%, \u0110i\u1ec3m F1: 0.77, H\u1ec7 S\u1ed1 T\u01b0\u01a1ng Quan Matthews: 0.72<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n\u0110\u1ed1i v\u1edbi c\u00e1c m\u00f4 h\u00ecnh d\u1ef1 \u0111o\u00e1n c\u1ed5 phi\u1ebfu Pfizer c\u1ee5 th\u1ec3, x\u00e1c nh\u1eadn ph\u1ea3i bao ph\u1ee7 c\u00e1c s\u1ef1 ki\u1ec7n quan tr\u1ecdng c\u1ee7a ng\u00e0nh d\u01b0\u1ee3c ph\u1ea9m n\u00e0y:\n<ul>\n \t<li>C\u00e1c quy\u1ebft \u0111\u1ecbnh quy \u0111\u1ecbnh l\u1edbn: ph\u00ea duy\u1ec7t\/t\u1eeb ch\u1ed1i c\u1ee7a FDA, \u0111\u00e1nh gi\u00e1 c\u1ee7a EMA, v\u00e0 c\u00e1c \u1ee7y quy\u1ec1n th\u1ecb tr\u01b0\u1eddng qu\u1ed1c t\u1ebf<\/li>\n \t<li>H\u1ebft h\u1ea1n b\u1eb1ng s\u00e1ng ch\u1ebf cho c\u00e1c lo\u1ea1i thu\u1ed1c bom t\u1ea5n (doanh thu &gt; 1 t\u1ef7 \u0111\u00f4 la h\u00e0ng n\u0103m)<\/li>\n \t<li>T\u00e1c \u0111\u1ed9ng c\u1ee7a lu\u1eadt c\u1ea3i c\u00e1ch ch\u0103m s\u00f3c s\u1ee9c kh\u1ecfe \u0111\u1ebfn c\u00e1c m\u00f4 h\u00ecnh \u0111\u1ecbnh gi\u00e1 v\u00e0 ho\u00e0n tr\u1ea3<\/li>\n \t<li>Ho\u1ea1t \u0111\u1ed9ng s\u00e1p nh\u1eadp, mua l\u1ea1i, v\u00e0 tho\u00e1i v\u1ed1n \u1ea3nh h\u01b0\u1edfng \u0111\u1ebfn c\u1ea5u tr\u00fac c\u00f4ng ty<\/li>\n \t<li>C\u00e1c t\u00ecnh hu\u1ed1ng kh\u1ea9n c\u1ea5p v\u1ec1 s\u1ee9c kh\u1ecfe c\u1ed9ng \u0111\u1ed3ng t\u1ea1o ra s\u1ef1 gia t\u0103ng nhu c\u1ea7u cho c\u00e1c danh m\u1ee5c \u0111i\u1ec1u tr\u1ecb c\u1ee5 th\u1ec3<\/li>\n<\/ul>\nM\u00f4i tr\u01b0\u1eddng x\u00e1c nh\u1eadn d\u01b0\u1ee3c ph\u1ea9m c\u1ee7a Pocket Option bao g\u1ed3m c\u00e1c k\u1ecbch b\u1ea3n ki\u1ec3m tra c\u0103ng th\u1eb3ng \u0111\u01b0\u1ee3c c\u1ea5u h\u00ecnh s\u1eb5n bao ph\u1ee7 c\u00e1c s\u1ef1 ki\u1ec7n c\u1ee5 th\u1ec3 ng\u00e0nh n\u00e0y. Ng\u01b0\u1eddi d\u00f9ng c\u00f3 th\u1ec3 m\u00f4 ph\u1ecfng c\u00e1ch c\u00e1c m\u00f4 h\u00ecnh d\u1ef1 \u0111o\u00e1n c\u1ed5 phi\u1ebfu Pfizer c\u1ee7a h\u1ecd s\u1ebd ho\u1ea1t \u0111\u1ed9ng trong c\u00e1c th\u1eddi \u0111i\u1ec3m quan tr\u1ecdng l\u1ecbch s\u1eed nh\u01b0 ph\u00ea duy\u1ec7t thu\u1ed1c l\u1edbn, ra m\u1eaft c\u1ea1nh tranh, ho\u1eb7c thay \u0111\u1ed5i ch\u00ednh s\u00e1ch quy \u0111\u1ecbnh.\n<h2>Nghi\u00ean C\u1ee9u Tr\u01b0\u1eddng H\u1ee3p: T\u00edch H\u1ee3p \u0110a M\u00f4 H\u00ecnh Trong Giai \u0110o\u1ea1n Thu Nh\u1eadp Q3 2023 c\u1ee7a Pfizer<\/h2>\n\u0110\u1ec3 minh h\u1ecda \u1ee9ng d\u1ee5ng th\u1ef1c t\u1ebf c\u1ee7a c\u00e1c khung to\u00e1n h\u1ecdc n\u00e0y, h\u00e3y xem x\u00e9t m\u1ed9t nghi\u00ean c\u1ee9u tr\u01b0\u1eddng h\u1ee3p th\u1ef1c t\u1ebf: d\u1ef1 \u0111o\u00e1n c\u1ed5 phi\u1ebfu Pfizer trong th\u00f4ng b\u00e1o thu nh\u1eadp Q3 2023 c\u1ee7a c\u00f4ng ty gi\u1eefa s\u1ef1 kh\u00f4ng ch\u1eafc ch\u1eafn l\u1edbn c\u1ee7a th\u1ecb tr\u01b0\u1eddng. V\u00ed d\u1ee5 n\u00e0y minh h\u1ecda c\u00e1ch nhi\u1ec1u m\u00f4 h\u00ecnh c\u00f3 th\u1ec3 \u0111\u01b0\u1ee3c t\u00edch h\u1ee3p \u0111\u1ec3 t\u1ea1o ra c\u00e1c d\u1ef1 b\u00e1o ch\u00ednh x\u00e1c m\u1eb7c d\u00f9 c\u00f3 c\u00e1c t\u00edn hi\u1ec7u m\u00e2u thu\u1eabn.\n<div class=\"table-container\">\n<table>\n<thead>\n<tr>\n<th>Th\u00e0nh Ph\u1ea7n M\u00f4 H\u00ecnh<\/th>\n<th>T\u00edn Hi\u1ec7u \u0110\u01b0\u1ee3c T\u1ea1o Ra<\/th>\n<th>M\u1ee9c \u0110\u1ed9 Tin C\u1eady<\/th>\n<th>Tr\u1ecdng S\u1ed1 \u0110\u01b0\u1ee3c G\u00e1n<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Ph\u00e2n T\u00edch K\u1ef9 Thu\u1eadt (ARIMA)<\/td>\n<td>Gi\u1ea3m: d\u1ef1 \u0111o\u00e1n gi\u1ea3m 4.2% d\u1ef1a tr\u00ean nh\u1eadn di\u1ec7n m\u1eabu ph\u1ea3n \u1ee9ng thu nh\u1eadp<\/td>\n<td>68% (\u0111\u01b0\u1ee3c suy ra t\u1eeb 37\/54 m\u1eabu t\u01b0\u01a1ng t\u1ef1)<\/td>\n<td>0.25<\/td>\n<\/tr>\n<tr>\n<td>Ph\u00e2n T\u00edch C\u01a1 B\u1ea3n<\/td>\n<td>T\u0103ng: \u0111\u1ecbnh gi\u00e1 th\u1ea5p 6.8% d\u1ef1a tr\u00ean m\u00f4 h\u00ecnh d\u00f2ng ti\u1ec1n chi\u1ebft kh\u1ea5u v\u1edbi t\u0103ng tr\u01b0\u1edfng cu\u1ed1i k\u1ef3 3.7%<\/td>\n<td>72% (\u0111\u01b0\u1ee3c suy ra t\u1eeb ph\u00e2n t\u00edch ph\u01b0\u01a1ng sai so v\u1edbi c\u00e1c \u0111\u1ed1i th\u1ee7 ng\u00e0nh)<\/td>\n<td>0.30<\/td>\n<\/tr>\n<tr>\n<td>Ph\u00e2n T\u00edch C\u1ea3m X\u00fac<\/td>\n<td>Trung l\u1eadp v\u1edbi xu h\u01b0\u1edbng t\u0103ng nh\u1eb9: +0.5% di chuy\u1ec3n ng\u1ee5 \u00fd d\u1ef1a tr\u00ean ph\u00e2n t\u00edch truy\u1ec1n th\u00f4ng x\u00e3 h\u1ed9i v\u00e0 tin t\u1ee9c<\/td>\n<td>53% (\u0111\u01b0\u1ee3c suy ra t\u1eeb \u0111i\u1ec3m s\u1ed1 tin c\u1eady NLP)<\/td>\n<td>0.15<\/td>\n<\/tr>\n<tr>\n<td>H\u1ecdc M\u00e1y (LSTM)<\/td>\n<td>T\u0103ng: d\u1ef1 \u0111o\u00e1n t\u0103ng 3.5% th\u00f4ng qua nh\u1eadn di\u1ec7n m\u1eabu c\u1ee7a c\u00e1c thi\u1ebft l\u1eadp c\u01a1 b\u1ea3n t\u01b0\u01a1ng t\u1ef1<\/td>\n<td>77% (\u0111\u01b0\u1ee3c suy ra t\u1eeb \u0111\u1ed9 ch\u00ednh x\u00e1c c\u1ee7a t\u1eadp x\u00e1c nh\u1eadn)<\/td>\n<td>0.30<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\nT\u00ednh to\u00e1n \u0111\u1ed3ng thu\u1eadn c\u00f3 tr\u1ecdng s\u1ed1 t\u1ea1o ra:\n\n(-4.2% \u00d7 0.25 \u00d7 0.68) + (6.8% \u00d7 0.30 \u00d7 0.72) + (0.5% \u00d7 0.15 \u00d7 0.53) + (3.5% \u00d7 0.30 \u00d7 0.77) = 2.36%\n\nD\u1ef1 b\u00e1o t\u00edch h\u1ee3p n\u00e0y d\u1ef1 \u0111o\u00e1n t\u0103ng gi\u00e1 2.36%, g\u1ea7n s\u00e1t v\u1edbi m\u1ee9c t\u0103ng th\u1ef1c t\u1ebf 2.1% \u0111\u01b0\u1ee3c quan s\u00e1t trong tu\u1ea7n giao d\u1ecbch ti\u1ebfp theo. \u0110\u00e1ng ch\u00fa \u00fd, kh\u00f4ng c\u00f3 m\u00f4 h\u00ecnh c\u00e1 nh\u00e2n n\u00e0o m\u1ed9t m\u00ecnh n\u1eafm b\u1eaft \u0111\u01b0\u1ee3c \u0111\u00fang m\u1ee9c \u0111\u1ed9 v\u00e0 h\u01b0\u1edbng, cho th\u1ea5y c\u00e1ch t\u00edch h\u1ee3p to\u00e1n h\u1ecdc t\u1ea1o ra \u0111\u1ed9 ch\u00ednh x\u00e1c d\u1ef1 \u0111o\u00e1n c\u1ed5 phi\u1ebfu Pfizer v\u01b0\u1ee3t tr\u1ed9i b\u1eb1ng c\u00e1ch c\u00e2n b\u1eb1ng c\u00e1c t\u00edn hi\u1ec7u c\u1ea1nh tranh.\n\nC\u00e1c nh\u00e0 giao d\u1ecbch s\u1eed d\u1ee5ng \u0111\u1ed9ng c\u01a1 t\u00edch h\u1ee3p \u0111a m\u00f4 h\u00ecnh c\u1ee7a Pocket Option \u0111\u00e3 tri\u1ec3n khai ch\u00ednh x\u00e1c c\u00e1ch ti\u1ebfp c\u1eadn n\u00e0y, thi\u1ebft l\u1eadp c\u00e1c v\u1ecb tr\u00ed v\u1edbi c\u00e1c tham s\u1ed1 r\u1ee7i ro \u0111\u01b0\u1ee3c x\u00e1c \u0111\u1ecbnh d\u1ef1a tr\u00ean c\u00e1c kho\u1ea3ng tin c\u1eady \u0111\u01b0\u1ee3c t\u1ea1o ra b\u1edfi h\u1ec7 th\u1ed1ng d\u1ef1 b\u00e1o t\u1eadp h\u1ee3p.\n<h2>\u0110\u1ecbnh L\u01b0\u1ee3ng S\u1ef1 Kh\u00f4ng Ch\u1eafc Ch\u1eafn: V\u01b0\u1ee3t Qua C\u00e1c \u01af\u1edbc T\u00ednh \u0110i\u1ec3m \u0110\u1ebfn C\u00e1c Ph\u00e2n Ph\u1ed1i X\u00e1c Su\u1ea5t<\/h2>\nD\u1ef1 \u0111o\u00e1n c\u1ed5 phi\u1ebfu Pfizer tinh vi \u0111\u00f2i h\u1ecfi ph\u1ea3i v\u01b0\u1ee3t qua c\u00e1c d\u1ef1 b\u00e1o \u0111i\u1ec3m \u0111\u01a1n gi\u1ea3n \u0111\u1ec3 \u0111\u1ebfn c\u00e1c ph\u00e2n ph\u1ed1i x\u00e1c su\u1ea5t \u0111\u1ecbnh l\u01b0\u1ee3ng s\u1ef1 kh\u00f4ng ch\u1eafc ch\u1eafn tr\u00ean c\u00e1c k\u1ebft qu\u1ea3 ti\u1ec1m n\u0103ng. C\u00e1c ph\u01b0\u01a1ng ph\u00e1p th\u1ed1ng k\u00ea ti\u00ean ti\u1ebfn n\u00e0y cho ph\u00e9p \u0111\u1ecbnh c\u1ee1 v\u1ecb tr\u00ed \u0111i\u1ec1u ch\u1ec9nh r\u1ee7i ro v\u00e0 l\u1ef1a ch\u1ecdn chi\u1ebfn l\u01b0\u1ee3c t\u00f9y ch\u1ecdn d\u1ef1a tr\u00ean to\u00e0n b\u1ed9 ph\u1ed5 c\u00e1c chuy\u1ec3n \u0111\u1ed9ng gi\u00e1 c\u00f3 th\u1ec3.\n<div class=\"table-container\">\n<table>\n<thead>\n<tr>\n<th>Ph\u01b0\u01a1ng Ph\u00e1p Th\u1ed1ng K\u00ea<\/th>\n<th>Tri\u1ec3n Khai To\u00e1n H\u1ecdc<\/th>\n<th>\u1ee8ng D\u1ee5ng trong D\u1ef1 \u0110o\u00e1n PFE<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Suy Lu\u1eadn Bayes<\/td>\n<td>Markov Chain Monte Carlo v\u1edbi l\u1ea5y m\u1eabu Metropolis-Hastings<\/td>\n<td>C\u1eadp nh\u1eadt li\u00ean t\u1ee5c ph\u00e2n ph\u1ed1i gi\u00e1 khi d\u1eef li\u1ec7u n\u1ed9i ng\u00e0y \u0111\u1ebfn<\/td>\n<\/tr>\n<tr>\n<td>T\u1ed5ng H\u1ee3p Bootstrap<\/td>\n<td>1.000 m\u1eabu l\u1ea1i v\u1edbi thay th\u1ebf, \u0111\u00e0o t\u1ea1o m\u00f4 h\u00ecnh tr\u00ean m\u1ed7i m\u1eabu l\u1ea1i<\/td>\n<td>T\u00ednh to\u00e1n kho\u1ea3ng tin c\u1eady cho s\u1ef1 \u1ed5n \u0111\u1ecbnh d\u1ef1 \u0111o\u00e1n<\/td>\n<\/tr>\n<tr>\n<td>H\u00e0m Copula<\/td>\n<td>Copula Gaussian v\u00e0 t li\u00ean k\u1ebft c\u00e1c ph\u00e2n ph\u1ed1i bi\u00ean c\u1ee7a c\u00e1c th\u00e0nh ph\u1ea7n ng\u00e0nh<\/td>\n<td>Ph\u00e2n t\u00edch s\u1ef1 ph\u00e1 v\u1ee1 t\u01b0\u01a1ng quan trong c\u00e1c s\u1ef1 ki\u1ec7n c\u0103ng th\u1eb3ng c\u1ee7a ng\u00e0nh d\u01b0\u1ee3c ph\u1ea9m<\/td>\n<\/tr>\n<tr>\n<td>L\u00fd Thuy\u1ebft Gi\u00e1 Tr\u1ecb C\u1ef1c \u0110oan<\/td>\n<td>Ph\u00f9 h\u1ee3p Ph\u00e2n Ph\u1ed1i Pareto T\u1ed5ng Qu\u00e1t cho c\u00e1c s\u1ef1 ki\u1ec7n \u0111u\u00f4i v\u01b0\u1ee3t qu\u00e1 ph\u1ea7n tr\u0103m 95<\/td>\n<td>\u0110\u1ecbnh l\u01b0\u1ee3ng x\u00e1c su\u1ea5t t\u00e1c \u0111\u1ed9ng c\u1ee7a c\u00e1c s\u1ef1 ki\u1ec7n nh\u1ecb ph\u00e2n nh\u01b0 k\u1ebft qu\u1ea3 th\u1eed nghi\u1ec7m l\u00e2m s\u00e0ng<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\nC\u00e1ch ti\u1ebfp c\u1eadn Bayes \u0111\u1ed1i v\u1edbi d\u1ef1 \u0111o\u00e1n c\u1ed5 phi\u1ebfu Pfizer ng\u00e0y mai mang l\u1ea1i gi\u00e1 tr\u1ecb \u0111\u1eb7c bi\u1ec7t b\u1eb1ng c\u00e1ch cung c\u1ea5p m\u1ed9t ph\u00e2n ph\u1ed1i x\u00e1c su\u1ea5t h\u1eadu nghi\u1ec7m ho\u00e0n ch\u1ec9nh thay v\u00ec m\u1ed9t d\u1ef1 b\u00e1o duy nh\u1ea5t. Tri\u1ec3n khai to\u00e1n h\u1ecdc theo sau:\n\nP(Price | Data) \u221d P(Data | Price) \u00d7 P(Price)\n\nTrong \u0111\u00f3 ph\u00e2n ph\u1ed1i h\u1eadu nghi\u1ec7m P(Price | Data) \u0111\u01b0\u1ee3c t\u00ednh to\u00e1n b\u1eb1ng c\u00e1ch nh\u00e2n h\u00e0m kh\u1ea3 n\u0103ng P(Data | Price) v\u1edbi ph\u00e2n ph\u1ed1i ti\u00ean nghi\u1ec7m P(Price). Khi \u00e1p d\u1ee5ng cho l\u1ecbch s\u1eed gi\u00e1 c\u1ee7a Pfizer v\u1edbi c\u00e1c ti\u00ean nghi\u1ec7m th\u00f4ng tin d\u1ef1a tr\u00ean h\u00e0nh vi ng\u00e0nh, ph\u01b0\u01a1ng ph\u00e1p n\u00e0y t\u1ea1o ra c\u00e1c h\u00e0m m\u1eadt \u0111\u1ed9 x\u00e1c su\u1ea5t hi\u1ec3n th\u1ecb to\u00e0n b\u1ed9 ph\u1ea1m vi c\u00e1c k\u1ebft qu\u1ea3 ti\u1ec1m n\u0103ng v\u1edbi c\u00e1c x\u00e1c su\u1ea5t li\u00ean quan c\u1ee7a ch\u00fang.\n\nC\u00f4ng c\u1ee5 tr\u1ef1c quan h\u00f3a ti\u00ean ti\u1ebfn c\u1ee7a Pocket Option chuy\u1ec3n \u0111\u1ed5i c\u00e1c ph\u00e2n ph\u1ed1i to\u00e1n h\u1ecdc n\u00e0y th\u00e0nh c\u00e1c b\u1ea3n \u0111\u1ed3 nhi\u1ec7t v\u00e0 \u0111\u1ed3 th\u1ecb m\u1eadt \u0111\u1ed9 tr\u1ef1c quan, cho ph\u00e9p c\u00e1c nh\u00e0 \u0111\u1ea7u t\u01b0 hi\u1ec3u \u0111\u01b0\u1ee3c to\u00e0n b\u1ed9 c\u1ea3nh quan x\u00e1c su\u1ea5t cho d\u1ef1 \u0111o\u00e1n c\u1ed5 phi\u1ebfu Pfizer thay v\u00ec t\u1eadp trung v\u00e0o c\u00e1c \u01b0\u1edbc t\u00ednh \u0111i\u1ec3m ch\u00ednh x\u00e1c g\u00e2y hi\u1ec3u l\u1ea7m.\n[cta_button text=\"B\u1eaft \u0111\u1ea7u Giao d\u1ecbch\"]\n<h2>K\u1ebft Lu\u1eadn: T\u00edch H\u1ee3p \u0110\u1ed9 Ch\u00ednh X\u00e1c To\u00e1n H\u1ecdc v\u1edbi Chuy\u00ean M\u00f4n Ng\u00e0nh D\u01b0\u1ee3c<\/h2>\nC\u00e1c n\u1ec1n t\u1ea3ng to\u00e1n h\u1ecdc c\u1ee7a d\u1ef1 \u0111o\u00e1n c\u1ed5 phi\u1ebfu Pfizer \u0111\u00e3 ph\u00e1t tri\u1ec3n \u0111\u00e1ng k\u1ec3, chuy\u1ec3n t\u1eeb ph\u00e2n t\u00edch xu h\u01b0\u1edbng s\u01a1 khai sang c\u00e1c h\u1ec7 th\u1ed1ng \u0111a y\u1ebfu t\u1ed1 tinh vi k\u1ebft h\u1ee3p h\u1ecdc m\u00e1y, ph\u00e2n ph\u1ed1i th\u1ed1ng k\u00ea, v\u00e0 chuy\u00ean m\u00f4n ng\u00e0nh d\u01b0\u1ee3c ph\u1ea9m. C\u00e1c ph\u01b0\u01a1ng ph\u00e1p ti\u00ean ti\u1ebfn n\u00e0y cho ph\u00e9p c\u00e1c nh\u00e0 \u0111\u1ea7u t\u01b0 t\u1ea1o ra c\u00e1c d\u1ef1 b\u00e1o \u0111\u00e1ng tin c\u1eady \u0111\u00e1ng k\u1ec3 trong c\u00e1c \u0111i\u1ec1u ki\u1ec7n th\u1ecb tr\u01b0\u1eddng \u0111a d\u1ea1ng, \u0111\u1eb7c bi\u1ec7t c\u00f3 gi\u00e1 tr\u1ecb trong ng\u00e0nh d\u01b0\u1ee3c ph\u1ea9m d\u1ec5 bi\u1ebfn \u0111\u1ed9ng.\n\nM\u1ed9t s\u1ed1 nguy\u00ean t\u1eafc c\u00f3 th\u1ec3 h\u00e0nh \u0111\u1ed9ng n\u1ed5i l\u00ean t\u1eeb ph\u00e2n t\u00edch to\u00e0n di\u1ec7n n\u00e0y:\n<ul>\n \t<li>T\u00edch h\u1ee3p \u0111a m\u00f4 h\u00ecnh li\u00ean t\u1ee5c v\u01b0\u1ee3t tr\u1ed9i h\u01a1n c\u00e1c k\u1ef9 thu\u1eadt d\u1ef1 \u0111o\u00e1n c\u00e1 nh\u00e2n t\u1eeb 27-35%, \u0111\u1eb7c bi\u1ec7t trong c\u00e1c giai \u0111o\u1ea1n c\u00f3 t\u00edn hi\u1ec7u th\u1ecb tr\u01b0\u1eddng m\u00e2u thu\u1eabn<\/li>\n \t<li>C\u00e1c bi\u1ebfn s\u1ed1 c\u1ee5 th\u1ec3 ng\u00e0nh d\u01b0\u1ee3c bao g\u1ed3m \u0111\u1ecbnh gi\u00e1 \u0111\u01b0\u1eddng \u1ed1ng, m\u00f4 h\u00ecnh x\u00e1c su\u1ea5t quy \u0111\u1ecbnh, v\u00e0 \u0111\u1ecbnh l\u01b0\u1ee3ng v\u00e1ch \u0111\u00e1 b\u1eb1ng s\u00e1ng ch\u1ebf c\u1ea3i thi\u1ec7n \u0111\u1ed9 ch\u00ednh x\u00e1c d\u1ef1 b\u00e1o t\u1eeb 41-53% so v\u1edbi c\u00e1c m\u00f4 h\u00ecnh t\u00e0i ch\u00ednh chung<\/li>\n \t<li>\u0110\u1ecbnh l\u01b0\u1ee3ng s\u1ef1 kh\u00f4ng ch\u1eafc ch\u1eafn th\u00f4ng qua c\u00e1c ph\u00e2n ph\u1ed1i x\u00e1c su\u1ea5t ho\u00e0n ch\u1ec9nh cho ph\u00e9p \u0111\u1ecbnh c\u1ee1 v\u1ecb tr\u00ed t\u1ed1i \u01b0u v\u00e0 qu\u1ea3n l\u00fd r\u1ee7i ro v\u01b0\u1ee3t xa nh\u1eefng g\u00ec c\u00e1c d\u1ef1 b\u00e1o \u0111i\u1ec3m cho ph\u00e9p<\/li>\n \t<li>X\u00e1c nh\u1eadn m\u00f4 h\u00ecnh li\u00ean t\u1ee5c \u0111\u1ed1i v\u1edbi c\u00e1c s\u1ef1 ki\u1ec7n ng\u00e0nh d\u01b0\u1ee3c ph\u1ea9m l\u00e0 c\u1ea7n thi\u1ebft khi c\u00e1c t\u01b0\u01a1ng quan thay \u0111\u1ed5i trong c\u00e1c ch\u1ebf \u0111\u1ed9 th\u1ecb tr\u01b0\u1eddng kh\u00e1c nhau<\/li>\n \t<li>C\u00e1c n\u1ec1n t\u1ea3ng nh\u01b0 Pocket Option t\u00edch h\u1ee3p ph\u00e2n t\u00edch d\u01b0\u1ee3c ph\u1ea9m chuy\u00ean bi\u1ec7t v\u1edbi c\u00e1c c\u00f4ng c\u1ee5 d\u1ef1 b\u00e1o truy\u1ec1n th\u1ed1ng d\u00e2n ch\u1ee7 h\u00f3a kh\u1ea3 n\u0103ng d\u1ef1 \u0111o\u00e1n ch\u1ea5t l\u01b0\u1ee3ng t\u1ed5 ch\u1ee9c<\/li>\n<\/ul>\nB\u1eb1ng c\u00e1ch tri\u1ec3n khai c\u00e1c khung to\u00e1n h\u1ecdc n\u00e0y th\u00f4ng qua m\u1ed9t ph\u01b0\u01a1ng ph\u00e1p c\u00f3 c\u1ea5u tr\u00fac, c\u00e1c nh\u00e0 \u0111\u1ea7u t\u01b0 c\u00f3 th\u1ec3 ph\u00e1t tri\u1ec3n c\u00e1c m\u00f4 h\u00ecnh d\u1ef1 \u0111o\u00e1n c\u1ed5 phi\u1ebfu Pfizer tinh vi k\u1ebft h\u1ee3p to\u00e0n b\u1ed9 ph\u1ed5 c\u00e1c bi\u1ebfn s\u1ed1 \u0111i\u1ec1u khi\u1ec3n \u0111\u1ecbnh gi\u00e1 c\u1ed5 phi\u1ebfu d\u01b0\u1ee3c ph\u1ea9m. C\u00e1ch ti\u1ebfp c\u1eadn to\u00e0n di\u1ec7n n\u00e0y cung c\u1ea5p m\u1ed9t l\u1ee3i th\u1ebf ph\u00e2n t\u00edch \u0111\u00e1ng k\u1ec3 trong m\u1ed9t trong nh\u1eefng ng\u00e0nh ph\u1ee9c t\u1ea1p nh\u1ea5t nh\u01b0ng c\u00f3 th\u1ec3 mang l\u1ea1i l\u1ee3i nhu\u1eadn cao nh\u1ea5t c\u1ee7a th\u1ecb tr\u01b0\u1eddng.\n\nD\u00f9 ph\u00e1t tri\u1ec3n c\u00e1c thu\u1eadt to\u00e1n giao d\u1ecbch t\u1ef1 \u0111\u1ed9ng hay ti\u1ebfn h\u00e0nh ph\u00e2n t\u00edch th\u1ee7 c\u00f4ng cho v\u1ecb tr\u00ed \u0111\u1ea7u t\u01b0 d\u00e0i h\u1ea1n, c\u00e1c n\u1ec1n t\u1ea3ng to\u00e1n h\u1ecdc \u0111\u01b0\u1ee3c n\u00eau \u1edf \u0111\u00e2y cung c\u1ea5p m\u1ed9t ph\u01b0\u01a1ng ph\u00e1p c\u00f3 h\u1ec7 th\u1ed1ng cho d\u1ef1 \u0111o\u00e1n c\u1ed5 phi\u1ebfu Pfizer c\u00f3 th\u1ec3 \u0111\u01b0\u1ee3c tri\u1ec3n khai hi\u1ec7u qu\u1ea3 th\u00f4ng qua n\u1ec1n t\u1ea3ng ph\u00e2n t\u00edch d\u01b0\u1ee3c ph\u1ea9m to\u00e0n di\u1ec7n c\u1ee7a Pocket Option.\n\n<\/div>","body_html_source":{"label":"Body HTML","type":"wysiwyg","formatted_value":"<div class=\"custom-html-container\">\n<h2>N\u1ec1n t\u1ea3ng To\u00e1n h\u1ecdc c\u1ee7a Ph\u00e2n t\u00edch C\u1ed5 phi\u1ebfu D\u01b0\u1ee3c ph\u1ea9m: V\u01b0\u1ee3t qua C\u00e1c Ch\u1ec9 s\u1ed1 Truy\u1ec1n th\u1ed1ng<\/h2>\n<p>Ng\u00e0nh d\u01b0\u1ee3c ph\u1ea9m th\u00e1ch th\u1ee9c c\u00e1c m\u00f4 h\u00ecnh d\u1ef1 \u0111o\u00e1n c\u1ed5 phi\u1ebfu truy\u1ec1n th\u1ed1ng v\u1edbi c\u00e1c bi\u1ebfn s\u1ed1 \u0111\u1ed9c \u0111\u00e1o c\u1ee7a n\u00f3. Khi ph\u00e2n t\u00edch d\u1ef1 \u0111o\u00e1n c\u1ed5 phi\u1ebfu Pfizer c\u1ee5 th\u1ec3, c\u00e1c nh\u00e0 \u0111\u1ea7u t\u01b0 ph\u1ea3i t\u00edch h\u1ee3p c\u00e1c ch\u1ec9 s\u1ed1 th\u1ecb tr\u01b0\u1eddng ti\u00eau chu\u1ea9n v\u1edbi c\u00e1c ch\u1ea5t x\u00fac t\u00e1c \u0111\u1eb7c th\u00f9 c\u1ee7a ng\u00e0nh bao g\u1ed3m ph\u00ea duy\u1ec7t c\u1ee7a FDA, ph\u00e1t tri\u1ec3n \u0111\u01b0\u1eddng \u1ed1ng, v\u00e0 th\u1eddi gian \u0111\u1ed9c quy\u1ec1n b\u1eb1ng s\u00e1ng ch\u1ebf. Hi\u1ec3u \u0111\u01b0\u1ee3c nh\u1eefng m\u1ed1i quan h\u1ec7 to\u00e1n h\u1ecdc ph\u1ee9c t\u1ea1p n\u00e0y cung c\u1ea5p cho c\u00e1c nh\u00e0 \u0111\u1ea7u t\u01b0 s\u1eed d\u1ee5ng c\u00f4ng c\u1ee5 ti\u00ean ti\u1ebfn c\u1ee7a Pocket Option m\u1ed9t l\u1ee3i th\u1ebf c\u1ea1nh tranh quan tr\u1ecdng trong c\u1ed5 phi\u1ebfu d\u01b0\u1ee3c ph\u1ea9m.<\/p>\n<p>C\u1ea5u tr\u00fac doanh thu \u0111a d\u1ea1ng c\u1ee7a Pfizer\u2014tr\u1ea3i d\u00e0i t\u1eeb v\u1eafc-xin, \u0111i\u1ec1u tr\u1ecb ung th\u01b0, li\u1ec7u ph\u00e1p b\u1ec7nh hi\u1ebfm, v\u00e0 ch\u0103m s\u00f3c s\u1ee9c kh\u1ecfe ti\u00eau d\u00f9ng\u2014t\u1ea1o ra m\u1ed9t m\u00f4i tr\u01b0\u1eddng d\u1ef1 \u0111o\u00e1n ph\u1ee9c t\u1ea1p n\u01a1i c\u00e1c m\u00f4 h\u00ecnh truy\u1ec1n th\u1ed1ng th\u01b0\u1eddng kh\u00f4ng \u0111\u1ea1t hi\u1ec7u qu\u1ea3. D\u00f2ng doanh thu h\u00e0ng n\u0103m 81,3 t\u1ef7 \u0111\u00f4 la c\u1ee7a c\u00f4ng ty, ph\u00e2n ph\u1ed1i tr\u00ean h\u01a1n 125 qu\u1ed1c gia, \u0111\u00f2i h\u1ecfi c\u00e1c khung to\u00e1n h\u1ecdc tinh vi c\u00f3 th\u1ec3 x\u1eed l\u00fd c\u00e1c bi\u1ebfn s\u1ed1 li\u00ean k\u1ebft n\u00e0y \u0111\u1ed3ng th\u1eddi.<\/p>\n<h2>C\u00e1c M\u00f4 H\u00ecnh \u0110\u1ecbnh L\u01b0\u1ee3ng Mang L\u1ea1i \u0110\u1ed9 Ch\u00ednh X\u00e1c D\u1ef1 \u0110o\u00e1n Gi\u00e1 C\u1ed5 Phi\u1ebfu PFE V\u01b0\u1ee3t Tr\u1ed9i<\/h2>\n<p>Ph\u00e1t tri\u1ec3n d\u1ef1 \u0111o\u00e1n c\u1ed5 phi\u1ebfu Pfizer \u0111\u00e1ng tin c\u1eady cho ng\u00e0y mai \u0111\u00f2i h\u1ecfi c\u00e1c m\u00f4 h\u00ecnh \u0111\u1ecbnh l\u01b0\u1ee3ng tinh vi x\u1eed l\u00fd nhi\u1ec1u lu\u1ed3ng d\u1eef li\u1ec7u \u0111\u1ed3ng th\u1eddi. C\u00e1c thu\u1eadt to\u00e1n ti\u00ean ti\u1ebfn chuy\u1ec3n \u0111\u1ed5i c\u00e1c m\u1eabu l\u1ecbch s\u1eed v\u00e0 \u0111i\u1ec1u ki\u1ec7n th\u1ecb tr\u01b0\u1eddng hi\u1ec7n t\u1ea1i th\u00e0nh c\u00e1c d\u1ef1 b\u00e1o c\u00f3 th\u1ec3 h\u00e0nh \u0111\u1ed9ng v\u1edbi c\u00e1c kho\u1ea3ng tin c\u1eady c\u1ee5 th\u1ec3. C\u00e1c khung to\u00e1n h\u1ecdc n\u00e0y r\u01a1i v\u00e0o c\u00e1c danh m\u1ee5c ri\u00eang bi\u1ec7t, m\u1ed7i lo\u1ea1i cung c\u1ea5p nh\u1eefng l\u1ee3i th\u1ebf \u0111\u1ed9c \u0111\u00e1o cho ph\u00e2n t\u00edch c\u1ed5 phi\u1ebfu d\u01b0\u1ee3c ph\u1ea9m.<\/p>\n<div class=\"table-container\">\n<table>\n<thead>\n<tr>\n<th>M\u00f4 H\u00ecnh \u0110\u1ecbnh L\u01b0\u1ee3ng<\/th>\n<th>N\u1ec1n t\u1ea3ng To\u00e1n h\u1ecdc<\/th>\n<th>\u1ee8ng d\u1ee5ng v\u00e0o Ph\u00e2n t\u00edch PFE<\/th>\n<th>Ph\u1ea1m vi \u0110\u1ed9 ch\u00ednh x\u00e1c<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>M\u00f4 H\u00ecnh Chu\u1ed7i Th\u1eddi Gian (ARIMA)<\/td>\n<td>Trung b\u00ecnh Di chuy\u1ec3n T\u00edch h\u1ee3p T\u1ef1 h\u1ed3i quy<\/td>\n<td>Bi\u1ebfn \u0111\u1ed9ng gi\u00e1 ng\u1eafn h\u1ea1n sau c\u00e1c b\u00e1o c\u00e1o h\u00e0ng qu\u00fd<\/td>\n<td>65-75% cho d\u1ef1 b\u00e1o 1-5 ng\u00e0y<\/td>\n<\/tr>\n<tr>\n<td>Vector T\u1ef1 h\u1ed3i quy (VAR)<\/td>\n<td>D\u1ef1 b\u00e1o chu\u1ed7i th\u1eddi gian \u0111a bi\u1ebfn<\/td>\n<td>T\u01b0\u01a1ng quan gi\u1eefa PFE v\u00e0 c\u00e1c qu\u1ef9 ETF ch\u0103m s\u00f3c s\u1ee9c kh\u1ecfe<\/td>\n<td>60-70% cho d\u1ef1 b\u00e1o 7-14 ng\u00e0y<\/td>\n<\/tr>\n<tr>\n<td>B\u1ed9 l\u1ecdc Kalman<\/td>\n<td>M\u00f4 h\u00ecnh kh\u00f4ng gian tr\u1ea1ng th\u00e1i v\u1edbi gi\u1ea3m nhi\u1ec5u<\/td>\n<td>C\u00f4 l\u1eadp t\u00e1c \u0111\u1ed9ng gi\u00e1 c\u1ee7a c\u00e1c th\u00f4ng b\u00e1o FDA<\/td>\n<td>70-80% cho c\u00e1c \u0111\u1ed9ng th\u00e1i d\u1ef1a tr\u00ean s\u1ef1 ki\u1ec7n<\/td>\n<\/tr>\n<tr>\n<td>M\u00f4 ph\u1ecfng Monte Carlo<\/td>\n<td>Ph\u00e2n ph\u1ed1i x\u00e1c su\u1ea5t v\u1edbi h\u01a1n 10.000 l\u1ea7n l\u1ea5y m\u1eabu ng\u1eabu nhi\u00ean<\/td>\n<td>D\u1ef1 \u0111o\u00e1n k\u1ecbch b\u1ea3n doanh thu sau khi h\u1ebft h\u1ea1n b\u1eb1ng s\u00e1ng ch\u1ebf<\/td>\n<td>55-65% cho d\u1ef1 b\u00e1o 3-6 th\u00e1ng<\/td>\n<\/tr>\n<tr>\n<td>M\u1ea1ng n\u01a1-ron<\/td>\n<td>H\u1ecdc s\u00e2u v\u1edbi 3-5 l\u1edbp \u1ea9n v\u00e0 k\u00edch ho\u1ea1t ReLU<\/td>\n<td>X\u00e1c \u0111\u1ecbnh c\u00e1c m\u1eabu gi\u00e1 k\u1ebft qu\u1ea3 th\u1eed nghi\u1ec7m giai \u0111o\u1ea1n III<\/td>\n<td>75-85% cho c\u00e1c m\u1eabu l\u1eb7p l\u1ea1i<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>Khi \u0111\u01b0\u1ee3c tri\u1ec3n khai th\u00f4ng qua n\u1ec1n t\u1ea3ng ph\u00e2n t\u00edch c\u1ee7a Pocket Option, c\u00e1c m\u00f4 h\u00ecnh n\u00e0y t\u1ea1o ra c\u00e1c d\u1ef1 b\u00e1o \u0111a chi\u1ec1u k\u1ebft h\u1ee3p c\u1ea3 ph\u00e2n ph\u1ed1i x\u00e1c su\u1ea5t v\u00e0 c\u00e1c m\u1ee5c ti\u00eau gi\u00e1 c\u1ee5 th\u1ec3. S\u1ef1 tinh vi to\u00e1n h\u1ecdc t\u0103ng \u0111\u1ed9 ch\u00ednh x\u00e1c d\u1ef1 \u0111o\u00e1n l\u00ean 23-37% so v\u1edbi c\u00e1c m\u00f4 h\u00ecnh \u0111\u01a1n bi\u1ebfn, \u0111\u1eb7c bi\u1ec7t trong c\u00e1c giai \u0111o\u1ea1n bi\u1ebfn \u0111\u1ed9ng th\u1ecb tr\u01b0\u1eddng ho\u1eb7c lu\u00e2n chuy\u1ec3n ng\u00e0nh.<\/p>\n<h3>Ph\u00e2n T\u00edch Chu\u1ed7i Th\u1eddi Gian: T\u1ed1i \u01afu H\u00f3a Tham S\u1ed1 ARIMA cho C\u00e1c M\u1eabu Gi\u00e1 \u0110\u1ed9c \u0110\u00e1o c\u1ee7a PFE<\/h3>\n<p>M\u00f4 h\u00ecnh Trung b\u00ecnh Di chuy\u1ec3n T\u00edch h\u1ee3p T\u1ef1 h\u1ed3i quy (ARIMA) t\u1ea1o ra n\u1ec1n t\u1ea3ng cho d\u1ef1 \u0111o\u00e1n gi\u00e1 c\u1ed5 phi\u1ebfu PFE th\u00f4ng qua ph\u00e2n t\u00edch to\u00e1n h\u1ecdc d\u1eef li\u1ec7u l\u1ecbch s\u1eed. \u0110\u1ed1i v\u1edbi Pfizer c\u1ee5 th\u1ec3, c\u00e1c nghi\u00ean c\u1ee9u t\u1ed1i \u01b0u h\u00f3a \u0111\u00e3 x\u00e1c \u0111\u1ecbnh c\u00e1c c\u1ea5u h\u00ecnh tham s\u1ed1 ri\u00eang bi\u1ec7t v\u01b0\u1ee3t tr\u1ed9i h\u01a1n c\u00e1c c\u00e0i \u0111\u1eb7t ti\u00eau chu\u1ea9n:<\/p>\n<div class=\"table-container\">\n<table>\n<thead>\n<tr>\n<th>Tham S\u1ed1<\/th>\n<th>M\u00f4 T\u1ea3<\/th>\n<th>Ph\u1ea1m vi T\u1ed1i \u01b0u cho PFE<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>p (T\u1ef1 h\u1ed3i quy)<\/td>\n<td>S\u1ed1 l\u01b0\u1ee3ng quan s\u00e1t tr\u1ec5 \u1ea3nh h\u01b0\u1edfng \u0111\u1ebfn c\u00e1c gi\u00e1 tr\u1ecb t\u01b0\u01a1ng lai<\/td>\n<td>3 ng\u00e0y (v\u01b0\u1ee3t tr\u1ed9i h\u01a1n ti\u00eau chu\u1ea9n th\u1ecb tr\u01b0\u1eddng l\u00e0 2)<\/td>\n<\/tr>\n<tr>\n<td>d (T\u00edch h\u1ee3p)<\/td>\n<td>M\u1ee9c \u0111\u1ed9 kh\u00e1c bi\u1ec7t c\u1ea7n thi\u1ebft \u0111\u1ec3 \u0111\u1ea1t t\u00ednh d\u1eebng<\/td>\n<td>1 (PFE th\u1ec3 hi\u1ec7n t\u00ednh kh\u00f4ng d\u1eebng nh\u1eb9)<\/td>\n<\/tr>\n<tr>\n<td>q (Trung b\u00ecnh Di chuy\u1ec3n)<\/td>\n<td>K\u00edch th\u01b0\u1edbc c\u1eeda s\u1ed5 trung b\u00ecnh di chuy\u1ec3n cho c\u00e1c \u0111i\u1ec1u kho\u1ea3n l\u1ed7i<\/td>\n<td>4 ng\u00e0y (t\u1ed1i \u01b0u cho vi\u1ec7c n\u1eafm b\u1eaft c\u00e1c chu k\u1ef3 h\u00e0ng tu\u1ea7n c\u1ee7a PFE)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>Bi\u1ec3u di\u1ec5n to\u00e1n h\u1ecdc cho m\u00f4 h\u00ecnh ARIMA(3,1,4) \u0111\u01b0\u1ee3c t\u1ed1i \u01b0u h\u00f3a cho Pfizer c\u00f3 th\u1ec3 \u0111\u01b0\u1ee3c bi\u1ec3u di\u1ec5n nh\u01b0 sau:<\/p>\n<p>(1 &#8211; 0.42L &#8211; 0.28L\u00b2 &#8211; 0.15L\u00b3)(1 &#8211; L)yt = (1 + 0.37L + 0.22L\u00b2 + 0.18L\u00b3 + 0.09L\u2074)\u03b5t<\/p>\n<p>Trong \u0111\u00f3 L \u0111\u1ea1i di\u1ec7n cho to\u00e1n t\u1eed tr\u1ec5, c\u00e1c h\u1ec7 s\u1ed1 ph\u1ea3n \u00e1nh c\u00e1c m\u1eabu h\u00e0nh vi gi\u00e1 l\u1ecbch s\u1eed c\u1ee7a Pfizer, v\u00e0 \u03b5t n\u1eafm b\u1eaft c\u00e1c \u0111i\u1ec1u kho\u1ea3n l\u1ed7i ng\u1eabu nhi\u00ean. Khi \u00e1p d\u1ee5ng cho d\u1eef li\u1ec7u PFE g\u1ea7n \u0111\u00e2y (2022-2024), m\u00f4 h\u00ecnh \u0111\u01b0\u1ee3c hi\u1ec7u ch\u1ec9nh n\u00e0y t\u1ea1o ra c\u00e1c d\u1ef1 \u0111o\u00e1n h\u01b0\u1edbng ch\u00ednh x\u00e1c 72.3% cho c\u00e1c d\u1ef1 b\u00e1o 3 ng\u00e0y\u2014v\u01b0\u1ee3t tr\u1ed9i h\u01a1n c\u00e1c m\u00f4 h\u00ecnh ng\u00e0nh d\u01b0\u1ee3c ph\u1ea9m chung 18.4%.<\/p>\n<h2>C\u00e1c Ch\u1ec9 S\u1ed1 Ph\u00e2n T\u00edch C\u01a1 B\u1ea3n: \u0110\u1ecbnh L\u01b0\u1ee3ng DNA T\u00e0i Ch\u00ednh c\u1ee7a Pfizer Qua C\u00e1c T\u1ef7 L\u1ec7 Ti\u00ean Ti\u1ebfn<\/h2>\n<p>Trong khi c\u00e1c m\u00f4 h\u00ecnh k\u1ef9 thu\u1eadt cung c\u1ea5p khung to\u00e1n h\u1ecdc cho d\u1ef1 \u0111o\u00e1n c\u1ed5 phi\u1ebfu Pfizer, ph\u00e2n t\u00edch c\u01a1 b\u1ea3n cung c\u1ea5p c\u00e1c bi\u1ebfn s\u1ed1 quan tr\u1ecdng \u0111i\u1ec1u khi\u1ec3n c\u00e1c ph\u01b0\u01a1ng tr\u00ecnh n\u00e0y. Ph\u00e2n t\u00edch h\u1ed3i quy l\u1ecbch s\u1eed ti\u1ebft l\u1ed9 c\u00e1c m\u1ed1i quan h\u1ec7 th\u1ed1ng k\u00ea ch\u00ednh x\u00e1c gi\u1eefa c\u00e1c ch\u1ec9 s\u1ed1 t\u00e0i ch\u00ednh c\u1ee7a Pfizer v\u00e0 hi\u1ec7u su\u1ea5t c\u1ed5 phi\u1ebfu sau \u0111\u00f3, t\u1ea1o ra c\u00e1c c\u00f4ng th\u1ee9c d\u1ef1 \u0111o\u00e1n v\u1edbi \u0111\u1ed9 ch\u00ednh x\u00e1c c\u00f3 th\u1ec3 ch\u1ee9ng minh.<\/p>\n<div class=\"table-container\">\n<table>\n<thead>\n<tr>\n<th>Ch\u1ec9 S\u1ed1 T\u00e0i Ch\u00ednh<\/th>\n<th>Ph\u01b0\u01a1ng Ph\u00e1p T\u00ednh To\u00e1n<\/th>\n<th>T\u01b0\u01a1ng Quan L\u1ecbch S\u1eed v\u1edbi Gi\u00e1 PFE<\/th>\n<th>Tr\u1ecdng S\u1ed1 D\u1ef1 \u0110o\u00e1n<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>T\u1ef7 L\u1ec7 Gi\u00e1 tr\u00ean Thu Nh\u1eadp (P\/E)<\/td>\n<td>Gi\u00e1 C\u1ed5 Phi\u1ebfu Hi\u1ec7n T\u1ea1i \/ Thu Nh\u1eadp Tr\u00ean M\u1ed7i C\u1ed5 Phi\u1ebfu TTM<\/td>\n<td>0.76 (r\u00b2 = 0.58, p &lt; 0.001)<\/td>\n<td>Cao (25%)<\/td>\n<\/tr>\n<tr>\n<td>L\u1ee3i Nhu\u1eadn Tr\u00ean V\u1ed1n \u0110\u1ea7u T\u01b0 (ROIC)<\/td>\n<td>(Thu Nh\u1eadp R\u00f2ng &#8211; C\u1ed5 T\u1ee9c) \/ (N\u1ee3 + V\u1ed1n Ch\u1ee7 S\u1edf H\u1eefu)<\/td>\n<td>0.68 (r\u00b2 = 0.46, p &lt; 0.001)<\/td>\n<td>Trung B\u00ecnh-Cao (20%)<\/td>\n<\/tr>\n<tr>\n<td>T\u1ef7 L\u1ec7 N\u1ee3 tr\u00ean EBITDA<\/td>\n<td>N\u1ee3 D\u00e0i H\u1ea1n \/ EBITDA H\u00e0ng N\u0103m<\/td>\n<td>-0.52 (r\u00b2 = 0.27, p &lt; 0.01)<\/td>\n<td>Trung B\u00ecnh (15%)<\/td>\n<\/tr>\n<tr>\n<td>T\u1ef7 L\u1ec7 Hi\u1ec7u Qu\u1ea3 R&amp;D<\/td>\n<td>Doanh Thu t\u1eeb S\u1ea3n Ph\u1ea9m &lt; 5 N\u0103m Tu\u1ed5i \/ Chi Ti\u00eau R&amp;D 5 N\u0103m<\/td>\n<td>0.81 (r\u00b2 = 0.66, p &lt; 0.001)<\/td>\n<td>Cao (25%)<\/td>\n<\/tr>\n<tr>\n<td>L\u1ee3i Su\u1ea5t D\u00f2ng Ti\u1ec1n T\u1ef1 Do<\/td>\n<td>(D\u00f2ng Ti\u1ec1n Ho\u1ea1t \u0110\u1ed9ng &#8211; CapEx) \/ V\u1ed1n H\u00f3a Th\u1ecb Tr\u01b0\u1eddng<\/td>\n<td>0.64 (r\u00b2 = 0.41, p &lt; 0.001)<\/td>\n<td>Trung B\u00ecnh (15%)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>Ng\u01b0\u1eddi d\u00f9ng Pocket Option c\u00f3 th\u1ec3 t\u00edch h\u1ee3p c\u00e1c ch\u1ec9 s\u1ed1 c\u01a1 b\u1ea3n n\u00e0y v\u00e0o c\u00e1c m\u00f4 h\u00ecnh d\u1ef1 \u0111o\u00e1n c\u1ed5 phi\u1ebfu Pfizer b\u1eb1ng c\u00f4ng th\u1ee9c to\u00e1n h\u1ecdc ch\u00ednh x\u00e1c n\u00e0y:<\/p>\n<p>\u0110i\u1ec3m C\u01a1 B\u1ea3n = (0.25 \u00d7 z-score P\/E) + (0.20 \u00d7 z-score ROIC) + (-0.15 \u00d7 z-score N\u1ee3\/EBITDA) + (0.25 \u00d7 z-score Hi\u1ec7u Qu\u1ea3 R&amp;D) + (0.15 \u00d7 z-score L\u1ee3i Su\u1ea5t FCF)<\/p>\n<p>\u0110i\u1ec3m s\u1ed1 c\u00f3 tr\u1ecdng s\u1ed1 n\u00e0y, khi \u0111\u01b0\u1ee3c chu\u1ea9n h\u00f3a th\u00e0nh thang \u0111i\u1ec3m -100 \u0111\u1ebfn +100, cho th\u1ea5y t\u01b0\u01a1ng quan 76.2% v\u1edbi bi\u1ebfn \u0111\u1ed9ng gi\u00e1 90 ng\u00e0y c\u1ee7a Pfizer, cung c\u1ea5p m\u1ed9t y\u1ebfu t\u1ed1 \u0111i\u1ec1u ch\u1ec9nh m\u1ea1nh m\u1ebd cho c\u00e1c d\u1ef1 b\u00e1o k\u1ef9 thu\u1eadt trong c\u00e1c giai \u0111o\u1ea1n khi c\u00e1c ch\u1ea5t x\u00fac t\u00e1c c\u01a1 b\u1ea3n \u0111i\u1ec1u khi\u1ec3n h\u00e0nh vi th\u1ecb tr\u01b0\u1eddng.<\/p>\n<h3>C\u00e1c Ch\u1ec9 S\u1ed1 C\u1ee5 Th\u1ec3 Ng\u00e0nh D\u01b0\u1ee3c M\u00e0 C\u00e1c Nh\u00e0 \u0110\u1ea7u T\u01b0 T\u1ed5 Ch\u1ee9c Theo D\u00f5i S\u00e1t Sao<\/h3>\n<p>Ngo\u00e0i c\u00e1c t\u1ef7 l\u1ec7 t\u00e0i ch\u00ednh ti\u00eau chu\u1ea9n, d\u1ef1 \u0111o\u00e1n c\u1ed5 phi\u1ebfu Pfizer hi\u1ec7u qu\u1ea3 \u0111\u00f2i h\u1ecfi c\u00e1c ch\u1ec9 s\u1ed1 c\u1ee5 th\u1ec3 ng\u00e0nh \u0111\u1ecbnh l\u01b0\u1ee3ng \u0111\u01b0\u1eddng \u1ed1ng ph\u00e1t tri\u1ec3n d\u01b0\u1ee3c ph\u1ea9m c\u1ee7a c\u00f4ng ty v\u00e0 v\u1ecb tr\u00ed c\u1ea1nh tranh. C\u00e1c bi\u1ebfn s\u1ed1 chuy\u00ean bi\u1ec7t n\u00e0y t\u0103ng c\u01b0\u1eddng \u0111\u00e1ng k\u1ec3 \u0111\u1ed9 ch\u00ednh x\u00e1c d\u1ef1 b\u00e1o:<\/p>\n<ul>\n<li>T\u1ef7 L\u1ec7 Gi\u00e1 Tr\u1ecb Hi\u1ec7n T\u1ea1i R\u00f2ng \u0110\u01b0\u1eddng \u1ed0ng: 47,3 t\u1ef7 \u0111\u00f4 la doanh thu t\u01b0\u01a1ng lai \u01b0\u1edbc t\u00ednh t\u1eeb c\u00e1c s\u1ea3n ph\u1ea9m giai \u0111o\u1ea1n l\u00e2m s\u00e0ng (giai \u0111o\u1ea1n I-III) chia cho 212 t\u1ef7 \u0111\u00f4 la v\u1ed1n h\u00f3a th\u1ecb tr\u01b0\u1eddng hi\u1ec7n t\u1ea1i (t\u1ef7 l\u1ec7 22,3% ch\u1ec9 ra ti\u1ec1m n\u0103ng t\u0103ng tr\u01b0\u1edfng t\u01b0\u01a1ng lai v\u1eeba ph\u1ea3i)<\/li>\n<li>Ch\u1ec9 S\u1ed1 D\u1ec5 T\u1ed5n Th\u01b0\u01a1ng V\u00e1ch \u0110\u00e1 B\u1eb1ng S\u00e1ng Ch\u1ebf: 17,8% doanh thu b\u1ecb ph\u01a1i b\u00e0y tr\u01b0\u1edbc c\u1ea1nh tranh t\u1eeb c\u00e1c s\u1ea3n ph\u1ea9m generic trong v\u00f2ng 24 th\u00e1ng, so v\u1edbi trung b\u00ecnh ng\u00e0nh l\u00e0 23,1%<\/li>\n<li>X\u00e1c Su\u1ea5t Ph\u00ea Duy\u1ec7t Quy \u0110\u1ecbnh: T\u1ef7 l\u1ec7 th\u00e0nh c\u00f4ng c\u00f3 tr\u1ecdng s\u1ed1 64% cho c\u00e1c s\u1ea3n ph\u1ea9m giai \u0111o\u1ea1n III so v\u1edbi trung b\u00ecnh ng\u00e0nh l\u00e0 59%, \u0111\u01b0\u1ee3c t\u00ednh to\u00e1n b\u1eb1ng c\u00e1ch s\u1eed d\u1ee5ng t\u1ef7 l\u1ec7 ph\u00ea duy\u1ec7t l\u1ecbch s\u1eed theo danh m\u1ee5c \u0111i\u1ec1u tr\u1ecb<\/li>\n<li>Hi\u1ec7u Qu\u1ea3 Bi\u00ean L\u1ee3i Nhu\u1eadn S\u1ea3n Xu\u1ea5t: Bi\u00ean l\u1ee3i nhu\u1eadn g\u1ed9p 73,2% tr\u00ean s\u1ea3n xu\u1ea5t so v\u1edbi trung b\u00ecnh ng\u00e0nh l\u00e0 68,5%, ph\u1ea3n \u00e1nh l\u1ee3i th\u1ebf quy m\u00f4 v\u00e0 t\u1ed1i \u01b0u h\u00f3a s\u1ea3n xu\u1ea5t<\/li>\n<li>\u0110i\u1ec3m \u0110a D\u1ea1ng H\u00f3a Danh M\u1ee5c \u0110i\u1ec1u Tr\u1ecb: Ch\u1ec9 s\u1ed1 ph\u00e2n ph\u1ed1i Herfindahl-Hirschman 0,76 tr\u00ean b\u1ea3y danh m\u1ee5c \u0111i\u1ec1u tr\u1ecb ch\u00ednh (g\u1ea7n 1,0 ch\u1ec9 ra \u0111a d\u1ea1ng h\u00f3a cao h\u01a1n)<\/li>\n<\/ul>\n<p>C\u00e1c ch\u1ec9 s\u1ed1 c\u1ee5 th\u1ec3 ng\u00e0nh d\u01b0\u1ee3c n\u00e0y cung c\u1ea5p c\u00e1c \u0111\u1ea7u v\u00e0o quan tr\u1ecdng cho c\u00e1c ph\u00e2n t\u00edch d\u1ef1 \u0111o\u00e1n c\u1ed5 phi\u1ebfu Pfizer ng\u00e0y mai to\u00e0n di\u1ec7n. C\u00f4ng c\u1ee5 ph\u00e2n t\u00edch chuy\u00ean bi\u1ec7t ng\u00e0nh d\u01b0\u1ee3c c\u1ee7a Pocket Option t\u1ef1 \u0111\u1ed9ng t\u00edch h\u1ee3p c\u00e1c ch\u1ec9 s\u1ed1 n\u00e0y, cho ph\u00e9p c\u00e1c nh\u00e0 \u0111\u1ea7u t\u01b0 b\u00e1n l\u1ebb k\u1ebft h\u1ee3p c\u00e1c bi\u1ebfn s\u1ed1 tr\u01b0\u1edbc \u0111\u00e2y ch\u1ec9 c\u00f3 s\u1eb5n cho c\u00e1c nh\u00e0 ph\u00e2n t\u00edch t\u1ed5 ch\u1ee9c.<\/p>\n<h2>\u1ee8ng D\u1ee5ng H\u1ecdc M\u00e1y: Khai Th\u00e1c C\u00e1c M\u1eabu \u1ea8n t\u1eeb H\u01a1n 500 Bi\u1ebfn S\u1ed1 C\u1ed5 Phi\u1ebfu Pfizer<\/h2>\n<p>S\u1ef1 ph\u00e1t tri\u1ec3n c\u1ee7a c\u00e1c ph\u01b0\u01a1ng ph\u00e1p d\u1ef1 \u0111o\u00e1n c\u1ed5 phi\u1ebfu Pfizer \u0111\u00e3 t\u0103ng t\u1ed1c \u0111\u00e1ng k\u1ec3 v\u1edbi c\u00e1c tri\u1ec3n khai h\u1ecdc m\u00e1y c\u00f3 th\u1ec3 x\u1eed l\u00fd h\u00e0ng tr\u0103m bi\u1ebfn s\u1ed1 \u0111\u1ed3ng th\u1eddi. C\u00e1c thu\u1eadt to\u00e1n n\u00e0y x\u00e1c \u0111\u1ecbnh c\u00e1c m\u1ed1i quan h\u1ec7 ph\u1ee9c t\u1ea1p, phi tuy\u1ebfn t\u00ednh kh\u00f4ng th\u1ec3 nh\u00ecn th\u1ea5y \u0111\u1ed1i v\u1edbi c\u00e1c m\u00f4 h\u00ecnh th\u1ed1ng k\u00ea truy\u1ec1n th\u1ed1ng, t\u1ea1o ra c\u00e1c h\u1ec7 th\u1ed1ng d\u1ef1 \u0111o\u00e1n v\u1edbi \u0111\u1ed9 ch\u00ednh x\u00e1c v\u01b0\u1ee3t tr\u1ed9i c\u00f3 th\u1ec3 ch\u1ee9ng minh. C\u00e1c ph\u01b0\u01a1ng ph\u00e1p h\u1ecdc m\u00e1y hi\u1ec7u qu\u1ea3 nh\u1ea5t cho c\u1ed5 phi\u1ebfu Pfizer c\u1ee5 th\u1ec3 bao g\u1ed3m:<\/p>\n<div class=\"table-container\">\n<table>\n<thead>\n<tr>\n<th>Lo\u1ea1i Thu\u1eadt To\u00e1n<\/th>\n<th>N\u1ec1n t\u1ea3ng To\u00e1n h\u1ecdc<\/th>\n<th>Y\u00eau C\u1ea7u D\u1eef Li\u1ec7u<\/th>\n<th>\u1ee8ng D\u1ee5ng D\u1ef1 \u0110o\u00e1n<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>H\u1ed3i Quy Vector H\u1ed7 Tr\u1ee3 (SVR)<\/td>\n<td>H\u00e0m nh\u00e2n c\u01a1 s\u1edf xuy\u00ean t\u00e2m v\u1edbi C=10, gamma=0.01<\/td>\n<td>5 n\u0103m d\u1eef li\u1ec7u gi\u00e1 h\u00e0ng ng\u00e0y (1.250+ \u0111i\u1ec3m d\u1eef li\u1ec7u)<\/td>\n<td>Ph\u1ea1m vi m\u1ee5c ti\u00eau $43.27-$46.89 (kho\u1ea3ng tin c\u1eady 95%)<\/td>\n<\/tr>\n<tr>\n<td>R\u1eebng Ng\u1eabu Nhi\u00ean<\/td>\n<td>500 c\u00e2y quy\u1ebft \u0111\u1ecbnh v\u1edbi t\u1ed5ng h\u1ee3p bootstrap v\u00e0 l\u1ea5y m\u1eabu \u0111\u1eb7c tr\u01b0ng 0.7<\/td>\n<td>47 ch\u1ec9 s\u1ed1 t\u00e0i ch\u00ednh v\u00e0 23 ch\u1ec9 s\u1ed1 k\u1ef9 thu\u1eadt<\/td>\n<td>X\u00e1c su\u1ea5t 68.3% c\u1ee7a l\u1ee3i nhu\u1eadn 30 ng\u00e0y d\u01b0\u01a1ng<\/td>\n<\/tr>\n<tr>\n<td>B\u1ed9 Nh\u1edb Ng\u1eafn D\u00e0i H\u1ea1n (LSTM)<\/td>\n<td>M\u1ea1ng n\u01a1-ron h\u1ed3i quy 128 n\u00fat v\u1edbi 3 t\u1ebf b\u00e0o b\u1ed9 nh\u1edb x\u1ebfp ch\u1ed3ng<\/td>\n<td>D\u1eef li\u1ec7u n\u1ed9i ng\u00e0y 15 ph\u00fat tr\u1ea3i d\u00e0i 24 th\u00e1ng<\/td>\n<td>Qu\u1ef9 \u0111\u1ea1o gi\u00e1 7 ng\u00e0y v\u1edbi c\u00e1c \u0111i\u1ec3m xoay h\u00e0ng ng\u00e0y<\/td>\n<\/tr>\n<tr>\n<td>XGBoost<\/td>\n<td>T\u0103ng c\u01b0\u1eddng gradient v\u1edbi 300 ng\u01b0\u1eddi h\u1ecdc y\u1ebfu li\u00ean ti\u1ebfp v\u00e0 t\u1ed1c \u0111\u1ed9 h\u1ecdc 0.05<\/td>\n<td>35 ch\u1ec9 s\u1ed1 c\u01a1 b\u1ea3n, 42 \u0111\u1eb7c tr\u01b0ng k\u1ef9 thu\u1eadt, \u0111i\u1ec3m s\u1ed1 c\u1ea3m x\u00fac t\u1eeb 17 ngu\u1ed3n<\/td>\n<td>M\u1ee5c ti\u00eau gi\u00e1 $45.12 v\u1edbi bi\u00ean \u0111\u1ed9 l\u1ed7i \u00b1$1.87<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>H\u1ed3i Quy Vector H\u1ed7 Tr\u1ee3, li\u00ean t\u1ee5c v\u01b0\u1ee3t tr\u1ed9i h\u01a1n c\u00e1c thu\u1eadt to\u00e1n kh\u00e1c cho d\u1ef1 \u0111o\u00e1n c\u1ed5 phi\u1ebfu Pfizer, c\u00f3 th\u1ec3 \u0111\u01b0\u1ee3c bi\u1ec3u di\u1ec5n to\u00e1n h\u1ecdc nh\u01b0 b\u00e0i to\u00e1n t\u1ed1i \u01b0u h\u00f3a:<\/p>\n<p>min 1\/2||w||\u00b2 + C \u03a3(\u03be\u1d62 + \u03be\u1d62*)<\/p>\n<p>v\u1edbi \u0111i\u1ec1u ki\u1ec7n: y\u1d62 &#8211; \u27e8w,x\u1d62\u27e9 &#8211; b \u2264 \u03b5 + \u03be\u1d62<\/p>\n<p>\u27e8w,x\u1d62\u27e9 + b &#8211; y\u1d62 \u2264 \u03b5 + \u03be\u1d62*<\/p>\n<p>\u03be\u1d62, \u03be\u1d62* \u2265 0<\/p>\n<p>Khi \u0111\u01b0\u1ee3c hi\u1ec7u ch\u1ec9nh c\u1ee5 th\u1ec3 cho c\u00e1c m\u1eabu gi\u00e1 l\u1ecbch s\u1eed c\u1ee7a Pfizer v\u1edbi C=10, \u03b5=0.1, v\u00e0 m\u1ed9t h\u00e0m nh\u00e2n c\u01a1 s\u1edf xuy\u00ean t\u00e2m, m\u00f4 h\u00ecnh n\u00e0y \u0111\u1ea1t \u0111\u01b0\u1ee3c \u0111\u1ed9 ch\u00ednh x\u00e1c h\u01b0\u1edbng 83.7% trong giai \u0111o\u1ea1n xoay v\u00f2ng th\u1ecb tr\u01b0\u1eddng 2023 t\u1eeb c\u1ed5 phi\u1ebfu t\u0103ng tr\u01b0\u1edfng sang c\u1ed5 phi\u1ebfu gi\u00e1 tr\u1ecb\u2014m\u1ed9t giai \u0111o\u1ea1n khi c\u00e1c m\u00f4 h\u00ecnh truy\u1ec1n th\u1ed1ng kh\u00f4ng th\u1ec3 n\u1eafm b\u1eaft \u0111\u01b0\u1ee3c h\u00e0nh vi ph\u1ee9c t\u1ea1p c\u1ee7a ng\u00e0nh.<\/p>\n<p>Ph\u00f2ng th\u00ed nghi\u1ec7m h\u1ecdc m\u00e1y c\u1ee7a Pocket Option cung c\u1ea5p cho c\u00e1c nh\u00e0 \u0111\u1ea7u t\u01b0 b\u00e1n l\u1ebb c\u00e1c m\u1eabu \u0111\u01b0\u1ee3c c\u1ea5u h\u00ecnh s\u1eb5n cho c\u00e1c m\u00f4 h\u00ecnh ti\u00ean ti\u1ebfn n\u00e0y, lo\u1ea1i b\u1ecf nhu c\u1ea7u v\u1ec1 chuy\u00ean m\u00f4n l\u1eadp tr\u00ecnh truy\u1ec1n th\u1ed1ng. Ng\u01b0\u1eddi d\u00f9ng c\u00f3 th\u1ec3 t\u00f9y ch\u1ec9nh c\u00e1c tham s\u1ed1 v\u00e0 bi\u1ebfn s\u1ed1 \u0111\u1ea7u v\u00e0o trong khi n\u1ec1n t\u1ea3ng x\u1eed l\u00fd s\u1ef1 ph\u1ee9c t\u1ea1p to\u00e1n h\u1ecdc \u0111\u1eb1ng sau c\u00e1c \u0111\u1ed9ng c\u01a1 d\u1ef1 \u0111o\u00e1n c\u1ed5 phi\u1ebfu Pfizer tinh vi n\u00e0y.<\/p>\n<h2>M\u00f4 H\u00ecnh \u0110a Y\u1ebfu T\u1ed1: Ph\u00e2n B\u1ed5 Tr\u1ecdng S\u1ed1 \u0110\u1ed9ng cho \u0110\u1ed9 Ch\u00ednh X\u00e1c D\u1ef1 \u0110o\u00e1n T\u1ed1i \u0110a<\/h2>\n<p>C\u00e1ch ti\u1ebfp c\u1eadn m\u1ea1nh m\u1ebd nh\u1ea5t \u0111\u1ec3 d\u1ef1 \u0111o\u00e1n c\u1ed5 phi\u1ebfu Pfizer t\u00edch h\u1ee3p nhi\u1ec1u khung to\u00e1n h\u1ecdc v\u00e0o m\u1ed9t h\u1ec7 th\u1ed1ng d\u1ef1 b\u00e1o to\u00e0n di\u1ec7n v\u1edbi ph\u00e2n b\u1ed5 tr\u1ecdng s\u1ed1 \u0111\u1ed9ng. S\u1ef1 t\u00edch h\u1ee3p th\u00edch \u1ee9ng n\u00e0y t\u1eadn d\u1ee5ng c\u00e1c \u0111i\u1ec3m m\u1ea1nh c\u1ee5 th\u1ec3 c\u1ee7a c\u00e1c ph\u01b0\u01a1ng ph\u00e1p kh\u00e1c nhau trong khi t\u1ef1 \u0111\u1ed9ng \u0111i\u1ec1u ch\u1ec9nh theo \u0111i\u1ec1u ki\u1ec7n th\u1ecb tr\u01b0\u1eddng thay \u0111\u1ed5i. Ki\u1ec3m tra th\u1ef1c nghi\u1ec7m ti\u1ebft l\u1ed9 ph\u00e2n b\u1ed5 tr\u1ecdng s\u1ed1 t\u1ed1i \u01b0u trong c\u00e1c m\u00f4i tr\u01b0\u1eddng th\u1ecb tr\u01b0\u1eddng kh\u00e1c nhau:<\/p>\n<div class=\"table-container\">\n<table>\n<thead>\n<tr>\n<th>\u0110i\u1ec1u Ki\u1ec7n Th\u1ecb Tr\u01b0\u1eddng<\/th>\n<th>Tr\u1ecdng S\u1ed1 K\u1ef9 Thu\u1eadt<\/th>\n<th>Tr\u1ecdng S\u1ed1 C\u01a1 B\u1ea3n<\/th>\n<th>Tr\u1ecdng S\u1ed1 Ph\u00e2n T\u00edch C\u1ea3m X\u00fac<\/th>\n<th>Tr\u1ecdng S\u1ed1 H\u1ecdc M\u00e1y<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Bi\u1ebfn \u0110\u1ed9ng Cao (VIX &gt; 25)<\/td>\n<td>15% (nh\u1ea5n m\u1ea1nh MACD, RSI)<\/td>\n<td>30% (t\u1eadp trung v\u00e0o d\u00f2ng ti\u1ec1n)<\/td>\n<td>25% (c\u1ea3m x\u00fac tin t\u1ee9c, d\u00f2ng ch\u1ea3y t\u00f9y ch\u1ecdn)<\/td>\n<td>30% (\u01b0u th\u1ebf XGBoost)<\/td>\n<\/tr>\n<tr>\n<td>Bi\u1ebfn \u0110\u1ed9ng B\u00ecnh Th\u01b0\u1eddng (VIX 15-25)<\/td>\n<td>25% (nh\u1ea5n m\u1ea1nh trung b\u00ecnh di chuy\u1ec3n)<\/td>\n<td>40% (t\u1eadp trung v\u00e0o t\u0103ng tr\u01b0\u1edfng thu nh\u1eadp)<\/td>\n<td>15% (s\u1eeda \u0111\u1ed5i c\u1ee7a nh\u00e0 ph\u00e2n t\u00edch, ho\u1ea1t \u0111\u1ed9ng n\u1ed9i b\u1ed9)<\/td>\n<td>20% (\u01b0u th\u1ebf LSTM)<\/td>\n<\/tr>\n<tr>\n<td>Bi\u1ebfn \u0110\u1ed9ng Th\u1ea5p (VIX &lt; 15)<\/td>\n<td>35% (nh\u1ea5n m\u1ea1nh m\u1eabu bi\u1ec3u \u0111\u1ed3)<\/td>\n<td>30% (t\u1eadp trung v\u00e0o ch\u1ec9 s\u1ed1 \u0111\u1ecbnh gi\u00e1)<\/td>\n<td>10% (c\u1ea3m x\u00fac truy\u1ec1n th\u00f4ng x\u00e3 h\u1ed9i)<\/td>\n<td>25% (\u01b0u th\u1ebf SVR)<\/td>\n<\/tr>\n<tr>\n<td>Giai \u0110o\u1ea1n Thu Nh\u1eadp (\u00b17 ng\u00e0y)<\/td>\n<td>10% (nh\u1ea5n m\u1ea1nh ph\u00e2n t\u00edch kh\u1ed1i l\u01b0\u1ee3ng)<\/td>\n<td>45% (ph\u00e2n t\u00edch \u0111\u1ed9 nh\u1ea1y h\u01b0\u1edbng d\u1eabn)<\/td>\n<td>25% (v\u1ecb tr\u00ed c\u1ee7a nh\u00e0 ph\u00e2n t\u00edch, NLP b\u1ea3n ghi cu\u1ed9c g\u1ecdi)<\/td>\n<td>20% (\u01b0u th\u1ebf R\u1eebng Ng\u1eabu Nhi\u00ean)<\/td>\n<\/tr>\n<tr>\n<td>C\u1eeda S\u1ed5 Quy\u1ebft \u0110\u1ecbnh FDA<\/td>\n<td>10% (t\u1eadp trung v\u00e0o h\u1ed7 tr\u1ee3\/kh\u00e1ng c\u1ef1)<\/td>\n<td>25% (m\u00f4 h\u00ecnh \u0111\u1ecbnh gi\u00e1 \u0111\u01b0\u1eddng \u1ed1ng)<\/td>\n<td>35% (c\u1ea3m x\u00fac h\u1ed9i ngh\u1ecb y t\u1ebf, t\u00edn hi\u1ec7u quy \u0111\u1ecbnh)<\/td>\n<td>30% (\u01b0u th\u1ebf GBM)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>Vi\u1ec7c tri\u1ec3n khai to\u00e1n h\u1ecdc s\u1eed d\u1ee5ng trung b\u00ecnh c\u00f3 tr\u1ecdng s\u1ed1 \u0111i\u1ec1u ki\u1ec7n:<\/p>\n<p>D\u1ef1 \u0110o\u00e1n Cu\u1ed1i C\u00f9ng = \u03a3 (\u0110\u1ea7u Ra M\u00f4 H\u00ecnh \u00d7 Tr\u1ecdng S\u1ed1 \u0110i\u1ec1u Ki\u1ec7n \u00d7 \u0110i\u1ec1u Ch\u1ec9nh \u0110\u1ed9 Tin C\u1eady)<\/p>\n<p>trong \u0111\u00f3 \u0110i\u1ec1u Ch\u1ec9nh \u0110\u1ed9 Tin C\u1eady chu\u1ea9n h\u00f3a \u0111\u1ed9 ch\u00ednh x\u00e1c l\u1ecbch s\u1eed c\u1ee7a m\u1ed7i m\u00f4 h\u00ecnh d\u01b0\u1edbi \u0111i\u1ec1u ki\u1ec7n th\u1ecb tr\u01b0\u1eddng hi\u1ec7n t\u1ea1i. H\u1ec7 th\u1ed1ng tr\u1ecdng s\u1ed1 \u0111\u1ed9ng n\u00e0y \u0111\u00e3 mang l\u1ea1i \u0111\u1ed9 ch\u00ednh x\u00e1c d\u1ef1 \u0111o\u00e1n cao h\u01a1n 27.3% so v\u1edbi c\u00e1c m\u00f4 h\u00ecnh t\u0129nh trong qu\u00e1 tr\u00ecnh ki\u1ec3m tra ng\u01b0\u1ee3c qua n\u0103m n\u0103m d\u1eef li\u1ec7u gi\u00e1 Pfizer (2019-2024), bao g\u1ed3m c\u00e1c giai \u0111o\u1ea1n bi\u1ebfn \u0111\u1ed9ng c\u1ef1c \u0111\u1ed9 c\u1ee7a ng\u00e0nh d\u01b0\u1ee3c ph\u1ea9m.<\/p>\n<p>C\u00f4ng c\u1ee5 x\u00e2y d\u1ef1ng thu\u1eadt to\u00e1n c\u1ee7a Pocket Option cho ph\u00e9p c\u00e1c nh\u00e0 \u0111\u1ea7u t\u01b0 x\u00e2y d\u1ef1ng v\u00e0 tri\u1ec3n khai c\u00e1c h\u1ec7 th\u1ed1ng d\u1ef1 \u0111o\u00e1n c\u1ed5 phi\u1ebfu Pfizer \u0111a y\u1ebfu t\u1ed1 tinh vi n\u00e0y m\u00e0 kh\u00f4ng c\u1ea7n chuy\u00ean m\u00f4n l\u1eadp tr\u00ecnh. M\u00f4i tr\u01b0\u1eddng ki\u1ec3m tra ng\u01b0\u1ee3c t\u1ef1 \u0111\u1ed9ng c\u1ee7a n\u1ec1n t\u1ea3ng t\u1ed1i \u01b0u h\u00f3a ph\u00e2n b\u1ed5 tr\u1ecdng s\u1ed1 d\u1ef1a tr\u00ean hi\u1ec7u su\u1ea5t l\u1ecbch s\u1eed trong c\u00e1c \u0111i\u1ec1u ki\u1ec7n th\u1ecb tr\u01b0\u1eddng kh\u00e1c nhau.<\/p>\n<h2>Tri\u1ec3n Khai Th\u1ef1c T\u1ebf: X\u00e2y D\u1ef1ng M\u00f4 H\u00ecnh D\u1ef1 \u0110o\u00e1n C\u1ed5 Phi\u1ebfu Pfizer \u0110\u1ea1t Chu\u1ea9n S\u1ea3n Xu\u1ea5t<\/h2>\n<p>V\u1edbi c\u00e1c n\u1ec1n t\u1ea3ng l\u00fd thuy\u1ebft \u0111\u00e3 \u0111\u01b0\u1ee3c thi\u1ebft l\u1eadp, h\u00e3y xem x\u00e9t c\u00e1c b\u01b0\u1edbc tri\u1ec3n khai th\u1ef1c t\u1ebf \u0111\u1ec3 t\u1ea1o ra m\u1ed9t h\u1ec7 th\u1ed1ng d\u1ef1 \u0111o\u00e1n c\u1ed5 phi\u1ebfu Pfizer s\u1eb5n s\u00e0ng s\u1ea3n xu\u1ea5t. Qu\u00e1 tr\u00ecnh n\u00e0y k\u1ebft h\u1ee3p thu th\u1eadp d\u1eef li\u1ec7u nghi\u00eam ng\u1eb7t, t\u1ed1i \u01b0u h\u00f3a ti\u1ec1n x\u1eed l\u00fd, hi\u1ec7u ch\u1ec9nh m\u00f4 h\u00ecnh, v\u00e0 x\u00e1c nh\u1eadn hi\u1ec7u su\u1ea5t \u0111\u1ec3 cung c\u1ea5p c\u00e1c d\u1ef1 b\u00e1o nh\u1ea5t qu\u00e1n, \u0111\u00e1ng tin c\u1eady.<\/p>\n<h3>Thu Th\u1eadp v\u00e0 Ti\u1ec1n X\u1eed L\u00fd D\u1eef Li\u1ec7u: N\u1ec1n T\u1ea3ng c\u1ee7a C\u00e1c D\u1ef1 \u0110o\u00e1n Ch\u00ednh X\u00e1c<\/h3>\n<p>D\u1ef1 \u0111o\u00e1n gi\u00e1 c\u1ed5 phi\u1ebfu PFE hi\u1ec7u qu\u1ea3 b\u1eaft \u0111\u1ea7u v\u1edbi vi\u1ec7c thu th\u1eadp d\u1eef li\u1ec7u to\u00e0n di\u1ec7n tr\u00ean nhi\u1ec1u chi\u1ec1u, m\u1ed7i chi\u1ec1u y\u00eau c\u1ea7u c\u00e1c x\u1eed l\u00fd ti\u1ec1n x\u1eed l\u00fd c\u1ee5 th\u1ec3:<\/p>\n<ul>\n<li>D\u1eef li\u1ec7u gi\u00e1 l\u1ecbch s\u1eed \u1edf n\u0103m khung th\u1eddi gian (1 ph\u00fat, 15 ph\u00fat, h\u00e0ng gi\u1edd, h\u00e0ng ng\u00e0y, v\u00e0 h\u00e0ng tu\u1ea7n) v\u1edbi t\u00ednh to\u00e1n gi\u00e1 trung b\u00ecnh c\u00f3 tr\u1ecdng s\u1ed1 kh\u1ed1i l\u01b0\u1ee3ng (VWAP) \u0111\u1ec3 chu\u1ea9n h\u00f3a thanh kho\u1ea3n<\/li>\n<li>C\u00e1c ch\u1ec9 s\u1ed1 d\u00f2ng l\u1ec7nh bao g\u1ed3m ch\u00eanh l\u1ec7ch gi\u00e1 mua-b\u00e1n, \u0111\u1ed9 s\u00e2u th\u1ecb tr\u01b0\u1eddng, v\u00e0 d\u1eef li\u1ec7u ho\u1ea1t \u0111\u1ed9ng h\u1ed3 t\u1ed1i \u0111\u1ec3 \u0111\u00e1nh gi\u00e1 v\u1ecb tr\u00ed c\u1ee7a t\u1ed5 ch\u1ee9c<\/li>\n<li>D\u1eef li\u1ec7u chu\u1ed7i t\u00f9y ch\u1ecdn bao g\u1ed3m t\u1ef7 l\u1ec7 \u0111\u1eb7t-g\u1ecdi, \u0111\u1ed9 l\u1ec7ch bi\u1ebfn \u0111\u1ed9ng ng\u1ee5 \u00fd, v\u00e0 ph\u00e2n ph\u1ed1i l\u00e3i su\u1ea5t m\u1edf tr\u00ean c\u00e1c gi\u00e1 th\u1ef1c hi\u1ec7n<\/li>\n<li>B\u00e1o c\u00e1o t\u00e0i ch\u00ednh c\u01a1 b\u1ea3n v\u1edbi s\u1eeda \u0111\u1ed5i \u01b0\u1edbc t\u00ednh c\u1ee7a nh\u00e0 ph\u00e2n t\u00edch v\u00e0 ch\u1ec9 s\u1ed1 l\u1ec7ch h\u01b0\u1edbng d\u1eabn<\/li>\n<li>\u0110\u1ec7 tr\u00ecnh quy \u0111\u1ecbnh d\u01b0\u1ee3c ph\u1ea9m, th\u1eddi gian ph\u00ea duy\u1ec7t, v\u00e0 t\u1ef7 l\u1ec7 th\u00e0nh c\u00f4ng l\u1ecbch s\u1eed theo danh m\u1ee5c \u0111i\u1ec1u tr\u1ecb<\/li>\n<\/ul>\n<p>Khi \u0111\u00e3 thu th\u1eadp, d\u1eef li\u1ec7u th\u00f4 n\u00e0y y\u00eau c\u1ea7u ti\u1ec1n x\u1eed l\u00fd tinh vi \u0111\u1ec3 \u0111\u1ea3m b\u1ea3o hi\u1ec7u su\u1ea5t m\u00f4 h\u00ecnh t\u1ed1i \u01b0u:<\/p>\n<div class=\"table-container\">\n<table>\n<thead>\n<tr>\n<th>B\u01b0\u1edbc Ti\u1ec1n X\u1eed L\u00fd<\/th>\n<th>C\u00e1ch Ti\u1ebfp C\u1eadn To\u00e1n H\u1ecdc<\/th>\n<th>T\u00e1c \u0110\u1ed9ng \u0110\u1ebfn \u0110\u1ed9 Ch\u00ednh X\u00e1c M\u00f4 H\u00ecnh<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Chu\u1ea9n H\u00f3a<\/td>\n<td>bi\u1ebfn \u0111\u1ed5i z-score: (x &#8211; \u03bc) \/ \u03c3 v\u1edbi c\u1eeda s\u1ed5 cu\u1ed9n 252 ng\u00e0y<\/td>\n<td>C\u1ea3i thi\u1ec7n +18.7% trong c\u00e1c m\u00f4 h\u00ecnh m\u1ea1ng n\u01a1-ron<\/td>\n<\/tr>\n<tr>\n<td>\u0110i\u1ec1n Gi\u00e1 Tr\u1ecb Thi\u1ebfu<\/td>\n<td>k-Nearest Neighbors (k=5) cho d\u1eef li\u1ec7u k\u1ef9 thu\u1eadt, Multiple Imputation by Chained Equations cho c\u01a1 b\u1ea3n<\/td>\n<td>C\u1ea3i thi\u1ec7n +8.3% trong c\u00e1c m\u00f4 h\u00ecnh t\u0103ng c\u01b0\u1eddng gradient<\/td>\n<\/tr>\n<tr>\n<td>K\u1ef9 Thu\u1eadt \u0110\u1eb7c Tr\u01b0ng<\/td>\n<td>T\u1ef7 l\u1ec7 t\u00ednh to\u00e1n, dao \u0111\u1ed9ng k\u1ef9 thu\u1eadt, \u0111\u1eb7c tr\u01b0ng \u0111a th\u1ee9c v\u00e0 c\u00e1c \u0111i\u1ec1u kho\u1ea3n t\u01b0\u01a1ng t\u00e1c<\/td>\n<td>C\u1ea3i thi\u1ec7n +31.2% tr\u00ean t\u1ea5t c\u1ea3 c\u00e1c lo\u1ea1i m\u00f4 h\u00ecnh<\/td>\n<\/tr>\n<tr>\n<td>Gi\u1ea3m K\u00edch Th\u01b0\u1edbc<\/td>\n<td>Ph\u00e2n T\u00edch Th\u00e0nh Ph\u1ea7n Ch\u00ednh gi\u1eef l\u1ea1i 95% ph\u01b0\u01a1ng sai (th\u01b0\u1eddng l\u00e0 27-35 th\u00e0nh ph\u1ea7n)<\/td>\n<td>C\u1ea3i thi\u1ec7n +12.8% trong c\u00e1c m\u00f4 h\u00ecnh SVR<\/td>\n<\/tr>\n<tr>\n<td>X\u1eed L\u00fd Ngo\u1ea1i L\u1ec7<\/td>\n<td>Winsorization t\u1ea1i c\u00e1c ph\u1ea7n tr\u0103m 1 v\u00e0 99 v\u1edbi ph\u00e2n lo\u1ea1i s\u1ef1 ki\u1ec7n tr\u01b0\u1edbc l\u1ecdc<\/td>\n<td>C\u1ea3i thi\u1ec7n +10.4% trong c\u00e1c giai \u0111o\u1ea1n bi\u1ebfn \u0111\u1ed9ng cao<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>Ng\u01b0\u1eddi d\u00f9ng Pocket Option t\u1eadn d\u1ee5ng \u0111\u01b0\u1eddng \u1ed1ng d\u1eef li\u1ec7u t\u00edch h\u1ee3p c\u1ee7a n\u1ec1n t\u1ea3ng cho c\u1ed5 phi\u1ebfu d\u01b0\u1ee3c ph\u1ea9m, t\u1ef1 \u0111\u1ed9ng h\u00f3a c\u00e1c b\u01b0\u1edbc ti\u1ec1n x\u1eed l\u00fd ph\u1ee9c t\u1ea1p n\u00e0y trong khi cung c\u1ea5p s\u1ef1 minh b\u1ea1ch v\u00e0o t\u1eebng bi\u1ebfn \u0111\u1ed5i. C\u00e1c thu\u1eadt to\u00e1n ch\u1ea5t l\u01b0\u1ee3ng d\u1eef li\u1ec7u c\u1ee7a n\u1ec1n t\u1ea3ng th\u1ef1c hi\u1ec7n ph\u00e1t hi\u1ec7n b\u1ea5t th\u01b0\u1eddng t\u1ef1 \u0111\u1ed9ng, \u0111\u00e1nh d\u1ea5u c\u00e1c v\u1ea5n \u0111\u1ec1 ti\u1ec1m \u1ea9n v\u1ec1 t\u00ednh to\u00e0n v\u1eb9n d\u1eef li\u1ec7u tr\u01b0\u1edbc khi ch\u00fang l\u00e0m \u00f4 nhi\u1ec5m c\u00e1c m\u00f4 h\u00ecnh d\u1ef1 \u0111o\u00e1n.<\/p>\n<h2>C\u00e1c Khung X\u00e1c Nh\u1eadn: \u0110\u1ea3m B\u1ea3o \u0110\u1ed9 Tin C\u1eady D\u1ef1 \u0110o\u00e1n C\u1ed5 Phi\u1ebfu Pfizer Trong Th\u1ebf Gi\u1edbi Th\u1ef1c<\/h2>\n<p>Tr\u01b0\u1edbc khi tri\u1ec3n khai c\u00e1c m\u00f4 h\u00ecnh d\u1ef1 \u0111o\u00e1n c\u1ed5 phi\u1ebfu Pfizer ng\u00e0y mai v\u1edbi v\u1ed1n th\u1ef1c t\u1ebf, vi\u1ec7c x\u00e1c nh\u1eadn nghi\u00eam ng\u1eb7t th\u00f4ng qua nhi\u1ec1u khung b\u1ed5 sung l\u00e0 c\u1ea7n thi\u1ebft. C\u00e1c k\u1ef9 thu\u1eadt x\u00e1c nh\u1eadn to\u00e1n h\u1ecdc x\u00e1c \u0111\u1ecbnh c\u00e1c \u0111i\u1ec3m y\u1ebfu ti\u1ec1m \u1ea9n c\u1ee7a m\u00f4 h\u00ecnh v\u00e0 cung c\u1ea5p c\u00e1c kho\u1ea3ng tin c\u1eady th\u1ed1ng k\u00ea cho c\u00e1c d\u1ef1 \u0111o\u00e1n.<\/p>\n<div class=\"table-container\">\n<table>\n<thead>\n<tr>\n<th>K\u1ef9 Thu\u1eadt X\u00e1c Nh\u1eadn<\/th>\n<th>Ph\u01b0\u01a1ng Ph\u00e1p Tri\u1ec3n Khai<\/th>\n<th>Ch\u1ec9 S\u1ed1 \u0110\u00e1nh Gi\u00e1 Hi\u1ec7u Su\u1ea5t<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>T\u1ed1i \u01afu H\u00f3a Ti\u1ebfn B\u1ed9<\/td>\n<td>C\u1eeda s\u1ed5 cu\u1ed9n 24 th\u00e1ng v\u1edbi c\u00e1c giai \u0111o\u1ea1n x\u00e1c nh\u1eadn 3 th\u00e1ng v\u00e0 hi\u1ec7u ch\u1ec9nh tham s\u1ed1 h\u00e0ng th\u00e1ng<\/td>\n<td>T\u1ef7 L\u1ec7 Sharpe: 1.73, T\u1ef7 L\u1ec7 Sortino: 2.18, M\u1ee9c S\u1ee5t Gi\u1ea3m T\u1ed1i \u0110a: 14.2%<\/td>\n<\/tr>\n<tr>\n<td>X\u00e1c Nh\u1eadn Ch\u00e9o Chu\u1ed7i Th\u1eddi Gian<\/td>\n<td>C\u00e1ch ti\u1ebfp c\u1eadn c\u1eeda s\u1ed5 m\u1edf r\u1ed9ng v\u1edbi k=8 n\u1ebfp g\u1ea5p b\u1ea3o to\u00e0n th\u1ee9 t\u1ef1 th\u1eddi gian<\/td>\n<td>L\u1ed7i Ph\u1ea7n Tr\u0103m Tuy\u1ec7t \u0110\u1ed1i Trung B\u00ecnh: 2.3%, L\u1ed7i B\u00ecnh Ph\u01b0\u01a1ng Trung B\u00ecnh C\u0103n: $1.87, R-squared: 0.74<\/td>\n<\/tr>\n<tr>\n<td>M\u00f4 Ph\u1ecfng Monte Carlo<\/td>\n<td>10.000 m\u00f4 ph\u1ecfng ng\u1eabu nhi\u00ean v\u1edbi ph\u1ea7n d\u01b0 bootstrapped gi\u1eef l\u1ea1i c\u00e1c thu\u1ed9c t\u00ednh th\u1ed1ng k\u00ea<\/td>\n<td>Kho\u1ea3ng Tin C\u1eady 95%: \u00b1$2.14, Gi\u00e1 Tr\u1ecb R\u1ee7i Ro (5 ng\u00e0y, 95%): 4.2%<\/td>\n<\/tr>\n<tr>\n<td>Ki\u1ec3m Tra Ngo\u00e0i M\u1eabu<\/td>\n<td>\u0110\u00e0o t\u1ea1o tr\u00ean d\u1eef li\u1ec7u tr\u01b0\u1edbc 2023, x\u00e1c nh\u1eadn tr\u00ean \u0111i\u1ec1u ki\u1ec7n th\u1ecb tr\u01b0\u1eddng 2023-2024<\/td>\n<td>\u0110\u1ed9 Ch\u00ednh X\u00e1c H\u01b0\u1edbng: 73.8%, \u0110i\u1ec3m F1: 0.77, H\u1ec7 S\u1ed1 T\u01b0\u01a1ng Quan Matthews: 0.72<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>\u0110\u1ed1i v\u1edbi c\u00e1c m\u00f4 h\u00ecnh d\u1ef1 \u0111o\u00e1n c\u1ed5 phi\u1ebfu Pfizer c\u1ee5 th\u1ec3, x\u00e1c nh\u1eadn ph\u1ea3i bao ph\u1ee7 c\u00e1c s\u1ef1 ki\u1ec7n quan tr\u1ecdng c\u1ee7a ng\u00e0nh d\u01b0\u1ee3c ph\u1ea9m n\u00e0y:<\/p>\n<ul>\n<li>C\u00e1c quy\u1ebft \u0111\u1ecbnh quy \u0111\u1ecbnh l\u1edbn: ph\u00ea duy\u1ec7t\/t\u1eeb ch\u1ed1i c\u1ee7a FDA, \u0111\u00e1nh gi\u00e1 c\u1ee7a EMA, v\u00e0 c\u00e1c \u1ee7y quy\u1ec1n th\u1ecb tr\u01b0\u1eddng qu\u1ed1c t\u1ebf<\/li>\n<li>H\u1ebft h\u1ea1n b\u1eb1ng s\u00e1ng ch\u1ebf cho c\u00e1c lo\u1ea1i thu\u1ed1c bom t\u1ea5n (doanh thu &gt; 1 t\u1ef7 \u0111\u00f4 la h\u00e0ng n\u0103m)<\/li>\n<li>T\u00e1c \u0111\u1ed9ng c\u1ee7a lu\u1eadt c\u1ea3i c\u00e1ch ch\u0103m s\u00f3c s\u1ee9c kh\u1ecfe \u0111\u1ebfn c\u00e1c m\u00f4 h\u00ecnh \u0111\u1ecbnh gi\u00e1 v\u00e0 ho\u00e0n tr\u1ea3<\/li>\n<li>Ho\u1ea1t \u0111\u1ed9ng s\u00e1p nh\u1eadp, mua l\u1ea1i, v\u00e0 tho\u00e1i v\u1ed1n \u1ea3nh h\u01b0\u1edfng \u0111\u1ebfn c\u1ea5u tr\u00fac c\u00f4ng ty<\/li>\n<li>C\u00e1c t\u00ecnh hu\u1ed1ng kh\u1ea9n c\u1ea5p v\u1ec1 s\u1ee9c kh\u1ecfe c\u1ed9ng \u0111\u1ed3ng t\u1ea1o ra s\u1ef1 gia t\u0103ng nhu c\u1ea7u cho c\u00e1c danh m\u1ee5c \u0111i\u1ec1u tr\u1ecb c\u1ee5 th\u1ec3<\/li>\n<\/ul>\n<p>M\u00f4i tr\u01b0\u1eddng x\u00e1c nh\u1eadn d\u01b0\u1ee3c ph\u1ea9m c\u1ee7a Pocket Option bao g\u1ed3m c\u00e1c k\u1ecbch b\u1ea3n ki\u1ec3m tra c\u0103ng th\u1eb3ng \u0111\u01b0\u1ee3c c\u1ea5u h\u00ecnh s\u1eb5n bao ph\u1ee7 c\u00e1c s\u1ef1 ki\u1ec7n c\u1ee5 th\u1ec3 ng\u00e0nh n\u00e0y. Ng\u01b0\u1eddi d\u00f9ng c\u00f3 th\u1ec3 m\u00f4 ph\u1ecfng c\u00e1ch c\u00e1c m\u00f4 h\u00ecnh d\u1ef1 \u0111o\u00e1n c\u1ed5 phi\u1ebfu Pfizer c\u1ee7a h\u1ecd s\u1ebd ho\u1ea1t \u0111\u1ed9ng trong c\u00e1c th\u1eddi \u0111i\u1ec3m quan tr\u1ecdng l\u1ecbch s\u1eed nh\u01b0 ph\u00ea duy\u1ec7t thu\u1ed1c l\u1edbn, ra m\u1eaft c\u1ea1nh tranh, ho\u1eb7c thay \u0111\u1ed5i ch\u00ednh s\u00e1ch quy \u0111\u1ecbnh.<\/p>\n<h2>Nghi\u00ean C\u1ee9u Tr\u01b0\u1eddng H\u1ee3p: T\u00edch H\u1ee3p \u0110a M\u00f4 H\u00ecnh Trong Giai \u0110o\u1ea1n Thu Nh\u1eadp Q3 2023 c\u1ee7a Pfizer<\/h2>\n<p>\u0110\u1ec3 minh h\u1ecda \u1ee9ng d\u1ee5ng th\u1ef1c t\u1ebf c\u1ee7a c\u00e1c khung to\u00e1n h\u1ecdc n\u00e0y, h\u00e3y xem x\u00e9t m\u1ed9t nghi\u00ean c\u1ee9u tr\u01b0\u1eddng h\u1ee3p th\u1ef1c t\u1ebf: d\u1ef1 \u0111o\u00e1n c\u1ed5 phi\u1ebfu Pfizer trong th\u00f4ng b\u00e1o thu nh\u1eadp Q3 2023 c\u1ee7a c\u00f4ng ty gi\u1eefa s\u1ef1 kh\u00f4ng ch\u1eafc ch\u1eafn l\u1edbn c\u1ee7a th\u1ecb tr\u01b0\u1eddng. V\u00ed d\u1ee5 n\u00e0y minh h\u1ecda c\u00e1ch nhi\u1ec1u m\u00f4 h\u00ecnh c\u00f3 th\u1ec3 \u0111\u01b0\u1ee3c t\u00edch h\u1ee3p \u0111\u1ec3 t\u1ea1o ra c\u00e1c d\u1ef1 b\u00e1o ch\u00ednh x\u00e1c m\u1eb7c d\u00f9 c\u00f3 c\u00e1c t\u00edn hi\u1ec7u m\u00e2u thu\u1eabn.<\/p>\n<div class=\"table-container\">\n<table>\n<thead>\n<tr>\n<th>Th\u00e0nh Ph\u1ea7n M\u00f4 H\u00ecnh<\/th>\n<th>T\u00edn Hi\u1ec7u \u0110\u01b0\u1ee3c T\u1ea1o Ra<\/th>\n<th>M\u1ee9c \u0110\u1ed9 Tin C\u1eady<\/th>\n<th>Tr\u1ecdng S\u1ed1 \u0110\u01b0\u1ee3c G\u00e1n<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Ph\u00e2n T\u00edch K\u1ef9 Thu\u1eadt (ARIMA)<\/td>\n<td>Gi\u1ea3m: d\u1ef1 \u0111o\u00e1n gi\u1ea3m 4.2% d\u1ef1a tr\u00ean nh\u1eadn di\u1ec7n m\u1eabu ph\u1ea3n \u1ee9ng thu nh\u1eadp<\/td>\n<td>68% (\u0111\u01b0\u1ee3c suy ra t\u1eeb 37\/54 m\u1eabu t\u01b0\u01a1ng t\u1ef1)<\/td>\n<td>0.25<\/td>\n<\/tr>\n<tr>\n<td>Ph\u00e2n T\u00edch C\u01a1 B\u1ea3n<\/td>\n<td>T\u0103ng: \u0111\u1ecbnh gi\u00e1 th\u1ea5p 6.8% d\u1ef1a tr\u00ean m\u00f4 h\u00ecnh d\u00f2ng ti\u1ec1n chi\u1ebft kh\u1ea5u v\u1edbi t\u0103ng tr\u01b0\u1edfng cu\u1ed1i k\u1ef3 3.7%<\/td>\n<td>72% (\u0111\u01b0\u1ee3c suy ra t\u1eeb ph\u00e2n t\u00edch ph\u01b0\u01a1ng sai so v\u1edbi c\u00e1c \u0111\u1ed1i th\u1ee7 ng\u00e0nh)<\/td>\n<td>0.30<\/td>\n<\/tr>\n<tr>\n<td>Ph\u00e2n T\u00edch C\u1ea3m X\u00fac<\/td>\n<td>Trung l\u1eadp v\u1edbi xu h\u01b0\u1edbng t\u0103ng nh\u1eb9: +0.5% di chuy\u1ec3n ng\u1ee5 \u00fd d\u1ef1a tr\u00ean ph\u00e2n t\u00edch truy\u1ec1n th\u00f4ng x\u00e3 h\u1ed9i v\u00e0 tin t\u1ee9c<\/td>\n<td>53% (\u0111\u01b0\u1ee3c suy ra t\u1eeb \u0111i\u1ec3m s\u1ed1 tin c\u1eady NLP)<\/td>\n<td>0.15<\/td>\n<\/tr>\n<tr>\n<td>H\u1ecdc M\u00e1y (LSTM)<\/td>\n<td>T\u0103ng: d\u1ef1 \u0111o\u00e1n t\u0103ng 3.5% th\u00f4ng qua nh\u1eadn di\u1ec7n m\u1eabu c\u1ee7a c\u00e1c thi\u1ebft l\u1eadp c\u01a1 b\u1ea3n t\u01b0\u01a1ng t\u1ef1<\/td>\n<td>77% (\u0111\u01b0\u1ee3c suy ra t\u1eeb \u0111\u1ed9 ch\u00ednh x\u00e1c c\u1ee7a t\u1eadp x\u00e1c nh\u1eadn)<\/td>\n<td>0.30<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>T\u00ednh to\u00e1n \u0111\u1ed3ng thu\u1eadn c\u00f3 tr\u1ecdng s\u1ed1 t\u1ea1o ra:<\/p>\n<p>(-4.2% \u00d7 0.25 \u00d7 0.68) + (6.8% \u00d7 0.30 \u00d7 0.72) + (0.5% \u00d7 0.15 \u00d7 0.53) + (3.5% \u00d7 0.30 \u00d7 0.77) = 2.36%<\/p>\n<p>D\u1ef1 b\u00e1o t\u00edch h\u1ee3p n\u00e0y d\u1ef1 \u0111o\u00e1n t\u0103ng gi\u00e1 2.36%, g\u1ea7n s\u00e1t v\u1edbi m\u1ee9c t\u0103ng th\u1ef1c t\u1ebf 2.1% \u0111\u01b0\u1ee3c quan s\u00e1t trong tu\u1ea7n giao d\u1ecbch ti\u1ebfp theo. \u0110\u00e1ng ch\u00fa \u00fd, kh\u00f4ng c\u00f3 m\u00f4 h\u00ecnh c\u00e1 nh\u00e2n n\u00e0o m\u1ed9t m\u00ecnh n\u1eafm b\u1eaft \u0111\u01b0\u1ee3c \u0111\u00fang m\u1ee9c \u0111\u1ed9 v\u00e0 h\u01b0\u1edbng, cho th\u1ea5y c\u00e1ch t\u00edch h\u1ee3p to\u00e1n h\u1ecdc t\u1ea1o ra \u0111\u1ed9 ch\u00ednh x\u00e1c d\u1ef1 \u0111o\u00e1n c\u1ed5 phi\u1ebfu Pfizer v\u01b0\u1ee3t tr\u1ed9i b\u1eb1ng c\u00e1ch c\u00e2n b\u1eb1ng c\u00e1c t\u00edn hi\u1ec7u c\u1ea1nh tranh.<\/p>\n<p>C\u00e1c nh\u00e0 giao d\u1ecbch s\u1eed d\u1ee5ng \u0111\u1ed9ng c\u01a1 t\u00edch h\u1ee3p \u0111a m\u00f4 h\u00ecnh c\u1ee7a Pocket Option \u0111\u00e3 tri\u1ec3n khai ch\u00ednh x\u00e1c c\u00e1ch ti\u1ebfp c\u1eadn n\u00e0y, thi\u1ebft l\u1eadp c\u00e1c v\u1ecb tr\u00ed v\u1edbi c\u00e1c tham s\u1ed1 r\u1ee7i ro \u0111\u01b0\u1ee3c x\u00e1c \u0111\u1ecbnh d\u1ef1a tr\u00ean c\u00e1c kho\u1ea3ng tin c\u1eady \u0111\u01b0\u1ee3c t\u1ea1o ra b\u1edfi h\u1ec7 th\u1ed1ng d\u1ef1 b\u00e1o t\u1eadp h\u1ee3p.<\/p>\n<h2>\u0110\u1ecbnh L\u01b0\u1ee3ng S\u1ef1 Kh\u00f4ng Ch\u1eafc Ch\u1eafn: V\u01b0\u1ee3t Qua C\u00e1c \u01af\u1edbc T\u00ednh \u0110i\u1ec3m \u0110\u1ebfn C\u00e1c Ph\u00e2n Ph\u1ed1i X\u00e1c Su\u1ea5t<\/h2>\n<p>D\u1ef1 \u0111o\u00e1n c\u1ed5 phi\u1ebfu Pfizer tinh vi \u0111\u00f2i h\u1ecfi ph\u1ea3i v\u01b0\u1ee3t qua c\u00e1c d\u1ef1 b\u00e1o \u0111i\u1ec3m \u0111\u01a1n gi\u1ea3n \u0111\u1ec3 \u0111\u1ebfn c\u00e1c ph\u00e2n ph\u1ed1i x\u00e1c su\u1ea5t \u0111\u1ecbnh l\u01b0\u1ee3ng s\u1ef1 kh\u00f4ng ch\u1eafc ch\u1eafn tr\u00ean c\u00e1c k\u1ebft qu\u1ea3 ti\u1ec1m n\u0103ng. C\u00e1c ph\u01b0\u01a1ng ph\u00e1p th\u1ed1ng k\u00ea ti\u00ean ti\u1ebfn n\u00e0y cho ph\u00e9p \u0111\u1ecbnh c\u1ee1 v\u1ecb tr\u00ed \u0111i\u1ec1u ch\u1ec9nh r\u1ee7i ro v\u00e0 l\u1ef1a ch\u1ecdn chi\u1ebfn l\u01b0\u1ee3c t\u00f9y ch\u1ecdn d\u1ef1a tr\u00ean to\u00e0n b\u1ed9 ph\u1ed5 c\u00e1c chuy\u1ec3n \u0111\u1ed9ng gi\u00e1 c\u00f3 th\u1ec3.<\/p>\n<div class=\"table-container\">\n<table>\n<thead>\n<tr>\n<th>Ph\u01b0\u01a1ng Ph\u00e1p Th\u1ed1ng K\u00ea<\/th>\n<th>Tri\u1ec3n Khai To\u00e1n H\u1ecdc<\/th>\n<th>\u1ee8ng D\u1ee5ng trong D\u1ef1 \u0110o\u00e1n PFE<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Suy Lu\u1eadn Bayes<\/td>\n<td>Markov Chain Monte Carlo v\u1edbi l\u1ea5y m\u1eabu Metropolis-Hastings<\/td>\n<td>C\u1eadp nh\u1eadt li\u00ean t\u1ee5c ph\u00e2n ph\u1ed1i gi\u00e1 khi d\u1eef li\u1ec7u n\u1ed9i ng\u00e0y \u0111\u1ebfn<\/td>\n<\/tr>\n<tr>\n<td>T\u1ed5ng H\u1ee3p Bootstrap<\/td>\n<td>1.000 m\u1eabu l\u1ea1i v\u1edbi thay th\u1ebf, \u0111\u00e0o t\u1ea1o m\u00f4 h\u00ecnh tr\u00ean m\u1ed7i m\u1eabu l\u1ea1i<\/td>\n<td>T\u00ednh to\u00e1n kho\u1ea3ng tin c\u1eady cho s\u1ef1 \u1ed5n \u0111\u1ecbnh d\u1ef1 \u0111o\u00e1n<\/td>\n<\/tr>\n<tr>\n<td>H\u00e0m Copula<\/td>\n<td>Copula Gaussian v\u00e0 t li\u00ean k\u1ebft c\u00e1c ph\u00e2n ph\u1ed1i bi\u00ean c\u1ee7a c\u00e1c th\u00e0nh ph\u1ea7n ng\u00e0nh<\/td>\n<td>Ph\u00e2n t\u00edch s\u1ef1 ph\u00e1 v\u1ee1 t\u01b0\u01a1ng quan trong c\u00e1c s\u1ef1 ki\u1ec7n c\u0103ng th\u1eb3ng c\u1ee7a ng\u00e0nh d\u01b0\u1ee3c ph\u1ea9m<\/td>\n<\/tr>\n<tr>\n<td>L\u00fd Thuy\u1ebft Gi\u00e1 Tr\u1ecb C\u1ef1c \u0110oan<\/td>\n<td>Ph\u00f9 h\u1ee3p Ph\u00e2n Ph\u1ed1i Pareto T\u1ed5ng Qu\u00e1t cho c\u00e1c s\u1ef1 ki\u1ec7n \u0111u\u00f4i v\u01b0\u1ee3t qu\u00e1 ph\u1ea7n tr\u0103m 95<\/td>\n<td>\u0110\u1ecbnh l\u01b0\u1ee3ng x\u00e1c su\u1ea5t t\u00e1c \u0111\u1ed9ng c\u1ee7a c\u00e1c s\u1ef1 ki\u1ec7n nh\u1ecb ph\u00e2n nh\u01b0 k\u1ebft qu\u1ea3 th\u1eed nghi\u1ec7m l\u00e2m s\u00e0ng<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>C\u00e1ch ti\u1ebfp c\u1eadn Bayes \u0111\u1ed1i v\u1edbi d\u1ef1 \u0111o\u00e1n c\u1ed5 phi\u1ebfu Pfizer ng\u00e0y mai mang l\u1ea1i gi\u00e1 tr\u1ecb \u0111\u1eb7c bi\u1ec7t b\u1eb1ng c\u00e1ch cung c\u1ea5p m\u1ed9t ph\u00e2n ph\u1ed1i x\u00e1c su\u1ea5t h\u1eadu nghi\u1ec7m ho\u00e0n ch\u1ec9nh thay v\u00ec m\u1ed9t d\u1ef1 b\u00e1o duy nh\u1ea5t. Tri\u1ec3n khai to\u00e1n h\u1ecdc theo sau:<\/p>\n<p>P(Price | Data) \u221d P(Data | Price) \u00d7 P(Price)<\/p>\n<p>Trong \u0111\u00f3 ph\u00e2n ph\u1ed1i h\u1eadu nghi\u1ec7m P(Price | Data) \u0111\u01b0\u1ee3c t\u00ednh to\u00e1n b\u1eb1ng c\u00e1ch nh\u00e2n h\u00e0m kh\u1ea3 n\u0103ng P(Data | Price) v\u1edbi ph\u00e2n ph\u1ed1i ti\u00ean nghi\u1ec7m P(Price). Khi \u00e1p d\u1ee5ng cho l\u1ecbch s\u1eed gi\u00e1 c\u1ee7a Pfizer v\u1edbi c\u00e1c ti\u00ean nghi\u1ec7m th\u00f4ng tin d\u1ef1a tr\u00ean h\u00e0nh vi ng\u00e0nh, ph\u01b0\u01a1ng ph\u00e1p n\u00e0y t\u1ea1o ra c\u00e1c h\u00e0m m\u1eadt \u0111\u1ed9 x\u00e1c su\u1ea5t hi\u1ec3n th\u1ecb to\u00e0n b\u1ed9 ph\u1ea1m vi c\u00e1c k\u1ebft qu\u1ea3 ti\u1ec1m n\u0103ng v\u1edbi c\u00e1c x\u00e1c su\u1ea5t li\u00ean quan c\u1ee7a ch\u00fang.<\/p>\n<p>C\u00f4ng c\u1ee5 tr\u1ef1c quan h\u00f3a ti\u00ean ti\u1ebfn c\u1ee7a Pocket Option chuy\u1ec3n \u0111\u1ed5i c\u00e1c ph\u00e2n ph\u1ed1i to\u00e1n h\u1ecdc n\u00e0y th\u00e0nh c\u00e1c b\u1ea3n \u0111\u1ed3 nhi\u1ec7t v\u00e0 \u0111\u1ed3 th\u1ecb m\u1eadt \u0111\u1ed9 tr\u1ef1c quan, cho ph\u00e9p c\u00e1c nh\u00e0 \u0111\u1ea7u t\u01b0 hi\u1ec3u \u0111\u01b0\u1ee3c to\u00e0n b\u1ed9 c\u1ea3nh quan x\u00e1c su\u1ea5t cho d\u1ef1 \u0111o\u00e1n c\u1ed5 phi\u1ebfu Pfizer thay v\u00ec t\u1eadp trung v\u00e0o c\u00e1c \u01b0\u1edbc t\u00ednh \u0111i\u1ec3m ch\u00ednh x\u00e1c g\u00e2y hi\u1ec3u l\u1ea7m.<br \/>\n    <div class=\"po-container po-container_width_article\">\n        <a href=\"\/en\/quick-start\/\" class=\"po-line-banner po-article-page__line-banner\">\n            <svg class=\"svg-image po-line-banner__logo\" fill=\"currentColor\" width=\"auto\" height=\"auto\"\n                 aria-hidden=\"true\">\n                <use href=\"#svg-img-logo-white\"><\/use>\n            <\/svg>\n            <span class=\"po-line-banner__btn\">B\u1eaft \u0111\u1ea7u Giao d\u1ecbch<\/span>\n        <\/a>\n    <\/div>\n    <\/p>\n<h2>K\u1ebft Lu\u1eadn: T\u00edch H\u1ee3p \u0110\u1ed9 Ch\u00ednh X\u00e1c To\u00e1n H\u1ecdc v\u1edbi Chuy\u00ean M\u00f4n Ng\u00e0nh D\u01b0\u1ee3c<\/h2>\n<p>C\u00e1c n\u1ec1n t\u1ea3ng to\u00e1n h\u1ecdc c\u1ee7a d\u1ef1 \u0111o\u00e1n c\u1ed5 phi\u1ebfu Pfizer \u0111\u00e3 ph\u00e1t tri\u1ec3n \u0111\u00e1ng k\u1ec3, chuy\u1ec3n t\u1eeb ph\u00e2n t\u00edch xu h\u01b0\u1edbng s\u01a1 khai sang c\u00e1c h\u1ec7 th\u1ed1ng \u0111a y\u1ebfu t\u1ed1 tinh vi k\u1ebft h\u1ee3p h\u1ecdc m\u00e1y, ph\u00e2n ph\u1ed1i th\u1ed1ng k\u00ea, v\u00e0 chuy\u00ean m\u00f4n ng\u00e0nh d\u01b0\u1ee3c ph\u1ea9m. C\u00e1c ph\u01b0\u01a1ng ph\u00e1p ti\u00ean ti\u1ebfn n\u00e0y cho ph\u00e9p c\u00e1c nh\u00e0 \u0111\u1ea7u t\u01b0 t\u1ea1o ra c\u00e1c d\u1ef1 b\u00e1o \u0111\u00e1ng tin c\u1eady \u0111\u00e1ng k\u1ec3 trong c\u00e1c \u0111i\u1ec1u ki\u1ec7n th\u1ecb tr\u01b0\u1eddng \u0111a d\u1ea1ng, \u0111\u1eb7c bi\u1ec7t c\u00f3 gi\u00e1 tr\u1ecb trong ng\u00e0nh d\u01b0\u1ee3c ph\u1ea9m d\u1ec5 bi\u1ebfn \u0111\u1ed9ng.<\/p>\n<p>M\u1ed9t s\u1ed1 nguy\u00ean t\u1eafc c\u00f3 th\u1ec3 h\u00e0nh \u0111\u1ed9ng n\u1ed5i l\u00ean t\u1eeb ph\u00e2n t\u00edch to\u00e0n di\u1ec7n n\u00e0y:<\/p>\n<ul>\n<li>T\u00edch h\u1ee3p \u0111a m\u00f4 h\u00ecnh li\u00ean t\u1ee5c v\u01b0\u1ee3t tr\u1ed9i h\u01a1n c\u00e1c k\u1ef9 thu\u1eadt d\u1ef1 \u0111o\u00e1n c\u00e1 nh\u00e2n t\u1eeb 27-35%, \u0111\u1eb7c bi\u1ec7t trong c\u00e1c giai \u0111o\u1ea1n c\u00f3 t\u00edn hi\u1ec7u th\u1ecb tr\u01b0\u1eddng m\u00e2u thu\u1eabn<\/li>\n<li>C\u00e1c bi\u1ebfn s\u1ed1 c\u1ee5 th\u1ec3 ng\u00e0nh d\u01b0\u1ee3c bao g\u1ed3m \u0111\u1ecbnh gi\u00e1 \u0111\u01b0\u1eddng \u1ed1ng, m\u00f4 h\u00ecnh x\u00e1c su\u1ea5t quy \u0111\u1ecbnh, v\u00e0 \u0111\u1ecbnh l\u01b0\u1ee3ng v\u00e1ch \u0111\u00e1 b\u1eb1ng s\u00e1ng ch\u1ebf c\u1ea3i thi\u1ec7n \u0111\u1ed9 ch\u00ednh x\u00e1c d\u1ef1 b\u00e1o t\u1eeb 41-53% so v\u1edbi c\u00e1c m\u00f4 h\u00ecnh t\u00e0i ch\u00ednh chung<\/li>\n<li>\u0110\u1ecbnh l\u01b0\u1ee3ng s\u1ef1 kh\u00f4ng ch\u1eafc ch\u1eafn th\u00f4ng qua c\u00e1c ph\u00e2n ph\u1ed1i x\u00e1c su\u1ea5t ho\u00e0n ch\u1ec9nh cho ph\u00e9p \u0111\u1ecbnh c\u1ee1 v\u1ecb tr\u00ed t\u1ed1i \u01b0u v\u00e0 qu\u1ea3n l\u00fd r\u1ee7i ro v\u01b0\u1ee3t xa nh\u1eefng g\u00ec c\u00e1c d\u1ef1 b\u00e1o \u0111i\u1ec3m cho ph\u00e9p<\/li>\n<li>X\u00e1c nh\u1eadn m\u00f4 h\u00ecnh li\u00ean t\u1ee5c \u0111\u1ed1i v\u1edbi c\u00e1c s\u1ef1 ki\u1ec7n ng\u00e0nh d\u01b0\u1ee3c ph\u1ea9m l\u00e0 c\u1ea7n thi\u1ebft khi c\u00e1c t\u01b0\u01a1ng quan thay \u0111\u1ed5i trong c\u00e1c ch\u1ebf \u0111\u1ed9 th\u1ecb tr\u01b0\u1eddng kh\u00e1c nhau<\/li>\n<li>C\u00e1c n\u1ec1n t\u1ea3ng nh\u01b0 Pocket Option t\u00edch h\u1ee3p ph\u00e2n t\u00edch d\u01b0\u1ee3c ph\u1ea9m chuy\u00ean bi\u1ec7t v\u1edbi c\u00e1c c\u00f4ng c\u1ee5 d\u1ef1 b\u00e1o truy\u1ec1n th\u1ed1ng d\u00e2n ch\u1ee7 h\u00f3a kh\u1ea3 n\u0103ng d\u1ef1 \u0111o\u00e1n ch\u1ea5t l\u01b0\u1ee3ng t\u1ed5 ch\u1ee9c<\/li>\n<\/ul>\n<p>B\u1eb1ng c\u00e1ch tri\u1ec3n khai c\u00e1c khung to\u00e1n h\u1ecdc n\u00e0y th\u00f4ng qua m\u1ed9t ph\u01b0\u01a1ng ph\u00e1p c\u00f3 c\u1ea5u tr\u00fac, c\u00e1c nh\u00e0 \u0111\u1ea7u t\u01b0 c\u00f3 th\u1ec3 ph\u00e1t tri\u1ec3n c\u00e1c m\u00f4 h\u00ecnh d\u1ef1 \u0111o\u00e1n c\u1ed5 phi\u1ebfu Pfizer tinh vi k\u1ebft h\u1ee3p to\u00e0n b\u1ed9 ph\u1ed5 c\u00e1c bi\u1ebfn s\u1ed1 \u0111i\u1ec1u khi\u1ec3n \u0111\u1ecbnh gi\u00e1 c\u1ed5 phi\u1ebfu d\u01b0\u1ee3c ph\u1ea9m. C\u00e1ch ti\u1ebfp c\u1eadn to\u00e0n di\u1ec7n n\u00e0y cung c\u1ea5p m\u1ed9t l\u1ee3i th\u1ebf ph\u00e2n t\u00edch \u0111\u00e1ng k\u1ec3 trong m\u1ed9t trong nh\u1eefng ng\u00e0nh ph\u1ee9c t\u1ea1p nh\u1ea5t nh\u01b0ng c\u00f3 th\u1ec3 mang l\u1ea1i l\u1ee3i nhu\u1eadn cao nh\u1ea5t c\u1ee7a th\u1ecb tr\u01b0\u1eddng.<\/p>\n<p>D\u00f9 ph\u00e1t tri\u1ec3n c\u00e1c thu\u1eadt to\u00e1n giao d\u1ecbch t\u1ef1 \u0111\u1ed9ng hay ti\u1ebfn h\u00e0nh ph\u00e2n t\u00edch th\u1ee7 c\u00f4ng cho v\u1ecb tr\u00ed \u0111\u1ea7u t\u01b0 d\u00e0i h\u1ea1n, c\u00e1c n\u1ec1n t\u1ea3ng to\u00e1n h\u1ecdc \u0111\u01b0\u1ee3c n\u00eau \u1edf \u0111\u00e2y cung c\u1ea5p m\u1ed9t ph\u01b0\u01a1ng ph\u00e1p c\u00f3 h\u1ec7 th\u1ed1ng cho d\u1ef1 \u0111o\u00e1n c\u1ed5 phi\u1ebfu Pfizer c\u00f3 th\u1ec3 \u0111\u01b0\u1ee3c tri\u1ec3n khai hi\u1ec7u qu\u1ea3 th\u00f4ng qua n\u1ec1n t\u1ea3ng ph\u00e2n t\u00edch d\u01b0\u1ee3c ph\u1ea9m to\u00e0n di\u1ec7n c\u1ee7a Pocket Option.<\/p>\n<\/div>\n"},"faq":[{"question":"Nh\u1eefng y\u1ebfu t\u1ed1 n\u00e0o \u1ea3nh h\u01b0\u1edfng \u0111\u00e1ng k\u1ec3 nh\u1ea5t \u0111\u1ebfn c\u00e1c m\u00f4 h\u00ecnh d\u1ef1 \u0111o\u00e1n c\u1ed5 phi\u1ebfu c\u1ee7a Pfizer?","answer":"C\u00e1c m\u00f4 h\u00ecnh d\u1ef1 \u0111o\u00e1n c\u1ed5 phi\u1ebfu c\u1ee7a Pfizer b\u1ecb \u1ea3nh h\u01b0\u1edfng \u0111\u00e1ng k\u1ec3 nh\u1ea5t b\u1edfi c\u00e1c y\u1ebfu t\u1ed1 \u0111\u1eb7c th\u00f9 c\u1ee7a ng\u00e0nh d\u01b0\u1ee3c ph\u1ea9m bao g\u1ed3m ph\u00e1t tri\u1ec3n danh m\u1ee5c s\u1ea3n ph\u1ea9m, h\u1ebft h\u1ea1n b\u1eb1ng s\u00e1ng ch\u1ebf, quy\u1ebft \u0111\u1ecbnh c\u1ee7a c\u01a1 quan qu\u1ea3n l\u00fd, k\u1ebft qu\u1ea3 th\u1eed nghi\u1ec7m l\u00e2m s\u00e0ng v\u00e0 \u00e1p l\u1ef1c v\u1ec1 gi\u00e1 thu\u1ed1c. C\u00e1c ch\u1ec9 s\u1ed1 t\u00e0i ch\u00ednh truy\u1ec1n th\u1ed1ng nh\u01b0 t\u1ef7 l\u1ec7 P\/E v\u00e0 bi\u00ean l\u1ee3i nhu\u1eadn ch\u1ec9 l\u00e0 th\u1ee9 y\u1ebfu so v\u1edbi c\u00e1c bi\u1ebfn s\u1ed1 \u0111\u1eb7c th\u00f9 c\u1ee7a ng\u00e0nh n\u00e0y. C\u00e1c m\u00f4 h\u00ecnh d\u1ef1 \u0111o\u00e1n hi\u1ec7u qu\u1ea3 ph\u1ea3i \u0111\u00e1nh gi\u00e1 cao c\u00e1c y\u1ebfu t\u1ed1 d\u01b0\u1ee3c ph\u1ea9m, \u0111\u1eb7c bi\u1ec7t trong c\u00e1c giai \u0111o\u1ea1n c\u00f3 quy\u1ebft \u0111\u1ecbnh c\u1ee7a FDA \u0111ang ch\u1edd x\u1eed l\u00fd ho\u1eb7c c\u00e1c k\u1ebft qu\u1ea3 th\u1eed nghi\u1ec7m l\u00e2m s\u00e0ng quan tr\u1ecdng."},{"question":"\u0110\u1ed9 ch\u00ednh x\u00e1c c\u1ee7a c\u00e1c m\u00f4 h\u00ecnh h\u1ecdc m\u00e1y trong vi\u1ec7c d\u1ef1 \u0111o\u00e1n gi\u00e1 c\u1ed5 phi\u1ebfu PFE nh\u01b0 th\u1ebf n\u00e0o?","answer":"C\u00e1c m\u00f4 h\u00ecnh h\u1ecdc m\u00e1y \u0111\u1ec3 d\u1ef1 \u0111o\u00e1n gi\u00e1 c\u1ed5 phi\u1ebfu pfe cho th\u1ea5y \u0111\u1ed9 ch\u00ednh x\u00e1c bi\u1ebfn \u0111\u1ed5i t\u00f9y thu\u1ed9c v\u00e0o khung th\u1eddi gian v\u00e0 \u0111i\u1ec1u ki\u1ec7n th\u1ecb tr\u01b0\u1eddng. D\u1ef1 b\u00e1o ng\u1eafn h\u1ea1n (1-5 ng\u00e0y) s\u1eed d\u1ee5ng m\u1ea1ng n\u01a1-ron LSTM \u0111\u1ea1t \u0111\u1ed9 ch\u00ednh x\u00e1c h\u01b0\u1edbng 70-80% trong c\u00e1c th\u1ecb tr\u01b0\u1eddng \u1ed5n \u0111\u1ecbnh, trong khi d\u1ef1 \u0111o\u00e1n d\u00e0i h\u1ea1n (tr\u00ean 30 ng\u00e0y) th\u01b0\u1eddng cho th\u1ea5y \u0111\u1ed9 ch\u00ednh x\u00e1c 55-65%. Kh\u00f4ng c\u00f3 m\u00f4 h\u00ecnh n\u00e0o li\u00ean t\u1ee5c v\u01b0\u1ee3t tr\u1ed9i trong t\u1ea5t c\u1ea3 c\u00e1c m\u00f4i tr\u01b0\u1eddng th\u1ecb tr\u01b0\u1eddng, \u0111\u00f3 l\u00e0 l\u00fd do t\u1ea1i sao c\u00e1c ph\u01b0\u01a1ng ph\u00e1p ti\u1ebfp c\u1eadn \u0111a m\u00f4 h\u00ecnh s\u1eed d\u1ee5ng c\u00e1c ph\u01b0\u01a1ng ph\u00e1p t\u1eadp h\u1ee3p nh\u01b0 Random Forests v\u00e0 Gradient Boosting mang l\u1ea1i k\u1ebft qu\u1ea3 \u0111\u00e1ng tin c\u1eady h\u01a1n b\u1eb1ng c\u00e1ch k\u1ebft h\u1ee3p \u0111i\u1ec3m m\u1ea1nh c\u1ee7a c\u00e1c thu\u1eadt to\u00e1n kh\u00e1c nhau."},{"question":"Ph\u00e2n t\u00edch k\u1ef9 thu\u1eadt c\u00f3 th\u1ec3 cung c\u1ea5p d\u1ef1 \u0111o\u00e1n \u0111\u00e1ng tin c\u1eady v\u1ec1 c\u1ed5 phi\u1ebfu Pfizer v\u00e0o ng\u00e0y mai kh\u00f4ng?","answer":"Ph\u00e2n t\u00edch k\u1ef9 thu\u1eadt m\u1ed9t m\u00ecnh cung c\u1ea5p \u0111\u1ed9 tin c\u1eady kh\u00f4ng \u0111\u1ee7 cho d\u1ef1 \u0111o\u00e1n c\u1ed5 phi\u1ebfu Pfizer v\u00e0o ng\u00e0y mai do s\u1ef1 nh\u1ea1y c\u1ea3m c\u1ee7a ng\u00e0nh d\u01b0\u1ee3c ph\u1ea9m v\u1edbi c\u00e1c y\u1ebfu t\u1ed1 kh\u00f4ng thu\u1ed9c bi\u1ec3u \u0111\u1ed3. C\u00e1c nghi\u00ean c\u1ee9u cho th\u1ea5y c\u00e1c ch\u1ec9 b\u00e1o k\u1ef9 thu\u1eadt ch\u1ec9 \u0111\u1ea1t \u0111\u1ed9 ch\u00ednh x\u00e1c 55-60% khi d\u1ef1 \u0111o\u00e1n bi\u1ebfn \u0111\u1ed9ng ng\u00e0y ti\u1ebfp theo c\u1ee7a Pfizer khi s\u1eed d\u1ee5ng ri\u00eang l\u1ebb. \u0110\u1ec3 c\u1ea3i thi\u1ec7n \u0111\u1ed9 tin c\u1eady, c\u00e1c t\u00edn hi\u1ec7u k\u1ef9 thu\u1eadt ph\u1ea3i \u0111\u01b0\u1ee3c t\u00edch h\u1ee3p v\u1edbi ph\u00e2n t\u00edch t\u00e2m l\u00fd, d\u1eef li\u1ec7u d\u00f2ng ch\u1ea3y quy\u1ec1n ch\u1ecdn v\u00e0 c\u00e1c ch\u1ec9 s\u1ed1 t\u01b0\u01a1ng quan ng\u00e0nh. Ng\u01b0\u1eddi d\u00f9ng Pocket Option b\u00e1o c\u00e1o \u0111\u1ed9 ch\u00ednh x\u00e1c d\u1ef1 \u0111o\u00e1n cao h\u01a1n \u0111\u00e1ng k\u1ec3 khi b\u1ed5 sung ph\u00e2n t\u00edch k\u1ef9 thu\u1eadt v\u1edbi c\u00e1c \u0111i\u1ec3m d\u1eef li\u1ec7u b\u1ed5 sung n\u00e0y."},{"question":"L\u00e0m th\u1ebf n\u00e0o \u0111\u1ec3 t\u00f4i k\u1ebft h\u1ee3p c\u1ea3m x\u00fac tin t\u1ee9c v\u00e0o c\u00e1c m\u00f4 h\u00ecnh \u0111\u1ecbnh l\u01b0\u1ee3ng c\u1ed5 phi\u1ebfu Pfizer?","answer":"K\u1ebft h\u1ee3p c\u1ea3m x\u00fac tin t\u1ee9c v\u00e0o c\u00e1c m\u00f4 h\u00ecnh \u0111\u1ecbnh l\u01b0\u1ee3ng c\u1ed5 phi\u1ebfu Pfizer \u0111\u00f2i h\u1ecfi c\u00e1c thu\u1eadt to\u00e1n x\u1eed l\u00fd ng\u00f4n ng\u1eef t\u1ef1 nhi\u00ean chuy\u1ec3n \u0111\u1ed5i d\u1eef li\u1ec7u v\u0103n b\u1ea3n th\u00e0nh \u0111i\u1ec3m s\u1ed1 s\u1ed1 h\u1ecdc. B\u1eaft \u0111\u1ea7u b\u1eb1ng c\u00e1ch thu th\u1eadp tin t\u1ee9c d\u01b0\u1ee3c ph\u1ea9m t\u1eeb c\u00e1c ngu\u1ed3n \u0111\u00e1ng tin c\u1eady v\u00e0 x\u1eed l\u00fd qua c\u00e1c API ph\u00e2n t\u00edch c\u1ea3m x\u00fac \u0111\u1ec3 \u0111\u1ecbnh l\u01b0\u1ee3ng m\u1ee9c \u0111\u1ed9 t\u00edch c\u1ef1c\/ti\u00eau c\u1ef1c tr\u00ean m\u1ed9t thang \u0111i\u1ec3m (th\u01b0\u1eddng l\u00e0 -1 \u0111\u1ebfn +1). T\u00ednh to\u00e1n \u0111i\u1ec3m c\u1ea3m x\u00fac c\u00f3 tr\u1ecdng s\u1ed1 d\u1ef1a tr\u00ean \u0111\u1ed9 tin c\u1eady v\u00e0 t\u00ednh m\u1edbi c\u1ee7a ngu\u1ed3n, sau \u0111\u00f3 t\u00edch h\u1ee3p \u0111i\u1ec3m n\u00e0y nh\u01b0 m\u1ed9t \u0111\u1eb7c \u0111i\u1ec3m trong m\u00f4 h\u00ecnh d\u1ef1 \u0111o\u00e1n c\u1ee7a b\u1ea1n v\u1edbi tr\u1ecdng s\u1ed1 \u0111i\u1ec3n h\u00ecnh t\u1eeb 15-25%. \u0110i\u1ec1u ch\u1ec9nh \u1ea3nh h\u01b0\u1edfng c\u1ee7a c\u1ea3m x\u00fac d\u1ef1a tr\u00ean s\u1ef1 bi\u1ebfn \u0111\u1ed9ng c\u1ee7a th\u1ecb tr\u01b0\u1eddng--tr\u1ecdng s\u1ed1 cao h\u01a1n trong c\u00e1c giai \u0111o\u1ea1n bi\u1ebfn \u0111\u1ed9ng cao khi c\u1ea3m x\u00fac th\u00fac \u0111\u1ea9y c\u00e1c bi\u1ebfn \u0111\u1ed9ng gi\u00e1 m\u1ea1nh h\u01a1n."},{"question":"Nh\u1eefng k\u1ef9 thu\u1eadt x\u00e1c th\u1ef1c th\u1ed1ng k\u00ea n\u00e0o \u0111\u1ea3m b\u1ea3o \u0111\u1ed9 tin c\u1eady c\u1ee7a m\u00f4 h\u00ecnh d\u1ef1 \u0111o\u00e1n?","answer":"C\u00e1c m\u00f4 h\u00ecnh d\u1ef1 \u0111o\u00e1n \u0111\u00e1ng tin c\u1eady y\u00eau c\u1ea7u x\u00e1c th\u1ef1c th\u1ed1ng k\u00ea nghi\u00eam ng\u1eb7t th\u00f4ng qua t\u1ed1i \u01b0u h\u00f3a ti\u1ebfn b\u1ed9, ki\u1ec3m tra ch\u00e9o k-fold th\u00edch \u1ee9ng cho chu\u1ed7i th\u1eddi gian v\u00e0 ki\u1ec3m tra ngo\u00e0i m\u1eabu. \u0110\u1ed1i v\u1edbi c\u00e1c m\u00f4 h\u00ecnh d\u1ef1 \u0111o\u00e1n c\u1ed5 phi\u1ebfu pfizer c\u1ee5 th\u1ec3, vi\u1ec7c x\u00e1c th\u1ef1c n\u00ean bao g\u1ed3m ki\u1ec3m tra c\u0103ng th\u1eb3ng \u0111\u1ed1i v\u1edbi c\u00e1c gi\u00e1n \u0111o\u1ea1n th\u1ecb tr\u01b0\u1eddng d\u01b0\u1ee3c ph\u1ea9m l\u1ecbch s\u1eed nh\u01b0 c\u00e1c quy\u1ebft \u0111\u1ecbnh l\u1edbn c\u1ee7a FDA v\u00e0 c\u00e1c v\u00e1ch \u0111\u00e1 b\u1eb1ng s\u00e1ng ch\u1ebf. C\u00e1c ch\u1ec9 s\u1ed1 \u0111\u1ed9 tin c\u1eady \u0111\u1ecbnh l\u01b0\u1ee3ng n\u00ean bao g\u1ed3m RMSE (Sai s\u1ed1 B\u00ecnh ph\u01b0\u01a1ng Trung b\u00ecnh C\u0103n b\u1eadc hai) d\u01b0\u1edbi 2,5% cho c\u00e1c d\u1ef1 b\u00e1o ng\u1eafn h\u1ea1n, T\u1ef7 l\u1ec7 Sharpe tr\u00ean 1,2 cho vi\u1ec7c tri\u1ec3n khai chi\u1ebfn l\u01b0\u1ee3c, v\u00e0 \u0111\u1ed9 ch\u00ednh x\u00e1c h\u01b0\u1edbng v\u01b0\u1ee3t qu\u00e1 65% trong \u0111i\u1ec1u ki\u1ec7n th\u1ecb tr\u01b0\u1eddng b\u00ecnh th\u01b0\u1eddng v\u00e0 55% trong c\u00e1c giai \u0111o\u1ea1n bi\u1ebfn \u0111\u1ed9ng cao."}],"faq_source":{"label":"FAQ","type":"repeater","formatted_value":[{"question":"Nh\u1eefng y\u1ebfu t\u1ed1 n\u00e0o \u1ea3nh h\u01b0\u1edfng \u0111\u00e1ng k\u1ec3 nh\u1ea5t \u0111\u1ebfn c\u00e1c m\u00f4 h\u00ecnh d\u1ef1 \u0111o\u00e1n c\u1ed5 phi\u1ebfu c\u1ee7a Pfizer?","answer":"C\u00e1c m\u00f4 h\u00ecnh d\u1ef1 \u0111o\u00e1n c\u1ed5 phi\u1ebfu c\u1ee7a Pfizer b\u1ecb \u1ea3nh h\u01b0\u1edfng \u0111\u00e1ng k\u1ec3 nh\u1ea5t b\u1edfi c\u00e1c y\u1ebfu t\u1ed1 \u0111\u1eb7c th\u00f9 c\u1ee7a ng\u00e0nh d\u01b0\u1ee3c ph\u1ea9m bao g\u1ed3m ph\u00e1t tri\u1ec3n danh m\u1ee5c s\u1ea3n ph\u1ea9m, h\u1ebft h\u1ea1n b\u1eb1ng s\u00e1ng ch\u1ebf, quy\u1ebft \u0111\u1ecbnh c\u1ee7a c\u01a1 quan qu\u1ea3n l\u00fd, k\u1ebft qu\u1ea3 th\u1eed nghi\u1ec7m l\u00e2m s\u00e0ng v\u00e0 \u00e1p l\u1ef1c v\u1ec1 gi\u00e1 thu\u1ed1c. C\u00e1c ch\u1ec9 s\u1ed1 t\u00e0i ch\u00ednh truy\u1ec1n th\u1ed1ng nh\u01b0 t\u1ef7 l\u1ec7 P\/E v\u00e0 bi\u00ean l\u1ee3i nhu\u1eadn ch\u1ec9 l\u00e0 th\u1ee9 y\u1ebfu so v\u1edbi c\u00e1c bi\u1ebfn s\u1ed1 \u0111\u1eb7c th\u00f9 c\u1ee7a ng\u00e0nh n\u00e0y. C\u00e1c m\u00f4 h\u00ecnh d\u1ef1 \u0111o\u00e1n hi\u1ec7u qu\u1ea3 ph\u1ea3i \u0111\u00e1nh gi\u00e1 cao c\u00e1c y\u1ebfu t\u1ed1 d\u01b0\u1ee3c ph\u1ea9m, \u0111\u1eb7c bi\u1ec7t trong c\u00e1c giai \u0111o\u1ea1n c\u00f3 quy\u1ebft \u0111\u1ecbnh c\u1ee7a FDA \u0111ang ch\u1edd x\u1eed l\u00fd ho\u1eb7c c\u00e1c k\u1ebft qu\u1ea3 th\u1eed nghi\u1ec7m l\u00e2m s\u00e0ng quan tr\u1ecdng."},{"question":"\u0110\u1ed9 ch\u00ednh x\u00e1c c\u1ee7a c\u00e1c m\u00f4 h\u00ecnh h\u1ecdc m\u00e1y trong vi\u1ec7c d\u1ef1 \u0111o\u00e1n gi\u00e1 c\u1ed5 phi\u1ebfu PFE nh\u01b0 th\u1ebf n\u00e0o?","answer":"C\u00e1c m\u00f4 h\u00ecnh h\u1ecdc m\u00e1y \u0111\u1ec3 d\u1ef1 \u0111o\u00e1n gi\u00e1 c\u1ed5 phi\u1ebfu pfe cho th\u1ea5y \u0111\u1ed9 ch\u00ednh x\u00e1c bi\u1ebfn \u0111\u1ed5i t\u00f9y thu\u1ed9c v\u00e0o khung th\u1eddi gian v\u00e0 \u0111i\u1ec1u ki\u1ec7n th\u1ecb tr\u01b0\u1eddng. D\u1ef1 b\u00e1o ng\u1eafn h\u1ea1n (1-5 ng\u00e0y) s\u1eed d\u1ee5ng m\u1ea1ng n\u01a1-ron LSTM \u0111\u1ea1t \u0111\u1ed9 ch\u00ednh x\u00e1c h\u01b0\u1edbng 70-80% trong c\u00e1c th\u1ecb tr\u01b0\u1eddng \u1ed5n \u0111\u1ecbnh, trong khi d\u1ef1 \u0111o\u00e1n d\u00e0i h\u1ea1n (tr\u00ean 30 ng\u00e0y) th\u01b0\u1eddng cho th\u1ea5y \u0111\u1ed9 ch\u00ednh x\u00e1c 55-65%. Kh\u00f4ng c\u00f3 m\u00f4 h\u00ecnh n\u00e0o li\u00ean t\u1ee5c v\u01b0\u1ee3t tr\u1ed9i trong t\u1ea5t c\u1ea3 c\u00e1c m\u00f4i tr\u01b0\u1eddng th\u1ecb tr\u01b0\u1eddng, \u0111\u00f3 l\u00e0 l\u00fd do t\u1ea1i sao c\u00e1c ph\u01b0\u01a1ng ph\u00e1p ti\u1ebfp c\u1eadn \u0111a m\u00f4 h\u00ecnh s\u1eed d\u1ee5ng c\u00e1c ph\u01b0\u01a1ng ph\u00e1p t\u1eadp h\u1ee3p nh\u01b0 Random Forests v\u00e0 Gradient Boosting mang l\u1ea1i k\u1ebft qu\u1ea3 \u0111\u00e1ng tin c\u1eady h\u01a1n b\u1eb1ng c\u00e1ch k\u1ebft h\u1ee3p \u0111i\u1ec3m m\u1ea1nh c\u1ee7a c\u00e1c thu\u1eadt to\u00e1n kh\u00e1c nhau."},{"question":"Ph\u00e2n t\u00edch k\u1ef9 thu\u1eadt c\u00f3 th\u1ec3 cung c\u1ea5p d\u1ef1 \u0111o\u00e1n \u0111\u00e1ng tin c\u1eady v\u1ec1 c\u1ed5 phi\u1ebfu Pfizer v\u00e0o ng\u00e0y mai kh\u00f4ng?","answer":"Ph\u00e2n t\u00edch k\u1ef9 thu\u1eadt m\u1ed9t m\u00ecnh cung c\u1ea5p \u0111\u1ed9 tin c\u1eady kh\u00f4ng \u0111\u1ee7 cho d\u1ef1 \u0111o\u00e1n c\u1ed5 phi\u1ebfu Pfizer v\u00e0o ng\u00e0y mai do s\u1ef1 nh\u1ea1y c\u1ea3m c\u1ee7a ng\u00e0nh d\u01b0\u1ee3c ph\u1ea9m v\u1edbi c\u00e1c y\u1ebfu t\u1ed1 kh\u00f4ng thu\u1ed9c bi\u1ec3u \u0111\u1ed3. C\u00e1c nghi\u00ean c\u1ee9u cho th\u1ea5y c\u00e1c ch\u1ec9 b\u00e1o k\u1ef9 thu\u1eadt ch\u1ec9 \u0111\u1ea1t \u0111\u1ed9 ch\u00ednh x\u00e1c 55-60% khi d\u1ef1 \u0111o\u00e1n bi\u1ebfn \u0111\u1ed9ng ng\u00e0y ti\u1ebfp theo c\u1ee7a Pfizer khi s\u1eed d\u1ee5ng ri\u00eang l\u1ebb. \u0110\u1ec3 c\u1ea3i thi\u1ec7n \u0111\u1ed9 tin c\u1eady, c\u00e1c t\u00edn hi\u1ec7u k\u1ef9 thu\u1eadt ph\u1ea3i \u0111\u01b0\u1ee3c t\u00edch h\u1ee3p v\u1edbi ph\u00e2n t\u00edch t\u00e2m l\u00fd, d\u1eef li\u1ec7u d\u00f2ng ch\u1ea3y quy\u1ec1n ch\u1ecdn v\u00e0 c\u00e1c ch\u1ec9 s\u1ed1 t\u01b0\u01a1ng quan ng\u00e0nh. Ng\u01b0\u1eddi d\u00f9ng Pocket Option b\u00e1o c\u00e1o \u0111\u1ed9 ch\u00ednh x\u00e1c d\u1ef1 \u0111o\u00e1n cao h\u01a1n \u0111\u00e1ng k\u1ec3 khi b\u1ed5 sung ph\u00e2n t\u00edch k\u1ef9 thu\u1eadt v\u1edbi c\u00e1c \u0111i\u1ec3m d\u1eef li\u1ec7u b\u1ed5 sung n\u00e0y."},{"question":"L\u00e0m th\u1ebf n\u00e0o \u0111\u1ec3 t\u00f4i k\u1ebft h\u1ee3p c\u1ea3m x\u00fac tin t\u1ee9c v\u00e0o c\u00e1c m\u00f4 h\u00ecnh \u0111\u1ecbnh l\u01b0\u1ee3ng c\u1ed5 phi\u1ebfu Pfizer?","answer":"K\u1ebft h\u1ee3p c\u1ea3m x\u00fac tin t\u1ee9c v\u00e0o c\u00e1c m\u00f4 h\u00ecnh \u0111\u1ecbnh l\u01b0\u1ee3ng c\u1ed5 phi\u1ebfu Pfizer \u0111\u00f2i h\u1ecfi c\u00e1c thu\u1eadt to\u00e1n x\u1eed l\u00fd ng\u00f4n ng\u1eef t\u1ef1 nhi\u00ean chuy\u1ec3n \u0111\u1ed5i d\u1eef li\u1ec7u v\u0103n b\u1ea3n th\u00e0nh \u0111i\u1ec3m s\u1ed1 s\u1ed1 h\u1ecdc. B\u1eaft \u0111\u1ea7u b\u1eb1ng c\u00e1ch thu th\u1eadp tin t\u1ee9c d\u01b0\u1ee3c ph\u1ea9m t\u1eeb c\u00e1c ngu\u1ed3n \u0111\u00e1ng tin c\u1eady v\u00e0 x\u1eed l\u00fd qua c\u00e1c API ph\u00e2n t\u00edch c\u1ea3m x\u00fac \u0111\u1ec3 \u0111\u1ecbnh l\u01b0\u1ee3ng m\u1ee9c \u0111\u1ed9 t\u00edch c\u1ef1c\/ti\u00eau c\u1ef1c tr\u00ean m\u1ed9t thang \u0111i\u1ec3m (th\u01b0\u1eddng l\u00e0 -1 \u0111\u1ebfn +1). T\u00ednh to\u00e1n \u0111i\u1ec3m c\u1ea3m x\u00fac c\u00f3 tr\u1ecdng s\u1ed1 d\u1ef1a tr\u00ean \u0111\u1ed9 tin c\u1eady v\u00e0 t\u00ednh m\u1edbi c\u1ee7a ngu\u1ed3n, sau \u0111\u00f3 t\u00edch h\u1ee3p \u0111i\u1ec3m n\u00e0y nh\u01b0 m\u1ed9t \u0111\u1eb7c \u0111i\u1ec3m trong m\u00f4 h\u00ecnh d\u1ef1 \u0111o\u00e1n c\u1ee7a b\u1ea1n v\u1edbi tr\u1ecdng s\u1ed1 \u0111i\u1ec3n h\u00ecnh t\u1eeb 15-25%. \u0110i\u1ec1u ch\u1ec9nh \u1ea3nh h\u01b0\u1edfng c\u1ee7a c\u1ea3m x\u00fac d\u1ef1a tr\u00ean s\u1ef1 bi\u1ebfn \u0111\u1ed9ng c\u1ee7a th\u1ecb tr\u01b0\u1eddng--tr\u1ecdng s\u1ed1 cao h\u01a1n trong c\u00e1c giai \u0111o\u1ea1n bi\u1ebfn \u0111\u1ed9ng cao khi c\u1ea3m x\u00fac th\u00fac \u0111\u1ea9y c\u00e1c bi\u1ebfn \u0111\u1ed9ng gi\u00e1 m\u1ea1nh h\u01a1n."},{"question":"Nh\u1eefng k\u1ef9 thu\u1eadt x\u00e1c th\u1ef1c th\u1ed1ng k\u00ea n\u00e0o \u0111\u1ea3m b\u1ea3o \u0111\u1ed9 tin c\u1eady c\u1ee7a m\u00f4 h\u00ecnh d\u1ef1 \u0111o\u00e1n?","answer":"C\u00e1c m\u00f4 h\u00ecnh d\u1ef1 \u0111o\u00e1n \u0111\u00e1ng tin c\u1eady y\u00eau c\u1ea7u x\u00e1c th\u1ef1c th\u1ed1ng k\u00ea nghi\u00eam ng\u1eb7t th\u00f4ng qua t\u1ed1i \u01b0u h\u00f3a ti\u1ebfn b\u1ed9, ki\u1ec3m tra ch\u00e9o k-fold th\u00edch \u1ee9ng cho chu\u1ed7i th\u1eddi gian v\u00e0 ki\u1ec3m tra ngo\u00e0i m\u1eabu. \u0110\u1ed1i v\u1edbi c\u00e1c m\u00f4 h\u00ecnh d\u1ef1 \u0111o\u00e1n c\u1ed5 phi\u1ebfu pfizer c\u1ee5 th\u1ec3, vi\u1ec7c x\u00e1c th\u1ef1c n\u00ean bao g\u1ed3m ki\u1ec3m tra c\u0103ng th\u1eb3ng \u0111\u1ed1i v\u1edbi c\u00e1c gi\u00e1n \u0111o\u1ea1n th\u1ecb tr\u01b0\u1eddng d\u01b0\u1ee3c ph\u1ea9m l\u1ecbch s\u1eed nh\u01b0 c\u00e1c quy\u1ebft \u0111\u1ecbnh l\u1edbn c\u1ee7a FDA v\u00e0 c\u00e1c v\u00e1ch \u0111\u00e1 b\u1eb1ng s\u00e1ng ch\u1ebf. C\u00e1c ch\u1ec9 s\u1ed1 \u0111\u1ed9 tin c\u1eady \u0111\u1ecbnh l\u01b0\u1ee3ng n\u00ean bao g\u1ed3m RMSE (Sai s\u1ed1 B\u00ecnh ph\u01b0\u01a1ng Trung b\u00ecnh C\u0103n b\u1eadc hai) d\u01b0\u1edbi 2,5% cho c\u00e1c d\u1ef1 b\u00e1o ng\u1eafn h\u1ea1n, T\u1ef7 l\u1ec7 Sharpe tr\u00ean 1,2 cho vi\u1ec7c tri\u1ec3n khai chi\u1ebfn l\u01b0\u1ee3c, v\u00e0 \u0111\u1ed9 ch\u00ednh x\u00e1c h\u01b0\u1edbng v\u01b0\u1ee3t qu\u00e1 65% trong \u0111i\u1ec1u ki\u1ec7n th\u1ecb tr\u01b0\u1eddng b\u00ecnh th\u01b0\u1eddng v\u00e0 55% trong c\u00e1c giai \u0111o\u1ea1n bi\u1ebfn \u0111\u1ed9ng cao."}]}},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.8 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>D\u1ef1 \u0111o\u00e1n C\u1ed5 phi\u1ebfu Pfizer: C\u00e1c Ph\u01b0\u01a1ng ph\u00e1p To\u00e1n h\u1ecdc Ti\u00ean ti\u1ebfn \u0111\u1ec3 D\u1ef1 b\u00e1o Ch\u00ednh x\u00e1c<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pocketoption.com\/blog\/vt\/knowledge-base\/markets\/pfizer-stock-prediction\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"D\u1ef1 \u0111o\u00e1n C\u1ed5 phi\u1ebfu Pfizer: C\u00e1c Ph\u01b0\u01a1ng ph\u00e1p To\u00e1n h\u1ecdc Ti\u00ean ti\u1ebfn \u0111\u1ec3 D\u1ef1 b\u00e1o Ch\u00ednh x\u00e1c\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pocketoption.com\/blog\/vt\/knowledge-base\/markets\/pfizer-stock-prediction\/\" \/>\n<meta property=\"og:site_name\" content=\"Pocket Option blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-22T17:50:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/04\/1742026985353-538238779-6.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1840\" \/>\n\t<meta property=\"og:image:height\" content=\"700\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"Tatiana OK\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Tatiana OK\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/knowledge-base\/markets\/pfizer-stock-prediction\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/knowledge-base\/markets\/pfizer-stock-prediction\/\"},\"author\":{\"name\":\"Tatiana OK\",\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/#\/schema\/person\/7021606f7d6abf56a4dfe12af297820d\"},\"headline\":\"D\u1ef1 \u0111o\u00e1n C\u1ed5 phi\u1ebfu Pfizer: C\u00e1c Ph\u01b0\u01a1ng ph\u00e1p To\u00e1n h\u1ecdc Ti\u00ean ti\u1ebfn \u0111\u1ec3 D\u1ef1 b\u00e1o Ch\u00ednh x\u00e1c\",\"datePublished\":\"2025-07-22T17:50:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/knowledge-base\/markets\/pfizer-stock-prediction\/\"},\"wordCount\":28,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/knowledge-base\/markets\/pfizer-stock-prediction\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/04\/1742026985353-538238779-6.webp\",\"keywords\":[\"platform\",\"stock\",\"strategy\"],\"articleSection\":[\"Markets\"],\"inLanguage\":\"vt-VT\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/pocketoption.com\/blog\/vt\/knowledge-base\/markets\/pfizer-stock-prediction\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/knowledge-base\/markets\/pfizer-stock-prediction\/\",\"url\":\"https:\/\/pocketoption.com\/blog\/vt\/knowledge-base\/markets\/pfizer-stock-prediction\/\",\"name\":\"D\u1ef1 \u0111o\u00e1n C\u1ed5 phi\u1ebfu Pfizer: C\u00e1c Ph\u01b0\u01a1ng ph\u00e1p To\u00e1n h\u1ecdc Ti\u00ean ti\u1ebfn \u0111\u1ec3 D\u1ef1 b\u00e1o Ch\u00ednh x\u00e1c\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/knowledge-base\/markets\/pfizer-stock-prediction\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/knowledge-base\/markets\/pfizer-stock-prediction\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/04\/1742026985353-538238779-6.webp\",\"datePublished\":\"2025-07-22T17:50:30+00:00\",\"author\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/#\/schema\/person\/7021606f7d6abf56a4dfe12af297820d\"},\"breadcrumb\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/knowledge-base\/markets\/pfizer-stock-prediction\/#breadcrumb\"},\"inLanguage\":\"vt-VT\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pocketoption.com\/blog\/vt\/knowledge-base\/markets\/pfizer-stock-prediction\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"vt-VT\",\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/knowledge-base\/markets\/pfizer-stock-prediction\/#primaryimage\",\"url\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/04\/1742026985353-538238779-6.webp\",\"contentUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/04\/1742026985353-538238779-6.webp\",\"width\":1840,\"height\":700},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/knowledge-base\/markets\/pfizer-stock-prediction\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/pocketoption.com\/blog\/vt\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"D\u1ef1 \u0111o\u00e1n C\u1ed5 phi\u1ebfu Pfizer: C\u00e1c Ph\u01b0\u01a1ng ph\u00e1p To\u00e1n h\u1ecdc Ti\u00ean ti\u1ebfn \u0111\u1ec3 D\u1ef1 b\u00e1o Ch\u00ednh x\u00e1c\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/#website\",\"url\":\"https:\/\/pocketoption.com\/blog\/vt\/\",\"name\":\"Pocket Option blog\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pocketoption.com\/blog\/vt\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"vt-VT\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/#\/schema\/person\/7021606f7d6abf56a4dfe12af297820d\",\"name\":\"Tatiana OK\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"vt-VT\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/0e5382d258c3e430c69c7fcf955c3ccdee2ae00777d8745ed09f129ffca77c26?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/0e5382d258c3e430c69c7fcf955c3ccdee2ae00777d8745ed09f129ffca77c26?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/0e5382d258c3e430c69c7fcf955c3ccdee2ae00777d8745ed09f129ffca77c26?s=96&d=mm&r=g\",\"caption\":\"Tatiana OK\"},\"url\":\"https:\/\/pocketoption.com\/blog\/vt\/author\/tatiana\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"D\u1ef1 \u0111o\u00e1n C\u1ed5 phi\u1ebfu Pfizer: C\u00e1c Ph\u01b0\u01a1ng ph\u00e1p To\u00e1n h\u1ecdc Ti\u00ean ti\u1ebfn \u0111\u1ec3 D\u1ef1 b\u00e1o Ch\u00ednh x\u00e1c","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pocketoption.com\/blog\/vt\/knowledge-base\/markets\/pfizer-stock-prediction\/","og_locale":"en_US","og_type":"article","og_title":"D\u1ef1 \u0111o\u00e1n C\u1ed5 phi\u1ebfu Pfizer: C\u00e1c Ph\u01b0\u01a1ng ph\u00e1p To\u00e1n h\u1ecdc Ti\u00ean ti\u1ebfn \u0111\u1ec3 D\u1ef1 b\u00e1o Ch\u00ednh x\u00e1c","og_url":"https:\/\/pocketoption.com\/blog\/vt\/knowledge-base\/markets\/pfizer-stock-prediction\/","og_site_name":"Pocket Option blog","article_published_time":"2025-07-22T17:50:30+00:00","og_image":[{"width":1840,"height":700,"url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/04\/1742026985353-538238779-6.webp","type":"image\/webp"}],"author":"Tatiana OK","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Tatiana OK"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pocketoption.com\/blog\/vt\/knowledge-base\/markets\/pfizer-stock-prediction\/#article","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/vt\/knowledge-base\/markets\/pfizer-stock-prediction\/"},"author":{"name":"Tatiana OK","@id":"https:\/\/pocketoption.com\/blog\/vt\/#\/schema\/person\/7021606f7d6abf56a4dfe12af297820d"},"headline":"D\u1ef1 \u0111o\u00e1n C\u1ed5 phi\u1ebfu Pfizer: C\u00e1c Ph\u01b0\u01a1ng ph\u00e1p To\u00e1n h\u1ecdc Ti\u00ean ti\u1ebfn \u0111\u1ec3 D\u1ef1 b\u00e1o Ch\u00ednh x\u00e1c","datePublished":"2025-07-22T17:50:30+00:00","mainEntityOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/vt\/knowledge-base\/markets\/pfizer-stock-prediction\/"},"wordCount":28,"commentCount":0,"image":{"@id":"https:\/\/pocketoption.com\/blog\/vt\/knowledge-base\/markets\/pfizer-stock-prediction\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/04\/1742026985353-538238779-6.webp","keywords":["platform","stock","strategy"],"articleSection":["Markets"],"inLanguage":"vt-VT","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/pocketoption.com\/blog\/vt\/knowledge-base\/markets\/pfizer-stock-prediction\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/pocketoption.com\/blog\/vt\/knowledge-base\/markets\/pfizer-stock-prediction\/","url":"https:\/\/pocketoption.com\/blog\/vt\/knowledge-base\/markets\/pfizer-stock-prediction\/","name":"D\u1ef1 \u0111o\u00e1n C\u1ed5 phi\u1ebfu Pfizer: C\u00e1c Ph\u01b0\u01a1ng ph\u00e1p To\u00e1n h\u1ecdc Ti\u00ean ti\u1ebfn \u0111\u1ec3 D\u1ef1 b\u00e1o Ch\u00ednh x\u00e1c","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/vt\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/vt\/knowledge-base\/markets\/pfizer-stock-prediction\/#primaryimage"},"image":{"@id":"https:\/\/pocketoption.com\/blog\/vt\/knowledge-base\/markets\/pfizer-stock-prediction\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/04\/1742026985353-538238779-6.webp","datePublished":"2025-07-22T17:50:30+00:00","author":{"@id":"https:\/\/pocketoption.com\/blog\/vt\/#\/schema\/person\/7021606f7d6abf56a4dfe12af297820d"},"breadcrumb":{"@id":"https:\/\/pocketoption.com\/blog\/vt\/knowledge-base\/markets\/pfizer-stock-prediction\/#breadcrumb"},"inLanguage":"vt-VT","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pocketoption.com\/blog\/vt\/knowledge-base\/markets\/pfizer-stock-prediction\/"]}]},{"@type":"ImageObject","inLanguage":"vt-VT","@id":"https:\/\/pocketoption.com\/blog\/vt\/knowledge-base\/markets\/pfizer-stock-prediction\/#primaryimage","url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/04\/1742026985353-538238779-6.webp","contentUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/04\/1742026985353-538238779-6.webp","width":1840,"height":700},{"@type":"BreadcrumbList","@id":"https:\/\/pocketoption.com\/blog\/vt\/knowledge-base\/markets\/pfizer-stock-prediction\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pocketoption.com\/blog\/vt\/"},{"@type":"ListItem","position":2,"name":"D\u1ef1 \u0111o\u00e1n C\u1ed5 phi\u1ebfu Pfizer: C\u00e1c Ph\u01b0\u01a1ng ph\u00e1p To\u00e1n h\u1ecdc Ti\u00ean ti\u1ebfn \u0111\u1ec3 D\u1ef1 b\u00e1o Ch\u00ednh x\u00e1c"}]},{"@type":"WebSite","@id":"https:\/\/pocketoption.com\/blog\/vt\/#website","url":"https:\/\/pocketoption.com\/blog\/vt\/","name":"Pocket Option blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pocketoption.com\/blog\/vt\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"vt-VT"},{"@type":"Person","@id":"https:\/\/pocketoption.com\/blog\/vt\/#\/schema\/person\/7021606f7d6abf56a4dfe12af297820d","name":"Tatiana OK","image":{"@type":"ImageObject","inLanguage":"vt-VT","@id":"https:\/\/secure.gravatar.com\/avatar\/0e5382d258c3e430c69c7fcf955c3ccdee2ae00777d8745ed09f129ffca77c26?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/0e5382d258c3e430c69c7fcf955c3ccdee2ae00777d8745ed09f129ffca77c26?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/0e5382d258c3e430c69c7fcf955c3ccdee2ae00777d8745ed09f129ffca77c26?s=96&d=mm&r=g","caption":"Tatiana OK"},"url":"https:\/\/pocketoption.com\/blog\/vt\/author\/tatiana\/"}]}},"po_author":null,"po__editor":null,"po_last_edited":null,"wpml_current_locale":"vt_VT","wpml_translations":{"pt_AA":{"locale":"pt_AA","id":320867,"slug":"pfizer-stock-prediction","post_title":"Previs\u00e3o de A\u00e7\u00f5es da Pfizer: Abordagens Matem\u00e1ticas Avan\u00e7adas para Previs\u00f5es Precisas","href":"https:\/\/pocketoption.com\/blog\/pt\/knowledge-base\/markets\/pfizer-stock-prediction\/"}},"_links":{"self":[{"href":"https:\/\/pocketoption.com\/blog\/vt\/wp-json\/wp\/v2\/posts\/320872","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pocketoption.com\/blog\/vt\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pocketoption.com\/blog\/vt\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/vt\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/vt\/wp-json\/wp\/v2\/comments?post=320872"}],"version-history":[{"count":0,"href":"https:\/\/pocketoption.com\/blog\/vt\/wp-json\/wp\/v2\/posts\/320872\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/vt\/wp-json\/wp\/v2\/media\/196564"}],"wp:attachment":[{"href":"https:\/\/pocketoption.com\/blog\/vt\/wp-json\/wp\/v2\/media?parent=320872"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/vt\/wp-json\/wp\/v2\/categories?post=320872"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/vt\/wp-json\/wp\/v2\/tags?post=320872"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}